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ABSTRACT 
 
Municipal wastewater effluent (MWWE) is a major source of contaminants of 
emerging concern (CECs) in the aquatic environment. Studies have shown ozonation of 
MWWE to be effective in disinfection as well as transformation of the CECs. However, 
the characteristics of the MWWE matrix influence the oxidation efficacy with ozone. In 
the current study, a pilot unit was set up to examine efficiency of ozonation of MWWE in 
disinfection and transformation of target CECs. A transferred ozone dose (TOD) of 
0.72 mg O3/mg DOC was sufficient to consistently achieve the Ontario MOE disinfection 
target of < 200 MPN E. coli/100 mL. A similar TOD transformed the majority of the 
detected CECs by over 80%. Out of the 31 CECs for which transformation efficiencies 
could be calculated, transformations of 21 CECs were > 80%. Transformations of 4 
CECs of antibiotics group were less than 30%. 
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CHAPTER I 
INTRODUCTION 
 
1.1  BACKGROUND 
Many municipal wastewater treatment plants (MWWTPs) discharge the effluent 
in water bodies such as rivers and lakes that are important sources of drinking water. The 
MWWTPs are typically designed for and are efficient in removing suspended solids, 
organics, and nutrients. Municipalities in North America have increasingly targeted 
treated municipal wastewater effluent (MWWE) since the 1970s to protect public health. 
They are typically required to achieve some level of disinfection before discharging the 
MWWE to receiving water bodies. The regulatory limit varies with jurisdiction as well as 
sensitivity of the receiving bodies. A disinfection limit of around 200 most probable 
number (MPN) of fecal coliform or Escherichia coli (E. coli) per 100 mL is common 
both in the USA and in Canada (Minnow Environmental and CCME, 2005; Black & 
Veatch, 2010). 
Historically, chlorine was used for disinfection of MWWE because of its 
effectiveness, residual properties, and low cost. However, studies in the early 1970s 
showed that free chlorine reacts with the organics to form disinfection by-products 
(DBPs) such as trihalomethanes and haloacetic acids. These DBPs could adversely affect 
public health and aquatic life because of their carcinogenic properties (Morris and 
McKay, 1975; Rice et al., 1981). Fish kills were also experienced in water bodies 
receiving municipal wastewater disinfected with chlorine (Rice, 1999). The concerns 
with adverse effects of chlorinated effluent led United States Environmental Protection 
 2 
Agency (USEPA) to promote research in alternate disinfection technologies such as 
ozonation and UV disinfection (Rice et al., 1981; Whitby and Scheible, 2004). At that 
time, both these technologies were already in use for disinfection of drinking water. The 
researchers quickly realized the advantages of using ozone for disinfection (Rice, 1999). 
However, the technology to produce ozone was not mature and reliable. This resulted in 
ozone treatment systems having high manufacturing cost, high operating and 
maintenance cost, and low reliability.  
The first full scale UV system was installed in a MWWTP in 1978 and in a 
MWWTP with gravity fed open channel in 1982 (Whitby and Scheible, 2004). The UV 
radiation technology continuously and rapidly improved, making it more reliable and cost 
effective. Hence, UV treatment became the preferred method for wastewater disinfection 
(Rice, 1999; Whitby and Scheible, 2004). 
Studies in the 1990s discovered an additional threat with MWWE due to the 
finding of trace amounts of estrogenic compounds and the possible link to the 
feminization of male fish (Folmar et al., 1996; Harries et al., 1997). Daughton and Ternes 
(1999) revealed that the active compounds in pharmaceutical and personal care products 
(PPCPs) released with municipal effluents could induce estrogenic effects. These 
discoveries have led to a significant increase in the research of occurrence, fate, transport, 
and removal of potential estrogenic compounds from water and wastewater (Snyder et al., 
2003; Ternes et al., 2004; Shon et al., 2006). Researchers have discovered many more 
chemicals and compounds in water and wastewater in concentrations that can be a cause 
of various other ecological concerns. These more recently discovered pollutants of 
concern are commonly being grouped as contaminants of emerging concern (CECs). As 
 3 
per Bhandari et al. (2009), the CECs are usually unregulated and consist of 
pharmaceutically active compounds (PhACs), personal care products (PCPs), antibiotics, 
hormones, endocrine disruptive chemicals (EDCs), plasticizers, surfactants, fire 
retardants, pesticides, herbicides, insecticides, industrial and household chemicals, and 
nanomaterials. The current knowledge base on many of these CECs in low concentrations 
does not give any indication if they pose risks to human health. However, researchers 
have shown that these micropollutants can cause reproductive abnormalities and 
feminization of fish as well as of other vertebrates such as reptiles, mammals, and birds 
(Bloetscher and Plummer, 2011). Hence, to protect the aquatic ecosystem and public 
health from probable adverse effects, it is advisable to take precautionary steps by 
limiting the release of the estrogenic compounds in the environment.  
Studies conducted in various parts of the world show the presence of CECs in 
potable water sources (Daughton and Ternes, 1999; Huber et al., 2003; Auriol et al., 
2006; Benotti et al., 2009; Tabe et al., 2009). Municipal wastewater treatment plants are 
an important point source of the CECs released in the environment and water bodies 
(Daughton and Ternes, 1999; Petrović et al., 2003). It makes logical sense to treat and 
remove the CECs from the MWWE when their concentration is higher, rather than from a 
water supply for potable water in which they have been diluted several orders of 
magnitude (Oneby et al., 2010). The conventional technologies to treat MWWE are 
efficient in removing suspended solids, organics, and nutrients. However, they are not 
effective in removing the CECs that are present in trace quantities (Ternes, 1998). Hence, 
new treatment technologies or additional treatment processes are required to remove 
these CECs, which are normally low molecular weight compounds in the size range of 
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about 150 to 500 Dalton (Snyder et al., 2003). These new treatment technologies or 
treatment processes should meet the following requirements: 
 Remove CECs to acceptable levels 
 Remove biologically active compounds 
 Provide effective disinfection 
 The disinfection by-products should have lower toxicity than the parent compounds 
 Use minimum possible resources such as energy and water 
 Require low maintenance (specially human labor) 
 Economically viable 
 Environmentally friendly 
The scientific community has been aware of the disinfection property of ozone 
since the start of the 19th century. Higher costs and operational problems related to it 
have led to the choice of UV as the preferred technology for wastewater disinfection in 
North America since the 1990s. Since then, studies have shown ozone and ozone based 
advanced oxidation processes (AOPs) to be effective in the oxidation of CECs both in 
water and wastewater matrices (Snyder et al., 2003; Ternes et al., 2003). The ozonation 
of MWWE has several other advantages such as an increase in dissolved oxygen, 
decrease in chemical oxygen demand, and improvement in aesthetic characteristics due to 
reduction in turbidity and color. Chlorination and UV radiation do not provide these 
additional benefits. In addition, due to the significant advances in the ozone 
manufacturing technology in the last couple of decades and the experience gained by 
ozone treatment of water and wastewater, ozonation is now a mature technology (Leong 
et al., 2008). The cost of ozonation is now almost at par or lower than that of UV 
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disinfection technology (Drury et al., 2006; Oneby et al., 2010). These developments 
have led to a huge surge in research related to ozone treatment of secondary and tertiary 
treated municipal wastewater the world over in recent years. While studies have 
demonstrated the potential for ozonation to transform effectively many CECs present in 
MWWE, such studies are still limited both in number and list of CECs examined. Studies 
have further shown that the effectiveness of such transformations by ozone is strongly 
dependent on the properties of the CEC and the matrix, particularly the nature and 
concentration of dissolved organic carbon. In addition, the list of CECs in the water 
environment continues to grow. Hence, there is a continued need to study the ozone and 
ozone-based advanced oxidation processes (AOPs) for different wastewater matrices and 
CEC groups to better understand and apply them for wastewater treatment. Ozone 
treatment of municipal wastewater in Canada for disinfection has been studied and is 
being considered as a special circumstance for the primary treated wastewater effluent in 
the City of Montreal. However, to the best knowledge of the author, study on disinfection 
and oxidation of CECs using ozone for treatment of the more common secondary treated 
municipal wastewater effluent has not been conducted in Canada. 
 
1.2  OBJECTIVES 
The main objective of this study was: 
 To investigate the effect of ozone treatment of secondary treated wastewater 
effluent on disinfection and the transformation of selected contaminants of 
emerging concern. 
Other objectives of the study were: 
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 Examine the effect of different ozone doses on the characteristics of the 
treated wastewater. 
 Check for the correlation of the transformation of the CECs and inactivation 
of the disinfection indicator microorganisms with easy to monitor surrogate 
parameters such as UV absorption at 254 nm (UVA) and color. 
 
1.3  SCOPE 
The scope of this project was to: 
 design and build a pilot unit keeping in view process parameters such as 
dissolution time, air-to-water flow ratio, hydraulic retention time, and length 
to diameter ratio of the contactors; 
 determine the effect of different air-to-water flow ratios on ozone transfer 
efficiency and residual ozone in water; 
 examine the effect of different transferred ozone dose, residual ozone, and 
hydraulic retention time on the level of disinfection; 
 study the reduction in the concentration of the monitored CECs at typical 
disinfection ozone dose; and 
 monitor the changes in the characteristics of the MWWE such as total organic 
carbon concentration, UV absorption at 254 nm, and color due to ozone 
treatment. 
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1.4  ORGANIZATION OF THE THESIS 
This thesis is organized into five chapters. Chapter I consists of the introduction 
and objective of this study. Chapter II consists of literature review related to the history 
of wastewater ozonation, factors effecting ozonation, disinfection by ozone and oxidation 
of the CECs. The topics included in Chapter III are details of the experimental setup and 
experiment methodology. The results and discussion are included in Chapter IV. Chapter 
V includes the conclusions of this study as well as recommendation for future study.  
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
2.1  HISTORY OF OZONATION OF MWWE 
Historically, chlorine was the choice of disinfectant for MWWE. In 1892, the 
disinfection of sewage with chlorine first occurred in Hamburg, Germany and Brewster, 
New York (Gascoigne, 1931). By 1906, disinfection of sewage by chlorination was 
established as a practical and economical process, and its application for sewage 
disinfection increased (Gascoigne, 1931). In 1911, eight sewage treatment plants in New 
York treated sewage effluent with chlorinated lime (Black & Veatch, 2010). Phelps 
(1912) has documented the use of chlorine for disinfection of sewage by several full-
scale sewage treatment plants, and its benefit for public health as well as shellfisheries. 
For comparison, in the USA the first successful commercial application of chlorine for 
water disinfection started in 1908 (Baker, 1925) and by 1912 the drinking water was 
regularly disinfected in several hundred American cities (Phelps, 1912). By 1911, 
Canadian cities - Montreal, Ottawa, and Toronto, chlorinated the drinking water (Race, 
1918). As per Baldwin (1927), laboratory scale to full scale experiments were being 
conducted in 1927 in USA, Canada, and Germany to determine all the possible and 
proper use of chlorine for sewage disinfection and disposal. Gascoigne (1931) has noted 
the use of chlorine in Toronto for improvement in performance of activated sludge 
process. The use of chlorine for disinfection of MWWE in United Sates became more 
common from 1945 (Black & Veatch, 2010).  
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Studies in the 1970s found that disinfection of MWWE with chlorine lead to the 
formation of carcinogenic disinfection by-products (Morris and McKay, 1975). This 
concern led to research in alternate disinfection technologies. Research revealed that 
ozone treatment and UV radiation were viable alternate modes for disinfection of 
MWWE (Rice, 1999; Whitby and Scheible, 2004).  
The use of ozone for MWWE disinfection started in the United States in the early 
1970s (Rice et al., 1981) and there was a gradual increase in the number of MWWTPs 
using this process. However, the change in the USEPA disinfection policy in 1976, 
higher capital cost, and operational problems lead to the gradual decline of the use of 
ozone for disinfection of MWWE (Rice, 1999). At the same time, its application in water 
treatment has continued to grow. The number of municipal wastewater plants using 
ozone peaked at around 45 in the early 1980s (Rice, 1999). Only nine MWWTPs were 
using ozone for disinfection in 2008 - 2009 (Black & Veatch, 2010; Oneby et al., 2010). 
For comparison, there were nearly 201 water treatment plants (WTPs) using ozone in the 
USA in 1997 (Rice, 1999). However, since 1990s, the concerns related to the toxic and 
mutagenic effect of CECs present in MWWE on aquatic species has renewed the interest 
in ozone treatment of MWWE for disinfection as well as transformation of CECs. 
Various full scale and pilot scale studies have been conducted (Snyder et al., 2006; Wert 
et al., 2007; Dickenson et al., 2009; Wert et al., 2009a; Gerrity et al., 2011; Lee et al., 
2012). 
As per  Larocque (1999), two Canadian MWWTPs were using ozone primarily 
for disinfection and six were using it probably for odor control. The paper does not 
provide any detail or name of these plants. Literature research did not reveal any full 
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scale MWWTP currently operating in Canada that uses ozone for final disinfection of 
MWWE. The Montreal Urban Community WWTP having capacity of 700 mgd is 
considering ozone treatment for effluent disinfection (Black & Veatch, 2010). Absi et al. 
(1993), Gehr and Nicell (1996), and Gehr et al. (2003) have conducted pilot-scale ozone 
disinfection study at this MWWTP. 
In general, the regulations in Europe do not require disinfection of MWWE (Rice 
et al., 1981; Black & Veatch, 2010). However, concerns related to CECs in MWWE have 
resulted in a surge in research and use of ozonation for the transformation of CECs in 
recent years around the globe. In Europe, full-scale MWWTPs that apply ozone mainly 
for micropollutant removal are now operational in Switzerland (Hollender et al., 2009), 
and France (Ruel et al., 2011). In Germany, three municipal wastewater treatment plants 
have full scale ozonation plants for micropollutant removal, one of which is in operation 
since 2009 (Grünebaum, 2011; Launer et al., 2012). A full-scale ozonation unit exists in 
Italy that treats effluent of a wastewater plant that receives municipal and industrial 
wastewater (Bertanza et al., 2012). Pilot scale ozonation studies are being conducted in 
Austria (Schaar et al., 2010), Germany (Bahr et al., 2005; Ried et al., 2009), and Great 
Britain (Ried et al., 2009). The results from these studies would be helpful to the 
MWWTPs exploring the possibility of upgrading to or selecting ozonation for 
disinfection of MWWE as well as micropollutant removal.  
In Japan, 65 sewage treatment plants had an ozonation process in the year 2004. 
Ten of them were constructed between 2002 and 2004 (Takahara et al., 2006). A full-
scale water reclamation plant in Australia uses ozone for disinfection of the effluent. It 
receives tertiary treated effluent from a WWTP that serves 40,000 people (van Leeuwen 
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et al., 2003; Reungoat et al., 2010). A water reclamation plant existed in South Africa in 
1978 that disinfected the effluent with ozone (van Leeuwen and Prinsloo, 1980). The 
ozone dosages used and the results obtained have varied considerably depending on the 
wastewater characteristics and the treatment objective. 
 
2.2  OZONE CHEMISTRY 
2.2.1 Properties of Ozone 
Ozone (O3) is a pale blue gas and has a pungent odor. It is generated from oxygen 
molecules. The electric discharge method is the most common method for generating 
ozone on industrial scale. The electrical discharge ionizes the oxygen molecules. The 
ionized oxygen atom then combines with molecular oxygen to form ozone. The feed gas 
to produce ozone can be air or oxygen. The concentration of ozone produced is 3 to 4% 
by weight with air as feed gas and 10 to 13.5% by weight when oxygen is the feed gas 
(Gottschalk et al., 2000). 
Ozone is one of the most powerful disinfectants having high oxidation potential of 
2.07 eV (Alvares et al., 2001). It is highly unstable and hence produced on site prior to 
use. Ozone is more than 10 times as soluble as oxygen, however only a few mg/L ozone 
dissolves in water in actual operating conditions due to its low partial pressure (Sawyer, 
1976). The solubility of ozone in water or wastewater is an important property as the 
disinfection and oxidation of the micropollutants depend on the amount of ozone 
transferred. The solubility of ozone in water or wastewater can be calculated using 
Henry’s law (USEPA, 1986b; Metcalf & Eddy et al., 2002): 
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s
g
u
C
C
H          (2.1) 
Hu Henry’s law constant, unitless  (Hu for ozone = 3.97 at 20 
o
C) 
Cg concentration of ozone in gas phase, mg/L 
Cs saturation concentration of ozone in liquid, mg/L 
 
Equation 2.1 shows that the solubility of ozone in water increases with an increase 
in the concentration of ozone in the gas that is bubbled through the water. 
 
2.2.2 Oxidation pathways 
As per Hoigné and Bader (1976), ozone can oxidize and transform a substrate (S) 
by the direct or indirect pathway. Figure 2.1 shows the two pathways. The ozone 
molecule reacts directly with the substrate to form product in the direct pathway. In the 
indirect pathway, ozone reacts with hydroxide ions (OH‾) or radicals (R•) and 
decomposes to form oxidants such as hydroxyl radical (OH•) which then reacts with the 
substrate (S). While the oxidation potential of molecular ozone is 2.07 eV, that of OH• 
formed is 2.8 eV (Alvares et al., 2001). The oxidation pathway that will dictate the 
transformation will depend on the reaction rate of ozone and the substrate, and the 
reaction products that may promote or inhibit ozone decomposition (S’).  
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Figure 2.1 Oxidation of substrate during ozonation of water and wastewater 
 (Adapted from Hoigné and Bader, 1976) 
 
The direct reaction of ozone is highly selective and slow. The second-order 
reaction rate constant of ozone with organics and inorganics in water is in the range of 
<1 to 10
9 
M
-1
 s
-1
, but most of the rate constants are in the order of 1 to 10
3
 M
-1
 s
-1
 (Hoigné 
and Bader, 1983a; b; Hoigné et al., 1985). Compounds that have reaction rate with ozone 
<< 10
3
 M
-1
 s
-1
 can be considered as “ozone refractory” and react slowly with ozone 
(Nöthe et al., 2009). The second-order reaction rate constant of E. coli with ozone is 
130 l/(mg.s), i.e.  6.24 x 10
6
 M
-1
 s
-1 
(Hunt and Mariñas, 1997).  
In comparison with molecular ozone, hydroxyl radical is less selective and its 
diffusion rate controls its reaction rate with solutes such as aromatic hydrocarbons, 
unsaturated compounds, aliphatic alcohols, and formic acid (Hoigné and Bader, 1976). 
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The second-order reaction rate constants of hydroxyl radical with these solutes are in the 
range of 10
7
 to 10
10
 M
-1
 s
-1
 (Hoigné and Bader, 1976; Glaze and Kang, 1989; von Gunten 
and Ramseier, 2010). With carbonates and bicarbonates, their reaction rate constant is 
2 - 3.9 x 10
8
 M
-1
 s
-1
 and 0.85 - 1.5 x 10
7
 M
-1
 s
-1
 (Hoigné and Bader, 1976; Buxton et al., 
1988). Due to such high rate constants, they are scavenged quickly (Hoigné and Bader, 
1976) and their lifetime is in the range of 10
-3
 to 10
-7
 seconds (Dhar, 1934; Hoigné and 
Bader, 1983a; b; Buxton et al., 1988). In addition, the concentration of hydroxyl radicals 
in water is less than 10
-12
 M (Elovitz and von Gunten, 1999; von Gunten, 2003a).  
 
2.2.3 Factors affecting oxidation efficacy with ozone 
The main factors affecting the stability of ozone are the water or wastewater 
characteristics such as pH, alkalinity, and the organic matter content (von Gunten, 
2003a). The effects of each of these parameters are discussed in the following sections. 
 
2.2.3.1  Alkalinity 
Carbonate and bicarbonate ions act as hydroxyl radical scavengers (Hoigné and 
Bader, 1976). The hydroxyl radicals are a part of the chain reaction that results in 
decomposition of ozone (Figure 2.1). Hence, the decomposition rate of ozone molecules 
decreases with an increase in the carbonates and bicarbonates. In addition, they compete 
with organics and other micropollutants for hydroxyl radicals and hence protect them 
from oxidation (Hoigné, 1994). The reaction rate of hydroxyl radicals with bicarbonates 
 3HCO  is 0.85 - 1.5 x 107 M-1 s-1 (Buxton and Elliot, 1986; Glaze and Kang, 1989), and 
with carbonates  23CO  is 2 - 4.2 x 108 M-1 s-1 (Hoigné and Bader, 1976; Glaze and 
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Kang, 1989). Even with this high reaction rate, Nöthe et al. (2009) found the hydroxyl 
radical scavenging capacity of the bicarbonates in MWWE to be only around 10% of that 
of the DOC.  
 
2.2.3.2  Dissolved Organic Matter  
The dissolved organic matter (DOM) reacts directly with ozone and decreases its 
stability or it reacts with the hydroxyl radicals, which in turn affect the ozone stability. 
Ozone reacts directly mostly with aromatic compounds, amines, and sulfides. If DOM 
reacts with hydroxyl radicals, it can scavenge it and increase the ozone stability, or it can 
form superoxide radicals that react with ozone to form hydroxyl radicals. This chain 
reaction can decrease the ozone stability (von Gunten, 2003a). The DOM scavenges 
ozone and hydroxyl radicals and shields the micropollutants (Hoigné, 1994) and 
microorganisms from oxidation. Hence, it reduces the oxidation efficacy. The reaction 
rate of organic matter with hydroxyl radicals is in the order of 10
4
 (mg C/L)
-1
 s
-1 
(Elovitz 
and von Gunten, 1999; Reisz et al., 2003; Nöthe et al., 2009) to 10
8
 (mg C/L)
-1
 s
-1
 
(Westerhoff et al., 1999). Rosario-Ortiz et al. (2008) have reported this rate constant to be 
in the range of 0.27 to 1.21 x 10
9
 Mc
-1
 s
-1
 (where Mc is the molarity of NOM present and 
is calculated assuming 12 g C per mole C). Dong et al. (2010) have shown that the 
effluent organic matter with smaller apparent molecular weight have higher reactivity 
with hydroxyl radicals. The reactivity of <1 kDa fraction organic matter with hydroxyl 
radical was approximately 2.31 times higher than that of corresponding bulk organic 
matter. 
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2.2.3.3  Temperature 
The reaction rate of ozone with organic as well as inorganic compound increases 
with increase in temperature (Hoigné and Bader, 1983a). The reaction rate constant as per 
the Arrhenius equation is as follows (Gottschalk et al., 2000): 
RT
Ea
eAk

          (2.2) 
 k reaction rate constant 
 A frequency factor or pre-exponential factor 
 e mathematical quantity, 2.71828 
 Ea activation energy, J mol
-1
 
 R ideal gas law constant, 8.314 J mol
-1
 K
-1
  
 T temperature, K 
 
Activation energy required for reaction of most of the compounds with ozone is 
35 to 50 kJ mol
-1
 (Hoigné and Bader, 1983a). The frequency factor can be considered 
constant across a small temperature range. Considering the above and from Equation 2.2, 
an increase in temperature by 10 
o
C will increase the reaction rate by a factor close to 
two. 
The temperature also affects the ozone exposure. Ozone exposure is commonly 
known as CT value, i.e. product of residual ozone concentration and the time of exposure 
of a compound or microorganism to ozone. The ozone depletion rate increases with 
increase in temperature. Hence, the ozone exposure decreases substantially but the 
hydroxyl radical exposure remains unchanged (Elovitz et al., 2000).  
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The temperature affects the solubility of ozone in water. The solubility of ozone 
in water decreases with increase in water temperature (Sotelo et al., 1989). The empirical 
formula of solubility of ozone in water as given by Morris (1988) is: 
Log
10
S   =   - 0.25   -   0.013 T      (2.3) 
S aqueous solubility of ozone (mg per liter in water/mg per liter in gas) 
T temperature of water, 
o
C 
 
2.2.3.4  pH 
Ozone reacts with substrates directly or indirectly by decomposing to hydroxyl 
radicals that then react with the substrate. However, the indirect mode of reaction is 
predominant above a critical pH value (Hoigné and Bader, 1976). Studies have shown 
that hydroxide ions initiate the decomposition of ozone (Tomiyasu et al., 1985; von 
Gunten, 2003a). The following are the initiation reaction as per von Gunten (2003a): 
11
223 sM70kOHOOHO
 
    (2.4) 
116
2223 sM10x2.8kOOOHHOO
    (2.5) 
 
Since, at lower pH the hydroxide ions are less in water solution, decreasing the 
pH of the solution will result in a lower rate of decomposition of ozone (Hoigné and 
Bader, 1983a). The dissolved ozone concentration decreases with increase in pH (Sotelo 
et al., 1989). 
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2.2.3.5  Other factors 
The turbidity of water and the concentration of the following compounds in water 
can also affect the oxidation efficiency with ozone: nitrites, iron, manganese, chloride 
ion, bromide ion, and ammonia (Hoigné, 1994). 
 
2.3  DISINFECTION OF MWWE BY OZONE 
2.3.1 MWWE disinfection standards 
Disinfection of MWWE is not required unless the receiving water body is used 
for (a) a drinking water intake source (b) cultivation of shell fish or aquaculture, or (c) 
recreation use resulting is human contact (Rice, 1999). For the protection of public 
health, disinfection of MWWE before discharge to receiving bodies is important 
(Chambers et al., 1997). Municipalities in North America are typically required to 
achieve some level of disinfection, but the regulatory limit varies with jurisdiction or 
sensitivity of the receiving bodies. In the Ontario province of Canada, as per the Ontario 
Water Resources Act (Section 17 and 24 – R.S.O. 1980), unless specifically exempted by 
the Guidelines, all municipal, institutional, and private communal sewage works that 
discharge their effluent to surface water are required to disinfect the effluent (Ontario 
MOE, 2001). A disinfection limit of around 200 MPN/100 mL or less of fecal coliform or 
E. coli is common both in the USA and in Canada (Minnow Environmental and CCME, 
2005; Black & Veatch, 2010). In Ontario, as per the regulations the monthly geometric 
mean density of E. coli should not exceed 200 MPN per 100 mL (Ontario MOE, 2008). 
Total coliform, fecal coliform and E. coli are the most common microorganisms 
monitored to determine the effectiveness of disinfection treatment. The method for 
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enumeration of fecal coliform may overestimate the true fecal level in water due to the 
interference from non-fecal coliforms (Elmund et al., 1999). The fecal coliform has been 
the preferred disinfection indicator in North America only because of the simple method 
required for its enumeration (Dufour, 1977). The E. coli accounts for more than 90% of 
coliform species in human feces (Dufour, 1977; Rice et al., 1990), and is a better 
indicator of disinfection than fecal coliform (USEPA, 1986a; Rice et al., 1990; Elmund et 
al., 1999).  
 
2.3.2 Pathways of inactivation of microorganism with ozone 
Theoretically, the inactivation of microorganisms by ozone can occur through the 
direct as well as the indirect pathway. The microorganisms are inactivated by attack of 
molecular ozone in the direct pathway and by the hydroxyl radicals formed on 
decomposition of molecular ozone in the indirect pathway. There is no clear agreement 
among the researchers on the predominant mode responsible for the inactivation of 
disinfection indicator microorganism E. coli. As per Hoigné and Bader (1976), the 
inactivation is mainly due to the direct attack of ozone. They hypothesize that the 
dissolved species in water react quickly with hydroxyl radicals and scavenge them before 
the radicals can react with dispersed particles such as microorganisms. Hunt and Mariñas 
(1997) studied the inactivation of E. coli with ozone. They conducted ozonation 
experiments with and without radical scavengers in water. They concluded that dissolved 
ozone, i.e. direct attack by ozone, was primarily responsible for E. coli inactivation. von 
Gunten (2003b) estimated the reaction rate constant of hydroxyl radicals for inactivation 
of microorganisms from the kinetic data. They found that for hydroxyl radicals to be the 
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main mode of disinfection, the rate constant has to be a minimum of 10 times their 
typical rate constant. In addition, they observed that the cell wall of the microorganism 
would probably scavenge the hydroxyl radical before it can attack the DNA and cause 
inactivation of the microorganism. They concluded that hydroxyl radicals do not have a 
major effect on disinfection. However, as per Dahi (1976), the free radicals formed on 
decomposition of ozone are mainly responsible for disinfection. He hypothesized 
establishment of free radical activity at the end of initial ozone demand phase that causes 
rapid inactivation of the microorganisms. The results and hypothesis by Bancroft et al. 
(1984) also support the hydroxyl radical mediated mechanism as the primary mode of 
disinfection. 
The experimental results in recent literature show that direct attack by ozone is 
mainly responsible for inactivation of microorganisms. Wolfe et al. (1989), and Can and 
Çakir (2010) have conducted ozone based advanced oxidation process (AOP) 
experiments by adding hydrogen peroxide (H2O2) to ozone. They observed a decrease in 
disinfection efficiency with an increase in hydrogen peroxide to ozone ratio. The residual 
ozone concentration decreases with an increase in hydrogen peroxide to ozone ratio. 
Hence, the decrease in disinfection efficiency in the AOP can be due to the decrease in 
the residual ozone concentration, and this can indicate that the direct attack by ozone is 
the predominant mode of disinfection. Finch et al. (1992) have also reported results of a 
study on disinfection of E. coli with ozone and peroxone. They observed that the rapid 
decomposition of ozone to form hydroxyl radicals did not increase the disinfection 
effectiveness. The presence of residual ozone improved inactivation of E. coli. Their 
results also indicate that E. coli inactivation is primarily through direct pathway.  
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Researchers have attempted to study the change in the E. coli structure after their 
inactivation by ozone. As per Finch and Smith (1987), ozone acts on the cell membrane 
and changes the permeability of the cell that results in the transfer of the contents of the 
cell into surrounding aqueous environment and inactivation. Cho et al. (2010) have 
shown that ozone inactivates the E. coli by causing damage to its cell surface. Ozone 
reacts with the cell wall, changes the permeability, and reacts with the cell wall 
components to destroy them. However, Hunt and Mariñas (1999) did not notice any 
notable change in the structure of E. coli at the ozone dose that resulted in approximately 
99.999% inactivation. They did observe change in structure of E. coli and subsequent 
lysis of the cells with an increase in the ozone dose.  
 
2.3.3 Kinetics of disinfection with ozone 
Conventionally, the Chick-Watson equation used to calculate the disinfection 
kinetics is (Haas and Karra, 1984; Metcalf & Eddy et al., 2002): 
tck
N
N
ln n
O








        (2.6)
 
No Number of microorganisms at time 0 
N Number of microorganisms at time t 
k Die-off constant, empirical constant 
c Concentration of the disinfectant 
n Coefficient of dilution, empirical constant 
t Contact time 
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In the above equation, the term c
n 
t relates to the exposure of disinfectant. 
Replacing this exposure term with ozone and hydroxyl radical exposure, the modified 
equation becomes: 
    






dtOHkdtOk
N
N
ln OH3O3
O     (2.7)
 
O3k  Second-order reaction rate constant for inactivation of microorganism with ozone 
OHk   Second-order reaction rate constant for inactivation of microorganism with 
hydroxyl radical 
 3O   Concentration of ozone 
 OH   Concentration of hydroxyl radical 
 
It is difficult to measure directly the concentration of hydroxyl radical. Elovitz 
and von Gunten (1999) measured their concentration indirectly by calculating the ratio of 
hydroxyl radical exposure and ozone exposure. They have termed this ratio as CTR  value, 
i.e.     dtOdtOHR 3CT . The CTR  value is calculated from the measured 
transformation of a compound having low reactivity with ozone (< 1 M
-1
 s
-1
) and high 
reactivity with hydroxyl radicals (> 10
9
 M
-1
 s
-1
). Substituting this value in Equation 2.7, it 
transforms to: 
 






dtO)Rk(k
N
N
ln 3CTOHO3
O
         (2.8) 
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The above equation includes the ozone exposure and OH radical exposure, as well 
as the second-order reaction rate constants of the microorganism with ozone and 
hydroxyl radical. 
If it is assumed that hydroxyl radicals do not play a major role in disinfection, 
then Equation 2.8 is reduced to: 
 






dtOk
N
N
ln 3O3
O       (2.9)
 
 
2.3.4 Factors affecting disinfection of MWWE with ozone 
2.3.4.1  Transferred ozone dose 
The transferred ozone dose (TOD) is the mass of the applied ozone dose that 
dissolves in the MWWE (i.e. product of applied ozone dose and ozone transfer 
efficiency). It is the most important parameter that affects ozone treatment (Paraskeva et 
al., 1998). The MWWE characteristics and the disinfection target dictate the TOD 
required. As per USEPA (1986b), good quality secondary or tertiary treated effluent 
require 4 to 10 mg/L of TOD to achieve the disinfection criterion of 200 fecal coliform 
MPN per 100 mL (approximately equal to 126 cfu E. coli per 100 mL as per Black & 
Veatch (2010)). However, TOD of 15 to 42 mg/L may be required to meet California’s 
stringent Title 22 standard of 2.2 total coliform per 100 mL. For practical disinfection 
applications, Gehr et al. (2003) consider an ozone dose up to 20 mg/L reasonable. In 
Japan, the typical dose for disinfection of MWWE is usually between 2 and 5 mg/L 
(Hashimoto et al., 2006). 
 24 
Researchers have reported the all-or-none effect of ozone on microorganisms. 
They have noted measurable disinfection only beyond a threshold dose of ozone 
(Bancroft et al., 1984). USEPA (1986b) defines this ozone dose as the initial ozone 
demand (IOD). It is difficult to determine the IOD of MWWE experimentally. However, 
it is possible to get an estimate of this value from the dose-response curve as suggested 
by USEPA (1986b). The IOD has a great impact on the effectiveness of disinfection by 
ozone (USEPA, 1986b).  
Studies have reported the presence of residual ozone in MWWE only beyond a 
certain ozone dose. Xu et al. (2002) have referred to this dose as the immediate ozone 
demand (ImOD) of the MWWE, and have defined it as the minimum ozone dose required 
to obtain measurable residual ozone. Researchers have reported inactivation of 
microorganisms even in the absence of residual ozone in effluent (Paraskeva et al., 1999; 
Xu et al., 2002; Gehr et al., 2003). Xu et al. (2002) have observed up to 3-log reduction 
of fecal coliform at residual ozone concentration less than measureable level. Figure 2.2 
shows the effect of TOD on measureable disinfection and residual ozone. 
 
 
Figure 2.2 Effect of TOD on disinfection and residual ozone in reference to ozone demand 
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As shown in Figure 2.2, the total transferred ozone dose can be hypothetically 
divided into three zones: (a) TOD less than initial ozone demand, (b) TOD more than 
initial ozone demand but less than immediate ozone demand, and (c) TOD more than 
immediate ozone demand. In the first zone, when the TOD is less than the initial ozone 
demand, researchers have observed that there is no measurable inactivation of the 
microorganisms. It is possible that in this zone, the compounds in the MWWE matrix 
with higher second-order reaction rate constants (with oxidants) than that of the 
microorganisms react with and scavenge the oxidants. This shielding of microorganisms 
leads to their negligible inactivation that is difficult to measure.  
The second zone relates to the ozone dose at which the TOD is more than the 
initial ozone demand but less than the immediate ozone demand. In this zone, the 
oxidants first react with compounds with comparatively higher reaction rates than the 
disinfection indicator microorganisms. The oxidants remaining then react with the 
microorganisms and compounds that have similar reaction rates. This results in 
measurable inactivation of the microorganisms. The rate of disinfection will depend on 
the characteristics of the MWWE. The rate of reaction between the oxidants and reactants 
such as the microorganisms and the compounds, would still be in the magnitude of 10
4
 to 
10
6
 M
-1
 s
-1
, resulting in the oxidants being consumed quickly. Hence, there is measurable 
disinfection but not measurable residual ozone in the effluent in this zone.  
In the third zone, the TOD is more than the immediate ozone demand and the 
ozone demand of the effluent is significantly less. Hence, an increase in ozone dose will 
result in an increase in the residual ozone concentration. If considerable disinfection has 
already occurred before fulfillment of the immediate ozone demand, then with an 
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increase in ozone dose the inactivation of microorganism may increase, however the rate 
of disinfection would be lower. 
 
2.3.4.2  MWWE characteristics 
The quality and the quantity of organic matter present in the MWWE can have a 
great impact on the efficacy of disinfection by ozone. In this context, organic matter 
includes natural organic matter (NOM), dissolved organic matter (DOM), dissolved 
organic carbon (DOC), and total organic carbon (TOC). 
 Bancroft et al. (1984) have proposed that in water above pH 6.5, disinfection 
with ozone might include the following steps: 
Ozone mass transfer; O3 (g)  O3 (aq)     (2.10) 
Ozone decomposition; O3 (aq)  Oxidants  (including OH•)  (2.11) 
Competitive reactions:  (a) Oxidants + TOC  products  (2.12 a) 
   (b) Oxidants + bacteria  disinfection (2.12 b) 
 
The mass transfer step is the slowest and rate limiting in the above reactions as 
per Bancroft et al. (1984). They indicate that in the presence of high organic load, the 
reaction between TOC and the oxidants get preference and the microorganism 
inactivation is lower. Hence, a larger ozone dose is required to meet the ozone demand of 
the organics as well as to achieve disinfection. Organic carbon in MWWE thus negatively 
affects the disinfection ability of ozone (Sawyer, 1976; Bancroft et al., 1984). The 
refractory materials that are present in the effluent can contain carbon-carbon double 
bonds and increase the ozone demand of effluent (Nebel et al., 1973). Drury et al. (2006) 
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noted in their experiments that most of the ozone demand was due to total organic 
carbon. Inorganics and suspended solids can also exert ozone demand (Gehr et al., 2003). 
Finch and Smith (1989) have observed that the secondary treated effluent required 960 
times more ozone than the ozone demand-free water for 99.99% inactivation of E. coli. In 
their experiment, the effluent had initial ozone demand of 1 mg/L. Even after this initial 
demand was fulfilled and disinfection was apparently favoured, they observed competing 
reactions for ozone. They concluded that the effectiveness of disinfection at a given TOD 
would also depend on the characteristics of the competing compounds present in the 
effluent. The concentration and composition of dissolved organic carbon can also affect 
the rate of decomposition of aqueous ozone (Buffle et al., 2006a), which can in turn 
affect disinfection. 
The microorganisms can also be shielded by the organic matter or flocs from 
direct attack of oxidants and the low residual ozone concentration may not be sufficient 
to cause their inactivation (Xu et al., 2002; Huber et al., 2005). Based on their 
hydrophobicity characteristics, 30 to 85% of the E. coli strains in activated sludge liquor 
may bind to the sludge flocs (Zita and Hermansson, 1997). 
Besides the organic matter, other effluent characteristics such as temperature, pH, 
and alkalinity can affect the reaction rate and the decomposition rate of ozone. Hence, 
they can affect the disinfection efficacy. A later section in this chapter discusses in detail 
their effects on the stability of ozone. 
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2.3.4.3  Hydraulic retention time 
Studies have been made on the effect of hydraulic retention time (HRT) in the 
ozone dissolution chamber on disinfection. Nebel et al. (1973) observed that disinfection 
occurred within 3 to 8 seconds of contact time. Liberti et al. (2000) observed that the 
mass of the inactivation of microorganism occurred within the initial 6 seconds of contact 
time with a sharp initial inactivation rate. They did not observe an increase in 
microorganism inactivation after 5 minutes of contact time. Xu et al. (2002) found that 
the HRT of the dissolution chamber did not have a major impact on the inactivation of 
E. coli and fecal coliform. In their experiments, the inactivation of microorganism was 
identical with dissolution chambers having 2 and 10 minutes of HRT. Ried et al. (2009) 
have reported similar disinfection levels with 10 to 30 minutes HRT in the contact 
column. 
As the HRT in the dissolution chamber does not have a major effect on the 
disinfection, the volume of the dissolution chamber should be just sufficient for efficient 
ozone transfer from gaseous phase to the aqueous phase. An increase in the ozonation 
rate (product of feed gas flow rate and concentration of ozone in the feed gas) results in a 
higher ozone mass transfer (Paraskeva et al., 1998). For similar TOD, this will result in a 
decrease in feed gas consumption as well as the size of dissolution chamber. Ried et al. 
(2009) also suggest ozonation with low feed gas flow rate and high ozone concentration 
for economic reasons. 
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2.3.5 Monitoring and control of disinfection by ozone 
Ozone dissipates quickly in the effluent and does not leave a residual for long 
(Sawyer, 1976). Since a typical ozone dose for disinfection of MWWE may not produce 
a measurable residual ozone in the MWWE, studies have attempted to correlate 
disinfection with surrogate parameters. Absi et al. (1993) have reported that disinfection 
efficiency cannot be predicted by monitoring parameters such as BOD, COD, TOC, pH, 
oxidation-reduction potential (ORP), ozone dose, suspended solids and turbidity. Buffle 
et al. (2006a) have observed a weak correlation between TOD and ozone exposure since 
the ozone exposure varied by a factor of more than two at the same TOD. Hence, they do 
not recommend TOD as a surrogate parameter to predict disinfection or oxidation of 
micropollutants. Venosa and Meckes (1983) and Rakness et al. (1984) have proposed the 
use of concentration of ozone in the off-gas for process control of disinfection because of 
ease in continuous monitoring and quick feedback in case of change in the effluent 
characteristic and flow-rate. Residual ozone in the liquid or in the off-gas (vent gas) is 
currently used as a technical control parameter in ozone treatment (Bahr et al., 2007). 
Since, the rate of reaction between disinfection indicator microorganisms and 
oxidants is fast, residual ozone can indicate attainment of a certain degree of inactivation 
of microorganisms. It implies fulfillment of the immediate ozone demand of the MWWE 
and the availability of oxidants to react with microorganisms. While residual ozone in the 
effluent leaving the dissolution chamber as well as the first contact chamber can be used 
as a surrogate parameter for monitoring disinfection, the residual at the outlet of the first 
contact chamber is a better indicator. Residual ozone of 0.2 to 1 mg/L can indicate 
fulfillment of disinfection criterion of 100 MPN E. coli per 100 mL (Paraskeva et al., 
1998). As discussed earlier, a typical ozone dose for disinfection may not produce 
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residual ozone in the MWWE. Paraskeva et al. (1998) observed that the residual ozone 
concentration was less than the detectable level within 20 to 120 seconds of contact time 
at the disinfection ozone dose of around 5 mg/L.  Buffle et al. (2006a) also observed that 
the TOD of 1.5, 2, and 2.5 mg/L failed to produce residual ozone after 20 seconds of 
contact time. Hence, an ozone dose higher than that typically required for disinfection is 
required to produce residual ozone in the MWWE. 
 Bahr et al. (2007) envisaged that it is difficult to measure and hence use as a 
process control parameter the concentration of ozone in the vent gas and MWWE when 
the TOD is low. They observed strong correlation between inactivation of 
microorganisms and reduction in UV absorption at 254 nm (UVA) of the effluent. The 
coefficient of correlation (R
2
 value) between UVA and inactivation of total coliform, and 
UVA and inactivation of fecal coliform was 0.764 and 0.572, respectively. They 
proposed the use of UVA as a process control parameter as it can be easily and 
continuously monitored. Ried et al. (2009) have confirmed the availability of instruments 
that can measure UVA of MWWE inline. 
 
2.4  OXIDATION OF CECs IN MWWE BY OZONE 
2.4.1 Background on the CECs 
The CECs consist of pharmaceutically active compounds (PhACs), personal care 
products (PCPs), antibiotics, hormones, endocrine disruptive chemicals (EDCs), 
plasticizers, surfactants, fire retardants, pesticides, herbicides, insecticides, industrial and 
household chemicals, and nanomaterials (Bhandari et al., 2009). Their presence in 
drinking source water is a major concern. While the long term effects of these CECs on 
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human health is still not clear, studies have linked them to feminization of vertebrates 
such as fish. Municipal wastewater plant effluent is a major contributor for many of these 
CECs. Earlier research has shown that ozonation is an effective method for 
transformation of these compounds in water and wastewater matrices. However, studies 
with actual wastewater matrix are limited. In addition, these studies have covered only a 
fraction of known CECs. With an ever-increasing list of emerging chemicals, there is a 
need to study their transformation with advanced oxidation processes including 
ozonation. 
 
2.4.2 Introduction of the CECs into the environment 
The use of chemicals and other compounds in everyday life in households, 
industries, animal farms, and agricultural farms, results in release of the CECs in the 
environment and water bodies. Figure 2.3 shows the origin and transportation of the 
CECs in the environment. The municipal wastewater treatment plants (MWWTPs), 
industries, and landfills are important point sources while animal and agricultural farms 
are some of the non-point sources. 
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Figure 2.3 Origin and transportation of micropollutants 
  (Adapted from Petrovic et al. 2003) 
 
PhACs and EDCs are two main groups of the CECs. The use of pharmaceuticals 
results in release of PhACs in the environment. Their main use is to treat or prevent 
diseases in the human body. Veterinary pharmaceuticals have a similar application but 
for animals. The pharmaceuticals are designed with biologically active sites and are 
supposed to be eliminated from the host body quickly (Daughton and Ternes, 1999). The 
body excretes the transformed and untransformed drugs from the body in feces and urine, 
in the form of parent compound, metabolites, or conjugates. The human body excretes up 
to 90% of some drugs in unchanged form (Table 2.1).  
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Table 2.1 Maximum excretion rate of some pharmaceuticals in unchanged form 
Category Pharmaceuticals Max Excretion rates 
(%) Unchanged 
Metabolites Reference 
Antiphlogistics Acetaminophen 2 – 3 NA MN 
Diclofenac 6–39 NA MN 
Ibuprofen 1–8 NA MN 
Indomethacin 15 ± 8 NA MN 
Ketoprofen < 10 53 - 65 IZ 
Naproxen < 1 NA MN 
Antibiotics Chloramphenicol ≤5,  5 - 10 NA MN 
 Chlortetracycline > 70 NA MN 
 Ciprofloxacin 45 – 60,  ≥70 40 - 45 MN 
 Doxycycline 41 ± 19 NA MN 
 Erythromycin 12 - 15 NA MN 
 Lincomycin 4 – 7 40 EM 
 Norfloxacin 40 - 69 NA MN 
 Oxytetracycline > 80 NA MN 
 Penicillin G 50 - 70 30 - 70 MN 
 Roxithromycin 74 NA PU 
 Sulfadiazine sodium 50 22 AD 
 Sulfadimethoxine 7 86 WS 
 Sulfamethazine 20 - 89  PL 
 Sulfamethoxazole 10 - 30 55 - 75 MN 
 Sulfathiazole 63 34 WP 
 Tetracycline 80 - 90 NA MN 
 Trimethoprim 50 - 60 NA MN 
Antiepileptic,  
Antidepressant 
Carbamazepine 1 - 2 NA MN 
Anitcoagulant Warfarin <2  AN, PL 
Lipid regulators Bezafibrate 40 - 69 NA MN 
Gemfibrozil < 2 70 MN 
Ovulation  
Inhibitors  
17-α-Ethynyl-Estradiol    23 - 59 30 - 53 MN 
Reproductive  
Hormones 
17-β-Estradiol (E2) <1 50 - 80 AN 
Progesterone 5 - 10 50 - 60 AN 
 
References: 
AD  Andreasen et al. (1978)    
AN  Anderson et al. (2002) 
EM  EMEA (1998)     
IZ  Ishizaki et al. (1980) 
MN  Various sources, refer to  Monteiro and Boxall (2010) 
PL  Pagliaro and Benet (1975)    
PU  Puri and Lassman (1987) 
WP  Williams and Parke (1964)    
WS  Williams (1971) 
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Sewage contains the PhACs and EDCs discharged from the human body in the 
solid and liquid waste, as well as the expired or unwanted drugs disposed directly into the 
sewage system (Daughton and Ternes, 1999). As per a survey in the USA, up to 35% of 
the general public flush medication down the drain (Kuspis and Krenzelok, 1996). In the 
same country, health care facilities probably dispose 250 million pounds of drugs each 
year by flushing them down the drain or throwing them in trash (Gorman, 2010). The 
municipal wastewater treatment plants (MWWTPs) treat the sewage that contains 
conventional pollutants as well as the CECs, before discharging it to receiving water 
bodies. The MWWTPs are effective in removing only the conventional pollutants and 
hence are a major point source in introducing the CECs in the aquatic ecosystem 
(Daughton and Ternes, 1999; Petrović et al., 2003; Ternes et al., 2004). 
 
2.4.3 Occurrence of PhACs in MWWE 
The use of pharmaceuticals results in release of PhACs in the environment. Some 
categories of widely used pharmaceuticals are antiphlogistics, antibiotics, antiepileptic, 
and lipid regulators. The following section discusses in detail the use and application of 
these drugs, their removal in the conventional sewage treatment process and their 
occurrence (ratio of detects to total number of samples) in the MWWE. 
2.4.3.1  Antiphlogistics 
 This group consist of analgesics, antipyretics, and anti-inflammatory agents. 
Use and consumption 
Many of the drugs in this category have high consumption rate, and some of them 
are available without prescription (Ternes, 1998). Some important antiphlogistics are 
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acetaminophen (paracetamol), diclofenac, ibuprofen, indomethacin, ketoprofen, 
naproxen, and phenazone. The main use of these drugs is as medicine for humans. 
Diclofenac and naproxen have additional application as veterinary medicine (Stumpf et 
al., 1999; Swan et al., 2006). All of the drugs have analgesic and antipyretic properties. 
Acetaminophen is the only drug in the earlier mentioned list that does not have anti-
inflammatory property. The other drugs are non-steroidal anti-inflammatory drugs 
(NSAIDs). 
Paracetamol is the other common name of acetaminophen. It is mainly used to 
treat pain and fever (Anderson et al., 2002). Diclofenac is an NSAID pharmaceutical 
prescribed to humans and livestock to reduce inflammation and to manage pain. The 
exposure of this drug to vultures, when they consume the carcasses of the cattle treated 
with diclofenac, has resulted in their death and a major decrease in their global 
population (Swan et al., 2006). Diclofenac is a more toxic drug compared to naproxen, 
ketoprofen, and ibuprofen as per Mehinto (2009). Their study has shown that continuous 
exposure to diclofenac in environmentally relevant concentrations can cause damage to 
the kidney and intestine of fish, and can disrupt key functional processes controlling 
metabolism and cell cycle. 
Acetaminophen is a widely used analgesic drug in Canada, with nearly 740 tonnes 
of this drug sold in 2001 (Metcalfe et al., 2004), which is equivalent to 24.7 g per capita 
per annum consumption. It is a popular analgesic in the United States (Sedlak and 
Pinkston, 2001). Table 2.2 compiles the data related to consumption of some of the drugs 
of the antiphlogistics group of several studies. Acetaminophen is widely used in France 
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and UK and its consumption is more than 3300 tonne/yr, which is approximately equal to 
50 g per capita per annum. 
 Zhang et al. (2008) have estimated the worldwide consumption of diclofenac to 
be 940 tonnes in 2008. In Canada, the sale of this drug in 2001 was approximately 3.5 
tonnes (Metcalfe et al., 2004).  
Ibuprofen is a NSAID that is available without prescription in Canada (Lévesque 
et al., 2005). The sale of this drug in Canada in the year 2001 was 176 tonnes (Metcalfe 
et al., 2004). As per Table 2.2, the sale of ibuprofen in France, Germany, Spain, and UK 
exceeds 200 tonne/yr. High consumption can indicate high occurrence and concentration 
in raw sewage. The occurrence and concentration in MWWE will depend on the removal 
of the compound in the MWWTP. 
The literature research did not reveal data related to consumption of ketoprofen in 
Canada. If per capita consumption of this drug in other countries may give any indication, 
Sadezky et al. (2008) have reported 0.018 and 0.025 g per capita per annum consumption 
of this drug in Germany and UK. They also report 0.337 and 0.366 g per capita per 
annum consumption of this drug in France and Poland, which translates into a total 
consumption of 22 and 13 t/yr, respectively. As per Table 2.2, the annual consumption of 
this drug in most of the other listed countries was below 2 tonnes. 
Naproxen is a widely used NSAID in Canada. Its consumption in Canada in year 
2001 was 25 tonnes as per Metcalfe et al. (2004). From data in Table 2.2, the annual 
consumption of naproxen in European countries such as France, UK, Spain, and Poland 
exceeds 30 tonnes each. The annual consumption in Australia was nearly 24 tonnes in 
2004. 
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Table 2.2 Consumption of antiphlogistics in various countries 
Compound Country Year Sale 
(tonne/yr) 
Reference 
Acetaminophen  
(Paracetamol) 
Canada 2001 740 Metcalfe et al. (2004) 
France 2004 3303 Besse et al (2008) 
France 1999-2006 2799 Sadezky et al (2008) 
Germany 1999-2006 367 Sadezky et al (2008) 
 Norway 2006 185 Grung et al. (2008) 
 Poland 1999-2006 186 Sadezky et al (2008) 
 Spain 1999-2006 147 Sadezky et al (2008) 
 UK 1999-2006 821 Sadezky et al (2008) 
 UK 2004 3535 Monteiro et al (2010) 
 Australia 1998 296 Khan et al (2004) 
Diclofenac Canada 2001 3.5 Metcalfe (2004) 
 Austria 1997 6 Zhang et al (2008) 
 Finland 2005 1.07 Vieno et al. (2007) 
 France 2004 9.9 Besse et al (2008) 
 France 1999-2006 9.90 Sadezky et al (2008) 
 Germany 1999 82 Zhang et al (2008) 
 Germany 1999-2006 72.7 Sadezky et al (2008) 
 Norway 2006 1.3 Grung et al. (2008) 
 Poland 1999-2006 19. 5 Sadezky et al (2008) 
 Spain 2003 32.3 Monteiro et al (2010) 
 Spain 1999-2006 2.42 Sadezky et al (2008) 
 Switzerland 2004 3.9 Tauxe-Wuersch et al (2005) 
 UK 2000 26 Zhang et al (2008) 
 UK 2004 35.4 Monteiro et al (2010) 
 UK 1999-2006 28.2 Sadezky et al (2008) 
 Australia 1998 4.4 Khan et al (2004) 
 China 2005 328 Sui et al. (2010) 
 Worldwide  2008 940 Zhang et al (2008) 
Ibuprofen Canada 2001 176 Metcalfe (2004) 
 Finland 2005 94 Vieno et al. (2007) 
 France  2004 240 Besse et al (2008) 
 France 1999-2006 203 Sadezky et al (2008) 
 Germany 1999-2006 261 Sadezky et al (2008) 
 Norway 2006 29 Grung et al. (2008) 
 Poland 1999-2006 193 Sadezky et al (2008) 
 Spain  2003 276 Monteiro et al (2010) 
 Spain 1999-2006 108 Sadezky et al (2008) 
 Switzerland 2004 18 Tauxe-Wuersch et al (2005) 
 UK  2004 330 Monteiro et al (2010) 
 UK 1999-2006 149 Sadezky et al (2008) 
 Australia  1998 14.2 Khan et al (2004) 
 Japan 2002 99 Nakada et al. (2006) 
     
     
     
 Table 2.2 continued (Consumption of antiphlogistics in various countries) 
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Compound Country Year Sale 
(tonne/yr) 
Reference 
Indomethacin Canada 2001 0.86 Metcalfe (2004) 
 Germany 1999-2006 3.40 Sadezky et al (2008) 
 Poland 1999-2006 0.855 Sadezky et al (2008) 
 UK 1999-2006 1.06 Sadezky et al (2008) 
 China 2005 277 Sui et al. (2010) 
Ketoprofen Finland 2005 11 Vieno et al. (2007) 
 France  2004 21.7 Besse et al (2008) 
 France 1999-2006 21.7 Sadezky et al (2008) 
 Germany 1999-2006 1.48 Sadezky et al (2008) 
 Poland 1999-2006 12.93 Sadezky et al (2008) 
 Spain 1999-2006 0.21 Sadezky et al (2008) 
 Switzerland 2004 0.254 Tauxe-Wuersch et al (2005) 
 UK 1999-2006 1.30 Sadezky et al (2008) 
 Australia  1998 4.4 Khan et al (2004) 
 China 2005 92 Sui et al. (2010) 
 Japan 2002 71 Nakada et al. (2006) 
Naproxen Canada 2001 25 Metcalfe (2004) 
 Finland 2005 6.05 Vieno et al. (2007) 
 France  2004 37.3 Besse et al (2008) 
 France 1999-2006 38.2 Sadezky et al (2008) 
 Germany 1999-2006 5.19 Sadezky et al (2008) 
 Poland 1999-2006 38.8 Sadezky et al (2008) 
 Spain  2003 42.6 Monteiro et al (2010) 
 Spain 1999-2006 10.6 Sadezky et al (2008) 
 UK  2004 33.6 Monteiro et al (2010) 
 UK 1999-2006 32.2 Sadezky et al (2008) 
 Australia  1998 23 Khan et al (2004) 
 Japan 2002 22-33 Nakada et al. (2006) 
 
Legends: 
UK United Kingdom 
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Abatement in conventional MWWTPs 
Conventional MWWTPs are effective in removing acetaminophen from sewage 
(Ternes, 1998; Heberer, 2002; Lee et al., 2003; Pedrouzo et al., 2011). Ternes (1998) 
have reported 98% elimination of this drug in the MWWTPs.  
 Ternes (1998) have also reported 50 to 65% reduction in the concentration of 
diclofenac in the MWWTPs. However,  Heberer (2002) found only 17% reduction in the 
concentration of diclofenac on passage through a MWWTP. They have reported it as 
difficult to degrade by conventional MWWTPs and have termed it as one of the most 
important PhACs in the water cycle. Joss et al. (2006) have reported the biological 
degradation constant of diclofenac to be low. Joss et al. (2006) and Radjenovic et al. 
(2009) have reported less than 25% reduction in its concentration after treatment of 
sewage in MWWTP. Zwiener and Frimmel (2003) also found diclofenac to be resistant to 
biodegradation. Lee et al. (2003) and Pedrouzo et al. (2011) found in their studies that 
diclofenac was not removed by the MWWTPs. Lishman et al. (2006) have observed 
negative removal of this compound. The results from various studies indicate that 
diclofenac is difficult to degrade biologically, and hence may have high occurrence in 
MWWE. 
The efficacy of removal of ibuprofen from sewage by conventional MWWTPs is 
high as per various studies. Radjenovic et al. (2009) and Lishman et al. (2006) have 
observed minimum 95% reduction in concentration of this drug after sewage treatment. 
Pedrouzo et al. (2011) have reported reduction of 80%. From the data compiled by 
Monteiro and Boxall (2010), while most studies have reported high removal of 75 to 
97%, a study has also reported low removal of 22%. Zwiener and Frimmel (2003), and 
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Joss et al. (2005) have found ibuprofen to be biodegradable in conventional MWWTPs.  
Joss et al. (2006) indicate that the biological degradation constant of ibuprofen is high 
and hence more than 90% removal of this drug during sewage treatment is possible.  
Castiglioni et al. (2006) have observed higher removal of ibuprofen in MWWTPs in 
summer compared to in winter. 
Indomethacin is not an easily biodegradable compound (Joss et al., 2006). Lee et 
al. (2003) have reported 40% transformations of this drug in the MWWTPs.  Lishman et 
al. (2006) and  Rosal et al. (2010) have reported less than 25% removal. Radjenovic et al. 
(2009) observed that the secondary treatment of sewage did not reduce the concentration 
of this compound. The findings from these studies indicate that indomethacin is resistant 
to degradation during the sewage treatment process. 
Results of various studies show low removal of ketoprofen by conventional 
sewage treatment processes. Lee et al. (2003) have observed 18% reduction of this drug. 
In a study covering 13 MWWTPs, Lishman et al. (2006) found the median removal of 
this drug to be 44%.  Radjenovic et al. (2009) have reported 55% removal of this drug in 
a conventional MWWTP. The data compiled from various sources by Monteiro and 
Boxall (2010) shows 65 to 77% removal of this drug in MWWTPs having activated 
sludge process. 
Naproxen has a low biodegradation constant and hence it is difficult to transform 
by conventional sewage treatment (Joss et al., 2006). Monteiro and Boxall (2010) have 
reported 15% removal of this drug from sewage after secondary treatment. Carballa et al. 
(2004) have found 40 to 55% reduction in the concentration of this drug after biological 
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treatment of sewage. However, Lee et al. (2003) and Lishman et al. (2006) have observed 
70% and 93% degradation of naproxen in the MWWTPs. 
 
Occurrence and concentration in MWWE 
Studies have frequently detected antiphlogistics in the MWWE in varying 
concentrations. Table 2.3 and Table 2.4 summarize pertinent data from some of the 
studies for the MWWE discharged in Canada and in other countries. 
Data in Table 2.2 shows that acetaminophen is one of the most consumed drugs in 
Canada. However, Lee et al. (2003) did not detect this drug in any of the 44 MWWE 
samples collected from nine WWTPs in Ontario. Brun et al. (2006) have reported less 
than 40% occurrence, and median concentration of 5 ng/L of acetaminophen in the 
MWWE samples collected from eight MWWTPs in Canada. However, in one sample 
they detected this drug at concentration of 9000 ng/L. The low concentration and 
occurrence may be due to high efficacy of conventional sewage treatment plants in 
removing acetaminophen from sewage. Sporadic high concentrations of 3,300 ng/L and 
6,000 ng/L have been reported by  Hope et al. (2012) and Ternes (1998). As per data in 
Table 2.4, most of the studies in other countries have reported less than 20% occurrence 
of this drug in MWWE. The only exception to this trend is the study by  Reungoat et al. 
(2012). They detected this compound in all the nine MWWE samples taken from three 
MWWTPs, in concentrations between < 5 ng/L and 154 ng/L.  
Studies have detected diclofenac in concentrations between 5 ng/L and 748 ng/L 
in the MWWE in Canada (Table 2.3). They have reported occurrence in the range of 40 
to 100%. However, Metcalfe et al. (2003a) did not detect diclofenac in any of the 
 42 
MWWE samples collected from 18 STPs located in five provinces. One of the reasons 
for this low occurrence can be the high method detection limit (MDL) of 250 ng/L of the 
compound in the study. Studies from Europe, Australia, and Asia have reported close to 
100% occurrence of diclofenac in MWWE (Table 2.4). Bahr et al. (2007) and Ternes et 
al. (2003) have reported a mean concentration of 4360 ng/L and 1300 ng/L, respectively. 
Many other studies from Europe also have found this drug in effluent in concentrations in 
excess of 1000 ng/L. Hence, the concentration of diclofenac in MWWE in Europe seems 
high. Comparison of the data in Table 2.3 and Table 2.4 shows that the occurrence and 
concentration of diclofenac in MWWE in Canada is lower than that in Europe. 
In MWWE in Canada, Metcalfe et al. (2003a) have detected ibuprofen in 
concentrations up to 24,600 ng/L. Brun et al. (2006) have also detected this drug at 
similar concentrations in the MWWE in Atlantic Canada. Metcalfe et al. (2003b), Sosiak 
et al. (2005), Comeau et al. (2008), and Crouse et al. (2012) have found this drug in 
concentrations more than 1000 ng/L and their occurrence in the range of 50 to 100%. 
However, Lishman et al. (2006) and Tabe et al. (2009) have found less than 50% 
occurrence of ibuprofen. From the drug consumption data, Sedlak and Pinkston (2001) 
have estimated the average concentration of ibuprofen in raw sewage in the United States 
to be 37,000 ng/L. Hence, high occurrence of this drug in MWWE even after its high 
removal during sewage treatment is expected. However,  Hope et al. (2012) found less 
than 5% occurrence of this drug in the MWWE of 52 MWWTPs in Oregon (USA). The 
high method detection limit of 223 ng/L of the drug can be a reason for the low 
occurrence. The concentration of the drug when detected in their samples was between 
2630 ng/L and 17000 ng/L. Conversely, Snyder et al. (2006) and Wert et al. (2009a) have 
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reported 100% occurrence but less than 90 ng/L concentration of this drug in MWWE. 
Studies from Europe, Australia, and Asia have reported high occurrence of ibuprofen in 
MWWE (Table 2.4). In Europe, Vieno (2007), Ruel et al. (2011), Ternes (1998), Muñoz 
et al. (2010) and Radjenovic et al. (2007) have detected ibuprofen in MWWE in 
concentrations more than 3000 ng/L. The data in Table 2.3 and Table 2.4 indicates that 
the concentration of ibuprofen in MWWE in Canada and in many European countries is 
higher than that in Australia, Japan, and Korea. This can indicate the consumption pattern 
of this drug in these countries. 
From Table 2.3, various studies have reported 75 to 100% occurrence of 
indomethacin in the MWWE in Canada. However, Hua et al. (2006) did not detect this 
drug in any of the 11 MWWE collected by them. Studies have found this drug in MWWE 
in Canada in concentrations in the range of 10 ng/L to 803 ng/L. In countries other than 
Canada,  Ternes (1998) has found occurrence of 100% and median concentration of 270 
ng/L of indomethacin in MWWE in Germany (Table 2.4). Stumpf et al. (1999) have 
reported a concentration of 1000 ng/L in a MWWE in Brazil. Reungoat et al. (2012) from 
Australia have reported 100% occurrence but less than 30 ng/L concentration of this drug 
in the effluent. 
 Lee et al. (2003) and Comeau et al. (2008) have reported more than 50% 
occurrence of ketoprofen in MWWE in Canada (Table 2.3). Majority of the other studies 
have reported less than 25% occurrence. Brun et al. (2006) have detected this drug in 
concentrations up to 310 ng/L. Studies from Germany, Australia, and Japan have reported 
high occurrence of ketoprofen in MWWE (Table 2.4). Ruel et al. (2011) from France 
have reported a mean concentration of 640 ng/L of this drug in the effluent.  Radjenovic 
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et al. (2007) have detected this drug in concentrations up to 1650 ng/L. Studies from 
Japan have reported concentrations up to 1400 ng/L.  
The data in Table 2.3 shows that six studies have reported close to 100% 
occurrence of naproxen in MWWE in Canada. Seven studies have reported the maximum 
concentration of the drug in MWWE in excess of 1000 ng/L. Metcalfe et al. (2003a) have 
detected this drug in the MWWE in concentrations up to 33,900 ng/L. The high 
occurrence and concentration of this drug in MWWE makes it one of the potential drugs 
that should be monitored in future in Canada. The data from Table 2.4 indicates a high 
occurrence and concentration of naproxen in MWWE in North America, Europe, 
Australia, and Asia. The concentrations reported of this drug in MWWE in United States 
are between 13 ng/L and 106 ng/L. In studies from Europe, Rosal et al. (2010), Carballa 
et al. (2004) and Radjenovic et al. (2007) have reported maximum concentrations in the 
range of 2,208 ng/L to 3,495 ng/L.  Stumpf et al. (1999) have detected this drug in 
MWWE in Brazil in concentrations up to 3000 ng/L. 
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Table 2.3 Occurrence of antiphlogistics in secondary treated MWWE in Canada 
Compound Region Det. Freq. RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD 
Acetaminophen Ontario 0/16 10     Lee et al. (2003) 
 Ontario 3/8 12.3 5 18   Tabe et al. (2009) 
 Atl Canada 6/16 10 27 9000  4471 ± 2903 Brun et al. (2006) 
Diclofenac Ontario 4/4 5 5 359   Metcalfe et al. (2003b) 
 Ontario 16/16 10 20 210   Lee et al. (2003) 
 Ontario 24/39 62  748 140 194 Lishman et al. (2006) 
 Ontario 11/11 15    538 ± 370 Hua et al. (2006) 
 Ontario 2/8 5.8 225 230   Tabe et al. (2009) 
 Alberta 2/7 ≤ 25 359 429   Sosiak et al. (2005) 
 Nova Scotia 6/7 3 25 190   Comeau et al. (2008) 
 Atl Canada 6/16 30 37 500 15 171 ± 176 Brun et al. (2006) 
 Canada 0/18 250     Metcalfe et al. (2003a) 
Ibuprofen Ontario 4/4 5-20 79 1885   Metcalfe et al. (2003b) 
 Ontario 16/16 10 40 970   Lee et al. (2003) 
 Ontario 16/39 61  773 353 384 Lishman et al. (2006) 
 Ontario 6/11 15    90 ± 47 Hua et al. (2006) 
 Ontario 3/8 6.4 157 203   Tabe et al. (2009) 
 Alberta 4/7 ≤ 25 383 1759   Sosiak et al. (2005) 
 Nova Scotia 5/5 6 140 6300   Comeau et al. (2008) 
 Nova Scotia 6/8 7 12 2200   Crouse et al. (2011) 
 Atl Canada 15/16 30 37 22000 2305 5523 ± 6795 Brun et al. (2006) 
 Canada 12/18 50 300 24600   Metcalfe et al. (2003a) 
Indomethacin Ontario 3/4 5-10 10 378   Metcalfe et al. (2003b) 
 Ontario 16/16 20 30 240   Lee et al. (2003) 
 Ontario 9/39 100  507 149 190 Lishman et al. (2006) 
 Ontario 0/11 10     Hua et al. (2006) 
 Ontario 8/8 6.4 19 46   Tabe et al. (2009) 
 Alberta 3/7 ≤ 25 105 803   Sosiak et al. (2005) 
 Nova Scotia 4/6 44 41 120   Comeau et al. (2008) 
 Atl Canada 12/16 30 35 310 54 92 ± 75 Brun et al. (2006) 
Ketoprofen Ontario 1/4 5-13  13   Metcalfe et al. (2003b) 
 Ontario 16/16 10 30 150   Lee et al. (2003) 
 Ontario 9/39 88  210 114 125 Lishman et al. (2006) 
 Ontario 5/11 150    348 ± 240 Hua et al. (2006) 
 Ontario 4/8 2.3 11 17   Tabe et al. (2009) 
 Alberta 0/7 ≤25     Sosiak et al. (2005) 
 Nova Scotia 5/7 11 18 120   Comeau et al. (2008) 
 Atl Canada 5/16 30 52 310 15 178 ± 116 Brun et al. (2006) 
 Canada 0/18 50     Metcalfe et al. (2003a) 
 Table 2.3 continued (Occurrence of antiphlogistics in secondary treated MWWE in 
Canada) 
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Compound Region Det. Freq. RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD 
Naproxen Ontario 4/4 5-20 21 524   Metcalfe et al. (2003b) 
 Ontario 16/16 10 210 1110   Lee et al. (2003) 
 Ontario 21/39 74  1189 351 452 Lishman et al. (2006) 
 Ontario 10/11 100    414 ± 246 Hua et al. (2006) 
 Ontario 8/8 2.4 126 555   Tabe et al. (2009) 
 Alberta 2/7 ≤ 25 1785 2668   Sosiak et al. (2005) 
 Nova Scotia 6/6 5 210 6900   Comeau et al. (2008) 
 Nova Scotia 8/8 41 61 2400   Crouse et al. (2011) 
 Canada 15/16 30 220 14000 1450 3483 ± 4020 Brun et al. (2006) 
 Canada 3/18 100 7200 33900   Metcalfe et al. (2003a) 
           
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
Atl Canada  Atlantic Canada 
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.4 Occurrence of antiphlogistics in secondary treated MWWE in other countries 
Compound Country Det. Freq. 
RL 
ng/L 
Concentration, ng/L 
Reference 
Min Max Median Mean ± SD 
Acetaminophen USA 1/4   46   Barber et al. (2011) 
 USA 0/12 50    < 50 Yang et al. (2011) 
 USA 2/102 223 2610 3300 2955 2955 Hope et al. (2012) 
 France NA/6 0.5-2    380 ± 170 Ruel et al. (2011) 
 Germany 4/49 500  6000 < 500  Ternes (1998) 
 Spain NA/8 5.35 48 418  207 Radjenovic et al. (2007) 
 Spain 2/13 2 9 30   Pedrouzo et al. (2011) 
 Switzerland 0/11 590     Hollender et al. (2009) 
 Australia NA/4 10 120 390 260  Reungoat et al. (2010) 
 Australia NA/16  90 580   Reungoat et al. (2011) 
 Australia 9/9  < 4.7 154   Reungoat et al. (2012) 
 Japan  43  1700   Okuda et al. (2008) 
 Korea 3/7 1 1.8 19  9.5 Kim et al. (2007) 
 Korea 2/12 5 6 9   Choi et al. (2008) 
 Korea NA/5 1.7 0 27  10 Behera et al. (2011) 
Diclofenac USA 3/3 1 54 73   Snyder et al. (2006) 
 USA 3/3  47 150 81  Wert et al. (2009) 
 USA 2/3 0.53 110 220  165 Gerrity et al. (2011) 
 USA NA/12 50 27 130  99 Yang et al. (2011) 
 Austria 5/5 20 780 1680   Clara et al. (2005b) 
 Austria 3/3 20 970 2300 2000  Schaar et al. (2010) 
 Finland 13/13 5 140 620 320 350 Vieno et al. (2007) 
 France NA/6 0.5-2    630 ± 310 Ruel et al. (2011) 
 Germany 49/49 50  2100 810  Ternes et al.(1998) 
 Germany NA/6 50    1300 ± 100 Ternes et al.(2003) 
 Germany NA/10     4360 ± 1360 Bahr et al. (2007) 
 Greece 11/11 2 10 365   Koutsouba et al. (2003) 
 Spain NA/8 40 786 1991  1241 Radjenovic et al. (2007) 
 Spain NA/17     1700 Muñoz et al (2010) 
 Spain NA/17     1500 Muñoz et al (2010) 
 Spain > 4/12 1 6 431  220 Rosal et al. (2010) 
 Spain 13/13 2 130 1032 368 418 ± 273 Pedrouzo et al. (2011) 
 Sweden NA/3 2.3    485 ± 30 Zorita et al. (2009)  
 Switzerland NA/15  500 1250   Joss et al. (2005) 
 Switzerland 11/11 50 501 1731 1096 1099 ± 323 Hollender et al. (2009) 
 Table 2.4 continued (Occurrence of antiphlogistics in secondary treated MWWE in other 
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Compound Country Det. Freq. 
RL 
ng/L 
Concentration, ng/L 
Reference 
Min Max Median Mean ± SD 
         
Diclofenac  Australia NA/4 10 140 270 200  Reungoat et al. (2010) 
(cont’d) Australia NA/16  80 290   Reungoat et al. (2011) 
 Australia 9/9  139 316   Reungoat et al. (2012) 
 China 4/4 4.7 130 260   Sui et al. (2010) 
 Korea 7/7 1 8.8 127  40 Kim et al. (2007) 
 Korea 11/11 1 7.8 26 14 14 Ryu et al. (2011)  
 Korea 5/5 0.24 13 49  24 Behera et al. (2011) 
 Brazil NA/10 50  1415 400  Stumpf et al. (1999) 
Ibuprofen USA 0/2 2.6     Boyd et al. (2003) 
 USA 3/3 1 5.6 19   Snyder et al. (2006) 
 USA 3/3  5 85 75  Wert et al. (2009) 
 USA 1/3 1  13   Gerrity et al. (2011) 
 USA 0/4 42     Barber et al. (2011) 
 USA 5/102 223 2630 17000 3350 6120 Hope et al. (2012) 
 USA NA/12 50 49 78  64 Yang et al. (2011) 
 Austria 3/5 20 20 2400   Clara et al. (2005b) 
 Austria 2/3 20 < 20 31   Schaar et al. (2010) 
 Finland 12/13 5 < 5 3910 120 650 Vieno et al. (2007) 
 France NA/6 0.5-2    2500 ± 3400 Ruel et al. (2011) 
 Germany 42/49 50  3400 370  Ternes et al.(1998) 
 Germany NA/6 50    130 ± 30 Ternes et al.(2003) 
 Germany NA/10     20 ± 10 Bahr et al. (2007) 
 Greece 0/11 1.6     Koutsouba et al. (2003) 
 Spain NA/17     4700 Muñoz et al (2010) 
 Spain NA/17     1.7 Muñoz et al (2010) 
 Spain > 4/12 4 < 4 653  135 Rosal et al. (2010) 
 Spain 9/13 7 15 955 137 261 ± 301 Pedrouzo et al. (2011) 
 Spain NA/8 20 336 6268  2559 Radjenovic et al. (2007) 
 Spain 3/3 20 910 2100 970  Carballa et al. (2004) 
 Sweden NA/3 2.7    88.5 ± 4.5 Zorita et al. (2009)  
 Switzerland NA/15  0.1 175   Joss et al. (2005) 
 Switzerland 3/11 80 56 86 80 74 ± 16 Hollender et al. (2009) 
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Compound Country Det. Freq. 
RL 
ng/L 
Concentration, ng/L 
Reference 
Min Max Median Mean ± SD 
         
Ibuprofen Australia NA/4 40 80 160 90  Reungoat et al. (2010) 
(cont’d) Australia NA/16  < 10 161   Reungoat et al. (2011) 
 Australia 8/9  < 16 88   Reungoat et al. (2012) 
 Japan 16/16 1 1.4 177 18 33 ± 44 Nakada et al. (2006) 
 Japan 4/4 0.3-21 4.3 15   Nakada et al. (2007) 
 Korea 5/7 1 10 137  65 Kim et al. (2007) 
 Korea 7/11 1 < 1 11 1.9 3.4 Ryu et al. (2011) 
 Korea 5/5 3 15 75  40 Behera et al. (2011) 
 Brazil NA/10 50  3625 600  Stumpf et al. (1999) 
Indomethacin Germany 49/49 50  600 270  Ternes et al.(1998) 
 Germany NA/6 50    100 ± 40 Ternes et al.(2003) 
 Spain NA/8 31 < RL 124  88 Radjenovic et al. (2007) 
 Australia NA/4 10 30 40 30  Reungoat et al. (2010) 
 Australia NA/16  < 10 30   Reungoat et al. (2011) 
 Australia 9/9  6 28   Reungoat et al. (2012) 
 China 4/4 1.3 70 130   Sui et al. (2010) 
 Brazil NA/10 50  1000 50  Stumpf et al. (1999) 
Ketoprofen Finland 12/13 25 < 25 1240 320 370 Vieno et al. (2007) 
 France NA/6 0.5-2    640 ± 390 Ruel et al. (2011) 
 Germany 37/49 50  380 200  Ternes et al.(1998) 
 Germany NA/10     130 ± 130 Bahr et al. (2007) 
 Spain NA/8 74 518 1650  777 Radjenovic et al. (2007) 
 Australia NA/16  < 0.2 70   Reungoat et al. (2011) 
 Australia 9/9  < 6.7 86   Reungoat et al. (2012) 
 China 0/4 5.5     Sui et al. (2010) 
 Japan 16/16 0.3 68 219 110 120 ± 46 Nakada et al. (2006) 
 Japan 4/4 0.03-15 96 299   Nakada et al. (2007) 
 Japan 12/12 43 ND 1400   Okuda et al. (2008) 
 Korea NA/5 1.65 0 37  12 Behera et al. (2011) 
 Brazil NA/10 50  656 168  Stumpf et al. (1999) 
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Compound Country Det. Freq. 
RL 
ng/L 
Concentration, ng/L 
Reference 
Min Max Median Mean ± SD 
Naproxen USA 2/2 0.4 81 106   Boyd et al. (2003) 
 USA 3/3 1 13 71   Snyder et al. (2006) 
 USA 3/3  23 51 48  Wert et al. (2009) 
 USA 3/3 0.5 52 100  72 ± 25 Gerrity et al. (2011) 
 Finland 13/13 25 170 1930 500 690 Vieno et al. (2007) 
 France NA/6 0.5-2    60 ± 30 Ruel et al. (2011) 
 Germany 10/10 50  520 300  Ternes et al.(1998) 
 Germany NA/6 50    100 ± 10 Ternes et al.(2003) 
 Germany NA/10     130 ± 80 Bahr et al. (2007) 
 Spain 3/3 20 800 2600 1850  Carballa et al. (2004) 
 Spain NA/8 20 491 3495  1682 Radjenovic et al. (2007) 
 Spain >4/12 24 359 2208  923 Rosal et al. (2010) 
 Spain 13/13 7 15 691 85 175 ± 194 Pedrouza et al. (2011) 
 Sweden NA/3 2    340 ± 15 Zorita et al. (2009) 
 Switzerland NA/15  190 600   Joss et al. (2005) 
 Switzerland 11/11 175 181 329 223 249 ± 53 Hollender et al. (2009) 
 Australia NA/4 100 240 510 290  Reungoat et al. (2010) 
 Australia NA/16  100 587   Reungoat et al. (2011) 
 Australia 9/9  83 587   Reungoat et al. (2012) 
 Japan 16/16 0.3 12 139 56 62 ± 41 Nakada et al. (2006) 
 Japan 4/4 0.24-27 33 85   Nakada et al. (2007) 
 Korea 7/7 1 20 483  128 Kim et al. (2007) 
 Korea 11/11 1 1.8 80 21 26 Ryu et al. (2011) 
 Korea 5/5 4.7 37 166  111 Behera et al. (2011) 
 Brazil NA/10 50  3000 610  Stumpf et al. (1999) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
USA United States of America 
Min  Minimum     Max  Maximum  
SD  Standard Deviation    VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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2.4.3.2  Antibiotics 
Antibiotics are compounds that can inhibit and/or destroy bacteria or single-celled 
organisms. They are used to treat bacterial infection. The main use of antibiotics is in 
human and veterinary medicines. McArdell et al. (2003) have reported that of the total 
antibiotics consumed in Switzerland in 1997, 38% was in human medicine and 62% was 
in veterinary medicine. Göbel et al. (2005a) report 5 g per person per year consumption 
of antimicrobials in Germany and Switzerland. The data regarding the consumption of 
the antibiotics in Canada and USA was not available in the published literature during 
literature research. 
The main sub-groups of antibiotics are fluoroquinolones, macrolides, penicillin, 
sulfonamides, and tetracyclines (Monteiro and Boxall, 2010). Table 2.5 compiles the data 
related to the consumption of antibiotics in other countries from various sources. The 
comparison of the data in Table 2.2 and Table 2.5 shows that the consumption of the 
antibiotics is lower by one to two orders than that of the antiphlogistics.  
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Table 2.5 Consumption of antibiotics in various countries 
Compound Country Year Sale 
(tonne/yr) 
Reference 
Fluoroquinolones    
Ciprofloxacin Finland 2005 0.85 Vieno et al. (2007) 
 France 2004 12.2 Besse et al (2008) 
 France 1999-2006 12.2 Sadezky et al (2008) 
 Germany 1999-2006 14.2 Sadezky et al (2008) 
 Norway 2006 0.885 Grung et al. (2008)  
 Poland 1999-2006 4.85 Sadezky et al (2008) 
 Spain 1999-2006 3.75 Sadezky et al (2008) 
 UK 2004 16.4 Monteiro et al (2010) 
 UK 1999-2006 6.51 Sadezky et al (2008) 
Enrofloxacin UK 2000 0.80 Sarmah et al. (2006) 
Norfloxacin Finland 2005 0.261 Vieno et al. (2007) 
 Germany 1999-2006 3.04 Sadezky et al (2008) 
 Poland 1999-2006 3.03 Sadezky et al (2008) 
 UK 1999-2006 0.393 Sadezky et al (2008) 
Macrolides     
Erythromycin Germany 1999-2006 21.12 Sadezky et al (2008) 
 Poland 1999-2006 6.37 Sadezky et al (2008) 
 Spain 2003 8.1 Monteiro et al (2010) 
 Switzerland 1999 0.22 Gobel et al (2005b)  
 UK 2004 48.7 Monteiro et al (2010) 
 UK 1999-2006 28.03 Sadezky et al (2008) 
 Australia 1998 11 Khan et al (2004) 
Lincomycin UK 2000 0.721 Sarmah et al. (2006) 
Roxithromycin France 2004 3.4 Besse et al (2008) 
 France 1999-2006 9.5 Sadezky et al (2008) 
 Germany 1999-2006 7.10 Sadezky et al (2008) 
 Poland 1999-2006 1.88 Sadezky et al (2008) 
 Switzerland 1999 0.15 Gobel et al (2005b) 
 UK 1999-2006 0 Sadezky et al (2008) 
 Australia 1998 3.75 Khan et al (2004) 
Tylosin UK 2000 5.14 Sarmah et al. (2006) 
Sulfonamides     
Sulfadiazine Germany 1999-2006 2.55 Sadezky et al (2008) 
 Switzerland 1999 0.070 Gobel et al (2005b) 
 UK 2000 14.2 Sarmah et al. (2006)* 
 UK 2004 0.362 Monteiro et al (2010) 
 UK 1999-2006 0.007 Sadezky et al (2008) 
Sulfamerazine Germany 1999-2006 0.923 Sadezky et al (2008) 
     
     
 Table 2.5 continued (Consumption of antibiotics in various countries) 
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Compound Country Year Sale 
(tonne/yr) 
Reference 
     
Sulfamethoxazole Finland 2005 0.269 Vieno et al. (2007) 
 France 2004 16.7 Besse et al (2008) 
 France 1999-2006 20 Sadezky et al (2008) 
 Germany 1999-2006 54 Sadezky et al (2008) 
 Norway 2006 0.26 Grung et al. (2008) 
 Poland 1999-2006 7 Sadezky et al (2008) 
 Spain 2003 12.7 Monteiro et al (2010) 
 Switzerland 1999 2.6 Gobel et al (2005) 
 UK 2004 3.13 Monteiro et al (2010) 
 UK 1999-2006 1 Sadezky et al (2008) 
 Australia 1998 7.3 Khan et al (2004) 
Tetracyclines     
Chlortetracycline Germany 1999-2006 0.28 Sadezky et al (2008) 
 UK 2000 6.26 Sarmah et al. (2006) 
Doxycycline France  2004 6.24 Besse et al (2008) 
 France 1999-2006 6.24 Sadezky et al (2008) 
 Germany 1999-2006 11.25 Sadezky et al (2008) 
 UK 1999-2006 1.41 Sadezky et al (2008) 
 Australia 1998 1.8 Khan et al (2004) 
Oxytetracycline Germany 1999-2006 2.03 Sadezky et al (2008) 
 UK 1999-2006 24.90 Sadezky et al (2008) 
Tetracycline Germany 1999-2006 1.40 Sadezky et al (2008) 
 Norway 2006 1.09 Grung et al. (2008) 
 Poland 1999-2006 3.26 Sadezky et al (2008) 
 UK 2004 2.1 Monteiro et al (2010) 
 UK 1999-2006 1.49 Sadezky et al (2008) 
Miscellaneous     
Chloramphenicol Germany 1999-2006 0.32 Sadezky et al (2008) 
 UK 1999-2006 0.104 Sadezky et al (2008) 
 China 2005 1929 Sui et al. (2010) 
Trimethoprim France 2004 3.35 Besse et al (2008) 
 France 1999-2006 3.35 Sadezky et al (2008) 
 Germany 1999-2006 12.1 Sadezky et al (2008) 
 Norway 2006 0.68 Grung et al. (2008) 
 Spain 2003 3.7 Monteiro et al (2010) 
 Switzerland 1999 0.52 Gobel et al (2005b) 
 UK 2004 11.2 Monteiro et al (2010) 
 UK 1999-2006 7.34 Sadezky et al (2008) 
 Australia 1998 2.7 Khan et al (2004) 
 China 2005 2352 Sui et al. (2010) 
* Sale for veterinary medicine 
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Antibiotics - Fluoroquinolones 
Use and consumption 
The fluoroquinolone class of anti-bacterial drugs can treat infections that affect 
different parts of the body as well as bacterial diarrhea and gonorrhea (Sweetman, 2009). 
Some of these drugs also have veterinary use. 
The data in Table 2.5 shows that the consumption of ciprofloxacin is three to four 
times higher than that of norfloxacin in European countries. The average consumption of 
ciprofloxacin in selected European countries is between 0.09 and 0.21 g per capita per 
annum (Sadezky et al., 2008). 
 
Abatement in conventional MWWTPs 
As per Xu et al. (2007), sorption to the sludge is the main elimination process of 
fluoroquinolones in MWWTPs. They observed 66% reduction in concentration of 
norfloxacin during the sewage treatment process. Gulkowska et al. (2008) have 
reported -16 to 78% removal of norfloxacin in secondary wastewater treatment plants.  
Ghosh et al. (2009) have observed of 75 to 95% reduction in concentration of norfloxacin 
and 60 to 83% reduction in ciprofloxacin. The reduction in concentration of enrofloxacin 
was comparatively lower, in the range of 38 to 74%.  
 
Occurrence in MWWE 
Table 2.6 contains the data regarding the occurrence data of fluoroquinolones in 
MWWE in Canada. Studies have reported occurrences of 50 to 85% for ciprofloxacin and 
norfloxacin. The reported concentration of ciprofloxacin in effluent is between 132 and 
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888 ng/L, while that of norfloxacin is in the range of 78 to 821 ng/L. Miao et al. (2004) 
and Sosiak et al. (2005) did not detect enrofloxacin in any of their sampling events. 
Table 2.7 compiles the occurrence data of fluoroquinolones in MWWE in 
countries other than Canada. The data indicates a high occurrence of ciprofloxacin in 
MMWE of most of the countries. Occurrence of enrofloxacin and norfloxacin is close to 
zero in USA and Australia. However, it is close to 100% in China and Japan. 
 
Table 2.6 Occurrence of fluoroquinolones in secondary treated MWWE in Canada 
Compound Region Det. Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Ciprofloxacin Ontario 7/8 22.7 132 344   Tabe et al. (2009) 
 Alberta 7/7 ≤ 15 207 888   Sosiak et al. (2005) 
 Canada 7/8 1  400 118  Miao et al. (2004) 
Enrofloxacin Alberta 0/7 ≤ 15     Sosiak et al. (2005) 
 Canada 0/8 8     Miao et al. (2004) 
Norfloxacin Alberta 6/7 ≤ 15 78 821   Sosiak et al. (2005) 
 Canada 4/8 5  112 50  Miao et al. (2004) 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends: Det. Freq.  Detection Frequency   
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources   
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.7 Occurrence of fluoroquinolones in secondary treated MWWE in other countries 
Compound Country Det.  
Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Ciprofloxacin USA 4/10 50  140 60  Karthikeyan et al. (2006) 
 USA 8/8 43    440 ± 118 Batt et al. (2007) 
 USA 3/4 5/50 28 522 91  Barber et al. (2011) 
 USA NA/12 50 70 240  130 Yang et al. (2011) 
 Finland 20/21 29 30 130 70 60 Vieno et al. (2007) 
 Spain NA/17     710 Muñoz et al (2010) 
 Spain NA/17     850 Muñoz et al (2010) 
 Spain > 4 / 12 10 <10 5692  2378 Rosal et al. (2010) 
 Sweden 9/10 6 7 60 14 20 ± 17 Lindberg et al. (2005) 
 Sweden NA/3 4.9    94 ± 12 Zorita et al. (2009) 
 Australia NA/4 10 <10 30 20  Reungoat et al. (2010) 
 Australia 0/8 10     Reungoat et al. (2011) 
 Japan 4/4 1-10 9 65 98 41 ± 22 Ghosh et al. (2009) 
 Various   < 6 90   VS, Lee-Minh et al. (2010) 
 Various   < 20 251   VS, Monteiro et al. (2010) 
 Various   7 970   VS, Zhang et al. (2011) 
Enrofloxacin USA 0/10 50     Karthikeyan et al. (2006) 
 Australia NA/4 10 <10 10   Reungoat et al. (2010) 
 Australia 0/8 10     Reungoat et al. (2011) 
 Japan 4/4 1-10 3 26 14 15 ± 9 Ghosh et al. (2009) 
 Various    10   VS, Zhang et al. (2011) 
Norfloxacin USA 0/10 50     Karthikeyan et al. (2006) 
 USA 0/4 5/50     Barber et al. (2011) 
 Finland 1/21 24 < 24 30 < 24 < 24 Vieno et al. (2007) 
 Sweden 9/10 7 7 37   Lindberg et al. (2005) 
 Sweden NA/3 5.5    19 ± 1.5 Zorita et al. (2009) 
 Australia NA/4 10 <10 40 30  Reungoat et al. (2010) 
 Australia 0/8 10     Reungoat et al. (2011) 
 China 4/4 10 27 85   Xu et al. (2007) 
 China 4/4 16 85 320   Gulkowska et al. (2008) 
 Japan 4/4 1-10 8 56 37 33 ± 17 Ghosh et al. (2009) 
 Various   < 7 320   VS, Lee-Minh et al.,2010 
 Various   30 112   VS, Monteiro et al. (2010) 
 Various   < 6 120   VS, Zhang et al. (2011) 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
USA United States of America 
Min  Minimum     Max  Maximum  
SD  Standard Deviation    VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Antibiotics - Macrolides 
Use and consumption 
Macrolides do not kill the bacteria but prevent them from multiplying (Monteiro 
and Boxall, 2010). As per Ebadi (2008) and  Monteiro and Boxall (2010), macrolides can 
treat streptococcal infections, syphilis, respiratory and mycoplasmal infection, Lyme 
disease, and tetanus. 
The most prescribed macrolides in Canada are azithromycin, clarithromycin, and 
erythromycin (Karlowsky et al., 2009). Table 2.8 shows the prescription rate for the 
macrolides in Canada. The data shows a decrease in consumption of erythromycin in 
Canada. In addition, the absence of roxithromycin in the list of most prescribed 
macrolides indicates that its consumption is less than that of erythromycin. 
 
Table 2.8 Annual macrolide prescription rate in Canada in 1995 and 2005 
Compound Prescriptions/1000 persons per year 
 1995 2005 
Azithromycin 4.8 52.5 
Clarithromycin 24.7 58.5 
Erythromycin 77.2 12.3 
Total Macrolides 106.7 123.2 
Reference:  Karlowsky et al. (2009) 
 
The average consumption of erythromycin in five European countries is in the 
range of 0.166 to 0.536 g per capita per annum, which is the highest in the macrolides 
group (Sadezky et al., 2008). Data in Table 2.5 indicates that consumption of 
roxithromycin is less than that of erythromycin in many of the European countries as well 
as in Australia.    
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Abatement in conventional MWWTP 
 Literature indicates that conventional MWWTPs do not remove effectively some 
of the macrolides. Joss et al. (2005) have also found roxithromycin to be resistant to 
biodegradation during wastewater treatment. Gulkowska et al. (2008) have observed less 
than 20% reduction in concentration of erythromycin in MWWTP. Xu et al. (2007) have 
reported reduction of 26% and 48% in the concentration of erythromycin and 
roxithromycin during the sewage treatment process. Castiglioni et al. (2006) have 
reported close to zero percent removal of erythromycin and lincomycin by conventional 
wastewater treatment. Ghosh et al. (2009) have reported almost similar reduction of -32 
to 59% and -39 to 57% in the concentration of roxithromycin and lincomycin in 
MWWTP. 
 
Occurrence in MWWE 
 Majority of the studies in Canada have reported 75% or higher occurrence of 
macrolides in MWWE in Canada (Table 2.9).  Miao et al. (2004) have detected 
erythromycin in effluent in concentrations up to 536 ng/L. The maximum reported 
concentration of lincomycin and roxithromycin in MWWE in Canada is 21 and 18 ng/L. 
Table 2.10 compiles the data related to the occurrence and concentration of 
macrolides in MWWE in other countries. Erythromycin is one of the most frequently 
detected antibiotics in the environment (Monteiro and Boxall, 2010). Most of the studies 
have reported high occurrence of erythromycin. Studies have reported maximum 
concentration of 561 ng/L and 760 ng/L of this drug in effluents in USA and Europe. 
From China, Xu et al. (2007) have reported concentrations up to 2,054 ng/L. However,  
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Monteiro and Boxall (2010) show that a study has reported concentration of 6,000 ng/L 
of erythromycin in MWWE. 
Studies have reported low occurrence and low concentration of lincomycin in 
MWWE in USA. Studies from other countries have reported low to high occurrence and 
low concentration of lincomycin. However, Behera et al. (2011) have detected 
lincomycin in MWWE in Korea in concentrations up to 21,278 ng/L.  
 Hope et al. (2012) have reported zero occurrence of roxithromycin in MWWE in 
over 100 sampling events. However, most of the other studies from Europe and Asia have 
reported 50 to 100% occurrence. The data compiled by Monteiro and Boxall (2010) 
shows that a study has reported maximum concentration of 1,000 ng/L of this compound 
in effluent. 
 
Table 2.9 Occurrence of macrolides in secondary treated MWWE in Canada 
Compound Region Det. Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Erythromycin Ontario 6/8 39.2 91 281   Tabe et al. (2009) 
 Canada 6/8 1  536 87  Miao et al. (2004) 
Lincomycin Ontario 8/8 2.7 4 21   Tabe et al. (2009) 
Roxithromycin Ontario 0/8 20.3     Tabe et al. (2009) 
 Canada 6/8 1  18 8  Miao et al. (2004) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:  Det. Freq.  Detection Frequency   
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources 
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.10 Occurrence of macrolides in secondary treated MWWE in other countries 
Compound Country Det. Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Erythromycin USA 3/3 1 133 162   Snyder et al. (2006) 
 USA 3/10 50  300 270  Karthikeyan et al. (2006) 
 USA 4/8 10-100 180 561   Barber et al. (2011) 
 USA NA/12 100 140 410  270 Yang et al. (2011) 
 Austria 3/3 20 170 210 170  Schaar et al. (2010) 
 Germany NA/6 50    620 ± 240 Ternes et al. (2003) 
 Spain NA/8 2 43 205  104 Radjenovic et al. (2007) 
 Spain NA/17     570 Muñoz et al (2010) 
 Spain NA/17     750 Muñoz et al (2010) 
 Spain > 4 / 12 99 <99 760  331 Rosal et al. (2010) 
 Sweden 0/10 160     Lindberg et al. (2005) 
 Switzerland 7/11 75 15 73 32 36 ± 22 Hollender et al. (2009) 
 Australia NA/4 10 180 460 260  Reungoat et al. (2010) 
 Australia NA/8  50 390   Reungoat et al. (2011) 
 Australia 8/8  20 324   Reungoat et al. (2012) 
 China 4/4 5 216 2054   Xu et al. (2007) 
 China 4/4 12 510 850   Gulkowska et al. (2008) 
 Japan 1/1 0.0012  92   Nakada et al. (2007) 
 Korea 5/7 1 8.9 294  130 Kim et al. (2007) 
 Various   10 6000   VS, Monteiro et al. (2010) 
 Various   145 620   VS, Zhang et al. (2011) 
Lincomycin USA 0/10 50     Karthikeyan et al. (2006) 
 USA 1/4 5/50  8   Barber et al. (2011) 
 USA NA/12 10 10 20  14 Yang et al. (2011) 
 Australia NA/4 10 < 10 60 30  Reungoat et al. (2010) 
 Australia 9/9  <0.2 3.1   Reungoat et al. (2012) 
 Japan 4/4 1-10 8 28 17 18 ± 6 Ghosh et al. (2009) 
 Korea 5/5 2.5 1437 21278  9089 Behera et al. (2011) 
 Various    31   VS, Monteiro et al. (2010) 
 Various   13 60   VS, Zhang et al. (2011) 
Roxithromycin USA 0/10 50     Karthikeyan et al. (2006) 
 USA 0/4 10/100     Barber et al. (2011) 
 USA 0/102 8.9     Hope et al. (2012) 
 Austria 5/5 20 36 69   Clara et al. (2005b) 
 Austria 3/3 10 < 20 160 27  Schaar et al. (2010) 
 France NA/6 1-2    10 ± 10 Ruel et al. (2011) 
 Germany NA/6 50    540 ± 40 Ternes et al. (2003) 
 Switzerland NA/15  7 33   Joss et al. (2005) 
 Switzerland 6/11 3 4 26 7 9 ± 8 Hollender et al. (2009) 
 Australia NA/4 10 230 370 290  Reungoat et al. (2010) 
 Australia NA/16  40 220   Reungoat et al. (2011) 
 Australia 9/9  60 703   Reungoat et al. (2012) 
         
 Table 2.10 continued (Occurrence of macrolides in secondary treated MWWE in other 
countries) 
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Compound Country Det. Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
         
Roxithromycin China 4/4 5 36 278   Xu et al. (2007) 
(cont’d) Japan 1/1 0.00018  22   Nakada et al. (2007) 
 Japan 4/4 1-10 14 276 71 90 ± 87 Ghosh et al. (2009) 
 Various   10 870   VS, Lee-Minh et al. (2010) 
 Various    1000   VS, Monteiro et al. (2010) 
 Various    540   VS, Zhang et al. (2011) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
USA United States of America 
Min  Minimum     Max  Maximum  
SD  Standard Deviation    VS  Various Sources 
Det. Freq.  Detection Frequency    NA Not available 
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Antibiotics - Sulfonamides 
Use and consumption 
Sulfonamides have anti-bacterial property due to the sulphur that is directly linked 
to the benzene ring, and they inhibit the growth of bacteria by inhibiting their DNA 
synthesis (Monteiro and Boxall, 2010). This category of drugs can treat urinary tract 
infections and burns (Ebadi, 2008). They also have veterinary use (Sweetman, 2009).  
The use of sulfathiazole has been reduced significantly due to its toxicity 
(Sweetman, 2009). Sulfamethoxazole is one of the most common sulfonamide used in 
human medicine (García-Galán et al., 2008). The data in Table 2.5 confirms that 
consumption of sulfamethoxazole for human medicine is higher than other sulfonamides. 
 
Abatement in conventional MWWTP 
 Joss et al. (2005) have found a huge variation in transformation efficiency of 
sulfamethoxazole. They have reported transformation in the range of 0 to 90%.  Xu et al. 
(2007) have reported 0 to 64% reduction of sulfamethoxazole during sewage treatment.  
Pedrouzo et al. (2011) have found the reduction of sulfamethoxazole and sulfathiazole in 
the range of 70 to 85%.  Ghosh et al. (2009) have observed 9 to 62% removal of 
sulfamethoxazole. In their study, the removal of sulfadimethoxine was in the range of 38 
to 100% while that of sulfamerazine was between 41 and 44%. 
 
Occurrence in MWWE 
Table 2.11 compiles the occurrence data of sulfonamides in MWWE in Canada 
from various studies. The occurrence of six of the eight drugs in this table is zero or close 
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to zero. The occurrence of sulfamethazine is between 0 and 30%. Miao et al. (2004) have 
detected it in one sample in concentration of 363 ng/L. Three studies have reported 100% 
occurrence of sulfamethoxazole.  Sosiak et al. (2005) have detected this drug in MWWE 
in concentrations up to 3,278 ng/L.  
The Table 2.12 summarizes the occurrence data of sulfonamides in MWWE in 
countries other than Canada. In the USA and other European countries, the occurrence 
and concentration of most of these drugs except sulfamethoxazole is low. Studies from 
different parts of the world have reported nearly 100% occurrence of sulfamethoxazole in 
MWWE.  Hope et al. (2012) have detected this drug in concentrations up to 5,280 ng/L.  
The data compiled by Zhang and Li (2011) shows that studies have reported up to 
6,000 ng/L concentration of sulfamethoxazole in MWWE. 
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Table 2.11 Occurrence of sulfonamides in secondary treated MWWE in Canada 
Compound Region 
Det.  
Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Sulfachloro- 
pyridazine 
Ontario 0/8 17.7     Tabe et al. (2009) 
Canada 0/8 1     Miao et al. (2004) 
Sulfadiazine Ontario 0/8 28.3     Tabe et al. (2009) 
 Canada 1/8 3  19 19  Miao et al. (2004) 
Sulfadimethoxine Ontario 0/8 5.7     Tabe et al. (2009) 
 Canada 0/8 1     Miao et al. (2004) 
Sulfamerazine Ontario 0/8 4.9     Tabe et al. (2009) 
 Canada 0/8 3     Miao et al. (2004) 
Sulfamethazine Ontario 0/8 3.4     Tabe et al. (2009) 
 Alberta 2/7 ≤ 15 23 72   Sosiak et al. (2005) 
 Canada 1/8 1  363 363  Miao et al. (2004) 
Sulfamethizole Ontario 0/8 7.1     Tabe et al. (2009) 
 Canada 0/8 2     Miao et al. (2004) 
Sulfamethoxazole Ontario 8/8 6.2 229 516   Tabe et al. (2009) 
 Alberta 7/7 ≤ 15 193 3278   Sosiak et al. (2005) 
 Canada 8/8 1  871 243  Miao et al. (2004) 
Sulfathiazole Ontario 0/8 9.7     Tabe et al. (2009) 
 Canada 0/8 4     Miao et al. (2004) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.12 Occurrence of sulfonamides in secondary treated MWWE in other countries 
Compound Country Det. Freq. RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Sulfachloropyridazine USA 0/10 100     Karthikeyan et al. (2006) 
USA 0/4 5/50     Barber et al. (2011) 
Korea 4/12 30 50 149   Choi et al. (2008) 
Sulfadiazine USA 3/4 5/50 90 260 110  Barber et al. (2011) 
 Switzerland 3/11 100 17 127 127 90 ± 64 Hollender et al. (2009) 
 Australia 0/4 10     Reungoat et al. (2010) 
 Australia NA/8   20   Reungoat et al. (2011) 
 China 1/4 1  36   Xu et al. (2007) 
 Various   < 1 < 150   VS, Lee-Minh et al. (2010) 
 Various    19   VS, Monteiro et al. (2010) 
Sulfadimethoxine USA 0/10 50     Karthikeyan et al. (2006) 
 USA 0/12 10    < 10 Yang et al. (2011) 
 USA 1/4 5/50  5   Barber et al. (2011) 
 Switzerland 0/11 60     Hollender et al. (2009) 
 Japan 1/1 0.012  0.15   Nakada et al. (2007) 
 Japan 4/4 1-10 4 44 14 19 ± 17 Ghosh et al. (2009) 
 Korea 4/12 10 13 70   Choi et al. (2008) 
 Various    < 30   VS, Lee-Minh et al. (2010) 
Sulfamerazine USA 0/10 50     Karthikeyan et al. (2006) 
 USA 0/4 5/50     Barber et al. (2011) 
 Japan 1/1 0.018  0.48   Nakada et al. (2007) 
 Japan 1/4 1-10  9   Ghosh et al. (2009) 
 Various    < 30   VS, Lee-Minh et al. (2010) 
Sulfamethazine USA 0/10 50     Karthikeyan et al. (2006) 
 USA 0/4 5/50     Barber et al. (2011) 
 Spain 0/13 10     Pedrouza et al. (2011) 
 Switzerland 4/11 5 7 20 8 11 ± 6 Hollender et al. (2009) 
 Japan 1/1 0.3  0.35   Nakada et al. (2007) 
 Korea NA/5 0.5 0 408  114 Behera et al. (2011) 
 Various    < 30   VS, Lee-Minh et al. (2010) 
 Various    363   VS, Monteiro et al. (2010) 
 Various    19   VS,  Zhang et al. (2011) 
Sulfamethizole USA 0/10 100     Karthikeyan et al. (2006) 
 Japan 1/1 0.06  1.11   Nakada et al. (2007) 
 Various    180   VS, Lee-Minh et al. (2010) 
Sulfamethoxazole USA 3/3 1 669 841   Snyder et al. (2006) 
USA 6/10 50  370 200  Karthikeyan et al. (2006) 
 USA 8/8 27    460 ± 180 Batt et al. (2007) 
 USA 3/3  330 1200 970  Wert et al. (2009) 
 USA 3/3 0.25 260 600  443 ± 172 Gerrity et al. (2011) 
 USA 4/4 5/50 137 813 406 232 ± 297 Barber et al. (2011) 
 USA 1/4 64  178   Barber et al. (2011) 
 USA 8/10 10    907 Oppenheimer et al. (2011) 
 USA NA/12 10 130 1600  420 Yang et al. (2011) 
 USA 94/102 11.2 136 5280 1040 1261 Hope et al. (2012) 
         
 Table 2.12 continued (Occurrence of sulfonamides in secondary treated MWWE in other 
countries) 
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Compound Country Det. Freq. RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Sulfamethoxazole Austria 4/5 20 18 91   Clara et al. (2005b) 
(cont’d) Austria 3/3 10 73 140 100  Schaar et al. (2010) 
 France NA/6 1-2    180 ± 270 Ruel et al. (2011) 
 Germany NA/6 50    620 ± 50 Ternes et al. (2003) 
 Spain 1/1   250   Carballa et al. (2004) 
 Spain NA/8 3.1 65 264  139 Radjenovic et al. (2007) 
 Spain NA/17     550 Muñoz et al (2010) 
 Spain NA/17     270 Muñoz et al (2010) 
 Spain > 4 / 12 15 104 370  231 Rosal et al. (2010) 
 Spain 8/13 10 44 670 260 286 ± 247 Pedrouza et al. (2011) 
 Sweden 4/10 80 135 304 248` 234 ± 84 Lindberg et al. (2005) 
 Switzerland NA/15  90 900   Joss et al. (2005) 
 Switzerland 11/11 25 84 434 155 197 ± 122 Hollender et al. (2009) 
 Australia NA/4 10 110 240 220  Reungoat et al. (2010) 
 Australia NA/8  60 330   Reungoat et al. (2011) 
 Australia 9/9  39 1701   Reungoat et al. (2012) 
 China 4/4 1 9 78   Xu et sl. (2007) 
 Japan 1/1 0.018  40   Nakada et al. (2007) 
 Japan 4/4 1-10 67 162 97 112 ± 40 Ghosh et al. (2009) 
 Korea 4/7 1 3.8 407  136 Kim et al. (2007) 
 Korea 12/12 5 25 492   Choi et al. (2008) 
 Korea 11/11 1 92 330 160 193 Ryu et al. (2011) 
 Korea 5/5 0.9 20 162  57 Behera et al. (2011) 
 Various   0.3 964   VS, Lee-Minh et al. (2010) 
 Various    2140   VS, Monteiro et al. (2010) 
 Various   < 5 6000   VS, Zhang et al. (2011) 
Sulfathiazole USA 0/10 100     Karthikeyan et al. (2006) 
 USA 0/4 5/50     Barber et al. (2011) 
 Spain 2/13 10 161 205   Pedrouza et al. (2011) 
 Australia 0/4 10     Reungoat et al. (2010) 
 Australia 0/16 10     Reungoat et al. (2011) 
 Australia 9/9  < 0.6 < 2.6   Reungoat et al. (2012) 
 Japan 1/1 0.015  0.50   Nakada et al. (2007) 
 Korea 0/12 30     Choi et al. (2008) 
 Various    < 30   VS, Zhang et al. (2011) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
USA United States of America 
Min  Minimum     Max  Maximum  
SD  Standard Deviation    VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Tetracyclines 
Use and Consumption 
As per Ebadi (2008), tetracyclines are bacteriostatic and have the broadest 
spectrum of activity. They are effective against the Gram-positive and Gram-negative 
bacteria (Ebadi, 2008). Some of the important drugs in this category are chlortetracycline, 
doxycycline, meclocycline, oxytetracycline, and tetracycline. 
Data in Table 2.5 indicates that the consumption of the drug tetracycline is the 
lowest in this group. Oxytetracycline is the most widely used tetracyclines in UK. If 
normalized by capita, the average consumption of this drug in UK is 0.476 g per capita 
per annum (Sadezky et al., 2008). 
 
Abatement in conventional MWWTPs 
 Gulkowska et al. (2008) have reported -88 to 73% reduction in the concentration 
of tetracycline in secondary wastewater treatment plants. Ghosh et al. (2009) have 
reported 40 to 73% reduction of this drug. 
 
Occurrence in MWWE 
In Canada, studies have reported zero or close to zero occurrences of tetracyclines 
such as chlortetracycline, doxycycline, meclocycline, and oxytetracycline; and 40 to 
100% occurrence of tetracycline (Table 2.13). Miao et al. (2004) have reported 
concentrations up to 977 ng/L of these drugs in MWWE in Canada. 
From the data compiled in Table 2.14, the occurrence of chlortetracycline, 
doxycycline, and oxytetracycline in MWWE in various countries is almost zero. The 
 68 
maximum reported concentration of chlortetracycline and oxytetracycline in MWWE is 
60 ng/L and < 30 ng/L as per Le-Minh et al. (2010). Lindberg et al. (2005) have reported 
concentration of 915 ng/L of doxycycline in effluent in Sweden. Most of the studies from 
China, Japan, and USA have reported close to 100% occurrence of tetracycline in 
MWWE. From Australia, two studies have reported zero occurrence of this compound. 
The maximum reported concentration of tetracycline in MWWE is around 1000 ng/L as 
per  Monteiro and Boxall (2010) and  Zhang and Li (2011). 
 
Table 2.13 Occurrence of tetracyclines in secondary treated MWWE in Canada 
Compound Region 
Det.  
Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Tetracyclines         
Chlortetracycline Ontario 0/8 55.8     Tabe et al. (2009) 
 Alberta 0/7 ≤ 15     Sosiak et al. (2005) 
 Canada 0/8 4     Miao et al. (2004) 
Doxycycline Ontario 0/8 17.7     Tabe et al. (2009) 
 Alberta 1/7 ≤ 15  102   Sosiak et al. (2005) 
 Canada 2/8 2  46 38  Miao et al. (2004) 
Meclocycline Ontario 0/8 21.3     Tabe et al. (2009) 
Oxytetracycline Ontario 0/8 24     Tabe et al. (2009) 
 Alberta 0/7 ≤ 15     Sosiak et al. (2005) 
 Canada 0/8 6     Miao et al. (2004) 
Tetracycline Ontario 8/8 32.9 48 103   Tabe et al. (2009) 
 Alberta 3/7 ≤ 15 81 320   Sosiak et al. (2005) 
 Canada 7/8 2  977 151  Miao et al. (2004) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.14 Occurrence of tetracyclines in secondary treated MWWE in other countries  
Compound Country 
Det.  
Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Tetracyclines         
Chlortetracycline USA 0/10 50     Karthikeyan et al. (2006) 
 USA 0/4 10/100     Barber et al. (2011) 
 Australia 0/4 100     Reungoat et al. (2010) 
 Australia 0/8      Reungoat et al. (2011) 
 Various   40 60   VS,  Lee-Minh et al. (2010) 
Doxycycline USA 0/10 100     Karthikeyan et al. (2006) 
 USA 1/4 10/100  180   Barber et al. (2011) 
 USA 0/12 20    < 20 Yang et al. (2011) 
 Sweden 7/10 64 64 915 227 380 ± 376 Lindberg et al. (2005) 
Meclocycline        No data available 
Oxytetracycline USA 0/10 50     Karthikeyan et al. (2006) 
 USA 0/4 10/100     Barber et al. (2011) 
 Australia 0/4 100     Reungoat et al. (2010) 
 Australia 0/8 100     Reungoat et al. (2011) 
 Various    < 30   VS, Lee-Minh et al. (2010) 
 Various    20   VS, Zhang et al. (2011) 
Tetracycline USA 8/10 50  850 170  Karthikeyan et al. (2006) 
 USA 8/8 52    181 ± 69 Batt et al. (2007) 
 USA 3/4 10/100 34 411 131  Barber et al. (2011) 
 USA 0/12 50    < 50 Yang et al. (2011) 
 Australia 0/4 100     Reungoat et al. (2010) 
 Australia 0/8 10     Reungoat et al. (2011) 
 China 4/4 14 180 620   Gulkowska et al. (2008) 
 Japan 4/4 1-10 4 39 25 23 ± 15 Ghosh et al. (2009) 
 Various    1,000   VS, Monteiro et al. (2010) 
 Various    977   VS, Zhang et al. (2011) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
USA United States of America 
Min  Minimum     Max  Maximum  
SD  Standard Deviation    VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Miscellaneous antibiotics 
The antibiotics not covered under the fluoroquinolones, macrolides, tetracyclines, 
and sulfonamides categories are included in this group.  
 
Use and consumption 
Carbadox is a veterinary medicine, antibiotic, added to swine feed to prevent 
dysentery and promote growth (Aga, 2008). Some European countries have banned its 
application because of its carcinogenic property (Sweetman, 2009). Chloramphenicol is a 
bacteriostatic antibiotic, and is useful in the treatment of ampicillin resistant influenza, 
rickettsial infections, typhoid fever and vancomycin-resistant enterococci (Anderson et 
al., 2002). Lasalocid A is an antibiotic and an antiprotozoal. It can prevent and treat 
parasitic disease that infects intestinal tracts of (Sweetman, 2009). As per Sweetman 
(2009), trimethoprim is an antibacterial used in the treatment of stomach flu, respiratory 
tract, and urinary tract infections. In combination with sulfamethoxazole, it is used to 
manage pneumonia. It also has use as a veterinary antibiotic (Sarmah et al., 2006). 
Limited data are available related to the consumption of the drugs such as 
carbadox, chloramphenicol, and Lasalocid-A. Table 2.15 shows the data related to 
consumption of trimethoprim in some countries. The annual consumption in most of the 
listed countries is less than 10 tonnes. However, China consumed nearly 2,352 tonnes of 
this drug in 2005. 
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Table 2.15 Consumption of antibiotic - trimethoprim in various countries 
Compound Country Time period Sale 
(tonne/yr) 
Reference 
Trimethoprim France 2004 3.35 Besse et al (2008) 
 France 1999-2006 3.35 Sadezky et al (2008) 
 Germany 1999-2006 12.1 Sadezky et al (2008) 
 Norway 2006 0.68 Grung et al. (2008) 
 Spain 2003 3.7 Monteiro et al (2010) 
 Switzerland 1999 0.52 Gobel et al (2005) 
 UK 2004 11.2 Monteiro et al (2010) 
 UK 1999-2006 7.34 Sadezky et al (2008) 
 Australia 1998 2.7 Khan et al (2004) 
 China 2005 2352 Sui et al. (2010) 
 
Abatement in conventional MWWTPs 
 Gulkowska et al. (2008) have reported -42 and 62% reduction in concentration of 
trimethoprim. Xu et al. (2007) have observed 45% removal of chloramphenicol during 
sewage treatment. Plósz et al. (2010) have reported increase in the concentration of 
trimethoprim in the MWWE after biological treatment, most probably due to the 
deconjugation process. 
 
Occurrence in MWWE 
Table 2.16 shows the data related to detection of the miscellaneous antibiotics in 
MWWE in Canada. Table 2.17 represents similar data for MWWE other countries.  
In Canada, studies have reported zero or close to zero occurrence of carbadox, 
chloramphenicol, Lasalocid A, and penicillin G. In contrast, studies have reported 100% 
occurrence of trimethoprim in the MWWE. Sosiak et al. (2005) have reported up to 
3,528 ng/L concentration of this drug in the MWWE. 
From studies outside Canada, Reungoat et al. (2012) have reported 100% 
occurrence but low concentration of chloramphenicol in MWWE in Australia. The 
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maximum concentration of this drug in their study is 3.1 ng/L. Most of the studies listed 
in Table 2.17 have reported 100% occurrence of trimethoprim in the MWWE. Studies 
from USA have reported 35 to 720 ng/L concentration of this drug in effluent. Lindberg 
et al. (2005) have detected this drug in concentration up to 1,340 ng/L. Studies have 
reported concentrations in the range of 10 to 780 ng/L of this drug in MWWE in Asia. 
 
Table 2.16 Occurrence of miscellaneous antibiotics in secondary treated MWWE in Canada 
Compound Region 
Det.  
Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Miscellaneous         
Carbadox Ontario 0/8 46.3     Tabe et al. (2009) 
 Canada 0/8 5     Miao et al. (2004) 
Chloramphenicol Ontario 0/8 8.8     Tabe et al. (2009) 
Lasalocid A Ontario 2/8 54.9 24 32   Tabe et al. (2009) 
Penicillin-G Ontario 0/8 16.9     Tabe et al. (2009) 
Trimethoprim Ontario 4/4 5-9 9 194   Metcalfe et al. (2003b) 
 Ontario 11/11 0.6    265 ± 122 Hua et al. (2006) 
 Ontario 8/8 5 164 486   Tabe et al. (2009) 
 Alberta 7/7 ≤ 15 514 3,528   Sosiak et al. (2005) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.17 Occurrence of miscellaneous antibiotics in secondary treated MWWE in other 
countries 
Compound Country Detection 
Frequency 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Miscellaneous         
Carbadox USA 0/10 100     Karthikeyan et al. (2006) 
 USA 0/3 5/50     Barber et al. (2011) 
Chloramphenicol Australia 0/4 100     Reungoat et al. (2010) 
 Australia NA/16  0.3 <100   Reungoat et al. (2011) 
 Australia 9/9  < 0.3 3.1   Reungoat et al. (2012) 
 China 1/4 5  17   Xu et al. (2007) 
 China 1/4 1  19   Sui et al. (2010) 
 Various    560   VS,  Monteiro et al. (2010) 
Lasalocid A        No data available 
Penicillin-G USA 0/4 10/100     Barber et al. (2004) 
 China 0/4 4     Gulkowska et al. (2008) 
 Various    < 2   VS,  Lee-Minh et al. (2010) 
 Various    ND   VS,  Monteiro et al. (2010) 
 Various   ND 300   VS,  Zhang et al. (2011) 
Trimethoprim USA 3/3 1 35 229   Snyder et al. (2006) 
 USA 6/10 50  550 170  Karthikeyan et al. (2006) 
 USA 8/8 68    993 ± 891 Batt et al. (2007) 
 USA 3/3  36 370 83  Wert et al. (2009) 
 USA 3/3 0.25 550 720  620 ± 89 Gerrity et al. (2011) 
 USA 3/4 5/50 61 641 367  Barber et al. (2011) 
 USA 4/4 13 130 327 186 207 ± 92 Barber et al. (2011) 
 USA NA/12 100 69 530  280 Yang et al. (2011) 
 Austria 3/3 20 150 320 240  Schaar et al. (2010) 
 Germany NA/6 50    340 ± 40 Ternes et al. (2003) 
 Spain > 4 / 12 29 < 29 148  99 Rosal et al. (2010) 
 Sweden 10/10 8 66 1340 396 499 ± 386 Lindberg et al. (2005) 
 Switzerland 11/11 30 71 234 108 119 ± 47 Hollender et al. (2009) 
 Australia NA/4 10 150 210 200  Reungoat et al. (2010) 
 Australia NA/16  10 380   Reungoat et al. (2011) 
 Australia 9/9  27 141   Reungoat et al. (2012) 
 China 4/4 6 120 230   Gulkowska et al. (2008) 
 China 4/4 1 20 200   Sui et al. (2010) 
 Japan 1/1 0.027  16   Nakada et al. (2007) 
 Japan 4/4 1-10 24 72 41 43 ± 16 Ghosh et al. (2009) 
 Korea 5/7 1 10 188  58 Kim et al. (2007) 
 Korea 7/12 10 13 174   Choi et al. (2008) 
 Korea 11/11 1 27 780 70 134 Ryu et al. (2011) 
 Korea 5/5 0.14 13 154  63 Behera et al. (2011) 
 Various   9 1760   VS, Monteiro et al. (2010) 
Note: If the study has detected the analyte only once, it is reported as maximum detected concentration in the above table. 
Legends:  USA = United States of America   VS = Various sources 
RL = Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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2.4.3.3  Antiepileptic/antidepressant 
Use and consumption 
Carbamazepine is an antiepileptic/antidepressant drug, and used to control and 
prevent seizures as well as other medical conditions (Ebadi, 2008). Sadezky et al. (2008) 
have reported the average consumption of this drug in five European countries in the 
range of 0.61 to 0.98 g per capita per annum. Table 2.18 summarizes the annual 
consumption of this drug in different countries. Metcalfe et al. (2004) and Miao et al. 
(2005) have reported 19 to 28 tonnes of consumption of carbamazepine in Canada in the 
year 2001. Zhang et al. (2008) have estimated the total worldwide consumption of this 
drug to be approximately 1014 tonnes in 2008. 
 
Table 2.18 Consumption of antiepileptic/antidepressant in various countries 
Compound Country Year Sale 
(tonne/yr) 
Reference 
Carbamazepine Canada 2001 19 Metcalfe et al. (2004) 
 Canada 2001 28 Miao et al (2005) 
 USA 2000 43 Zhang et al (2008) 
 USA 2003 35  Zhang et al (2008) 
 Austria 1997 6  Zhang et al (2008) 
 Finland 2005 4.35 Vieno et al. (2007) 
 France  2004 33.5  Besse et al (2008) 
 France 1999-2006 36.4   Sadezky et al (2008) 
 Germany 1999 87  Zhang et al (2008) 
 Germany 1999-2006 80.9   Sadezky et al (2008) 
 Poland 1999-2006 32.2   Sadezky et al (2008) 
 Spain  2003 20  Monteiro et al (2010) 
 UK 2000 40 Zhang et al (2008) 
 UK  2004 52.2  Monteiro et al (2010) 
 UK 1999-2006 40.1   Sadezky et al (2008) 
 Australia 1998 10  Khan et al (2004) 
 China 2005 395 Sui et al. (2010) 
 Japan 2002 107-162 Nakada et al. (2002) 
 World 2008 1014  Zhang et al (2008) 
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Abatement in conventional WWTP 
Carbamazepine is resistant to biodegradation and its concentration remains 
unchanged during conventional activated sludge treatment process (Clara et al., 2005b; 
Joss et al., 2005). Study by Andreozzi et al. (2002) shows that carbamazepine is 
persistent in the environment. In water, it degrades only when exposed to solar 
irradiation. They found its half-life to be 907 sunlight hours. As per their study, nitrate 
promotes the degradation of the compound while humic acid has the opposite effect. 
 
Occurrence in the MWWE 
Studies have reported 87 to 100% occurrence of carbamazepine in MWWE in 
Canada. Table 2.19 compiles the pertinent data from some studies. Sosiak et al. (2005) 
have reported the concentration of this drug in the range between 702 and 3,287 ng/L. 
Table 2.20 compiles the data of occurrence and concentration of carbamazepine in 
MWWE in other countries. Most of the studies referred to in this table have reported high 
occurrence of the drug. In addition, the data shows higher concentration of this drug in 
MWWE in Europe and Australia than in Asian countries. In Germany, Ternes (1998) 
have detected this drug in concentration up to 6,300 ng/L. Joss et al. (2005) and Vieno 
(2007) have reported maximum concentration of this drug to be more than 2,000 ng/L. 
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Table 2.19 Occurrence of antiepileptic/antidepressant in secondary treated MWWE in Canada 
Compound Region Det.  
Freq. 
DL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Carbamazepine Ontario 4/4 5-7 7 126   Metcalfe et al. (2003b) 
 Ontario 10/11 0.1    291 ± 71 Hua et al. (2006) 
 Ontario 8/8 4.3 361 735   Tabe et al. (2009) 
 Alberta 7/7  702 3287   Sosiak et al. (2005) 
 Atl Canada 14/16 20 24 240 79 100 ± 61 Brun et al. (2006) 
 Canada 18/18 100 100 2300   Metcalfe et al. (2003a) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
Atl Canada  Atlantic Canada 
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.20 Occurrence of antiepileptic/antidepressant in MWWE in other countries 
Compound Country Det. 
Freq. 
DL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Carbamazepine USA 3/3 1 139 210   Snyder et al. (2006) 
 USA 3/3  170 350 260  Wert et al. (2009) 
 USA 3/3 0.5 170 190  180 ± 10 Gerrity et al. (2011) 
 USA 4/4 11 90 230 122 141 ± 63 Barber et al. (2011) 
 USA 16/16 5    416 Oppenheimer et al. (2011) 
 USA NA/12 50 100 550  250 Yang et al. (2011) 
 USA 84/102 11.2 133 577 206 219 Hope et al. (2012) 
 Austria 5/5 20 465 1594   Clara et al. (2005) 
 Austria 3/3 1 500 900 900  Schaar et al. (2010) 
 Finland 21/21 1.4 290 2440 500 720 Vieno et al. (2007) 
 France NA/6 0.5-2    640 ± 650 Ruel et al. (2011) 
 Germany 30/30 50  6300 2100  Ternes et al. (1998) 
 Germany NA/6 50    2100 ± 40 Ternes et al. (2003) 
 Germany NA/10     1760 ± 420 Bahr et al. (2007) 
 Spain NA/8 0.6 65 305  237 Radjenovic et al. (2007) 
 Spain NA/17     260 Muñoz et al. (2010) 
 Spain NA/17     290 Muñoz et al. (2010) 
 Spain >4 / 12 1 69 173  117 Rosal et al. (2010) 
 Spain 13/13  8 170   Pedrouza et al. (2011) 
 Switzerland NA/15  210 2300   Joss et al. (2005) 
 Switzerland 11/11 15 186 714 570 512 ± 187 Hollender et al. (2009) 
 Australia NA/4  390 950 700  Reungoat et al. (2011) 
 Australia NA/16  330 1650   Reungoat et al. (2011) 
 Australia 8/9  119 1192   Reungoat et al. (2012) 
 China 4/4 1 69 120   Sui et al. (2010) 
 Japan 16/16 6 11 163 49 60 ± 45 Nakada et al. (2006) 
 Japan 4/4 1.5-36 2.32 46   Nakada et al. (2007) 
 Korea 6/7 1 73 729  226 Kim et al. (2007) 
 Korea 10/12 5 6 195   Choi et al. (2008) 
 Korea 11/11 1 140 270 190 196 Ryu et al. (2011) 
 Korea 5/5 0.09 40 74  55 Behera et al. (2011) 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
USA United States of America 
Min  Minimum     Max  Maximum  
SD  Standard Deviation    VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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2.4.3.4  Lipid Regulators 
Use and consumption 
In human blood, the fibrates/lipid regulators decrease the synthesis of 
triglycerides and very-low-density lipoprotein cholesterol that is harmful to human 
health, and increase the production of high-density lipoprotein cholesterol that is good for 
human health (Anderson et al., 2002). Clofibric acid is the active metabolite of several 
fibrate drugs (Stumpf et al., 1999). It can act as a plant growth regulator by inhibiting 
plant hormone auxin (Emblidge and DeLorenzo, 2006). Clofibric acid is recalcitrant in 
nature (Winkler et al., 2001) and can persist in the environment for up to 21 years 
(Zuccato et al., 2000). It can adversely affect the reproduction of the Fathead minnow 
fish (Runnalls et al., 2007). Based on the bioassay test results, Ferrari et al. (2003) have 
concluded that clofibric acid has a more adverse effect than carbamazepine and 
diclofenac on the receiving water bodies. 
Fenofibrate is the most commonly prescribed fibrate drug in Canada, accounting 
for 90.2 % of the total fibrate drug prescriptions in year 2009 (Jackevicius et al., 2011). 
Gemfibrozil and bezafibrate account for 4.6% and 5.2% of the remaining prescriptions. 
Fenofibrate is also the most prescribed fibrate drug in USA. Table 2.21 presents the data 
related to distribution of total fibrate prescriptions in North America. The fibrate 
prescriptions dispensed in Canada and United States in December 2009 was 474 
prescriptions/100,000 population per month and 730 prescriptions/100,000 population per 
month, respectively (Jackevicius et al., 2011). 
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Table 2.21 Distribution of total fibrate prescriptions in North America (2005 – 2009) 
 Portion of Total Prescription, % 
 2005 2006 2007 2008 2009 
Canada      
 Bezafibrate 6.8 6.2 5.5 4.9 4.6 
 Fenofibrate 85.4 86.7 88.3 89.5 90.2 
 Gemfibrozil 7.8 7.1 6.2 5.6 5.2 
United States      
 Fenofibrate 62.0 66.2 69.4 71.4 65.2 
 Gemfibrozil 38.0 33.8 30.6 28.6 26.1 
 Fenofibric acid 0 0 0 0 8.7 
 
Note:  Bezafibrate is only available in Canada, and fenofibric acid is only available in the United States. 
Reference: Jackevicius et al. (2011) 
 
Table 2.22 shows the consumption of a few lipid regulators in various countries. 
In general, the consumption of bezafibrate is higher than gemfibrozil. The annual 
consumption of bezafibrate in France and Germany is in the range of 27 to 32 tonne/yr, 
which translates to approximately 0.38 to 0.46 g/capita/annum (Sadezky et al., 2008). 
However, the consumption of bezafibrate and gemfibrozil is almost equal in Poland, and 
the annual consumption rate is around 0.007 g/capita/annum (Sadezky et al., 2008). 
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Table 2.22 Consumption of fibrates/lipid regulators in various countries 
Compound Country Year Sale 
(tonne/yr) 
Reference 
Bezafibrate Finland 2005 0.357 Vieno et al. (2007) 
 France  2004 20.9 Besse et al (2008) 
 France 1999-2006 27.4 Sadezky et al (2008) 
 Germany 1999-2006 31.5 Sadezky et al (2008) 
 Poland 1999-2006 0.273 Sadezky et al (2008) 
 UK 1999-2006 7.66 Sadezky et al (2008) 
Clofibric acid Switzerland 2004 0.143 Tauxe-Wuersch et al (2005) 
Gemfibrozil Canada 2001 1 Metcalfe (2004) 
 Germany 1999-2006 5.96 Sadezky et al (2008) 
 Poland 1999-2006 0.274 Sadezky et al (2008) 
 UK  2004 1.42 Monteiro et al (2010) 
 UK 1999-2006 0.902 Sadezky et al (2008) 
 Australia  1998 20 Khan et al (2004) 
 China 2005 17 Sui et al. (2010) 
 
 
Abatement in conventional WWTP 
As per Cermola et al. (2005), fenofibrate rapidly metabolizes to fenofibric acid. 
They also report that fenofibric acid is highly susceptible to photo-degradation and 
converts to phenol, ether, and alcohol. In comparison, bezafibrate and gemfibrozil 
degrade by only about 10% when exposed to sunlight irradiation (Cermola et al., 2005). 
As per Clara et al. (2005a), bezafibrate is susceptible to biodegradation and degrades up 
to 90% in conventional WWTPs. However, they report its lower transformation in the 
WWTPs that have low sludge retention time (SRT). Joss et al. (2005) did not find any 
effect of SRT on transformation of antibiotics during wastewater treatment. Lee et al. 
(2003) observed only 5% transformation of gemfibrozil. Studies have reported that 
clofibric acid is also not readily biodegradable in municipal treatment plants (Zwiener 
and Frimmel, 2003; Castiglioni et al., 2006).  
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Occurrence in MWWE 
Table 2.23 presents the data related to occurrence of lipid regulator/bezafibrate in 
MWWE in Canada. As per the data, most of the studies have reported more than 75% 
occurrence of bezafibrate and gemfibrozil. Studies have reported maximum concentration 
of 810 ng/L of bezafibrate and 1493 ng/L of gemfibrozil in MWWE. Lee et al. (2003) did 
not detect fenofibrate in the 44 municipal sewage plant influent and effluent samples 
collected in Ontario, Canada. Similarly, Lishman et al. (2006) did not detect fenofibrate 
in any of the 39 MWWE samples analyzed by them. 
Table 2.24 compiles data from various studies concerning the occurrence of the 
lipid regulators in MWWE in other countries. Majority of the studies have reported close 
to 100% occurrence of bezafibrate and gemfibrozil. The occurrence of clofibric acid is 
between 0 and 100%. From the data in the table, studies have reported 4,800 ng/L and 
5,223 ng/L as the maximum concentration of bezafibrate and gemfibrozil in MWWE. 
Studies have reported up to 1,600 ng/L concentration of clofibric acid. For fenofibrate, 
Ternes (1998) have reported only 10% occurrence and maximum concentration of 
30 ng/L in the MWWE in Germany. 
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Table 2.23 Occurrence of lipid regulators in MWWE in Canada 
Compound Region Det. 
Freq. 
DL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Bezafibrate Ontario 4/4 5-12 12 259   Metcalfe et al. (2003b) 
 Ontario 11/11 10    325 ± 79 Hua et al. (2006) 
 Ontario 8/8 3 145 315   Tabe et al. (2009) 
 Alberta 4/7 ≤25 144 547   Sosiak et al. (2005) 
 Nova 
Scotia 
3/4 12 29 260 120  Comeau et al. (2008) 
 Atlantic 
Canada 
14/16 30 42 810 250 290 ± 239 Brun et al. (2006) 
 Canada 3/18 50 200 600   Metcalfe et al. (2003a) 
Clofibric Acid Ontario 2/4 5 2 44   Metcalfe et al. (2003b) 
 Ontario 0/16 10     Lee et al. (2003) 
 Ontario 0/39 66     Lishman et al. (2006) 
 Ontario 7/11 45    260 ± 132 Hua et al. (2006) 
 Ontario 8/8 5.8 10 43   Tabe et al. (2009) 
 Alberta 0/7 ≤25     Sosiak et al. (2005) 
 Atlantic 
Canada 
1/16 30  38   Brun et al. 2006 
 Canada 0/18 50     Metcalfe et al. (2003a) 
Fenofibrate Ontario 0/16 10     Lee et al. (2003) 
 Ontario 0/39 26     Lishman et al. (2006) 
Gemfibrozil Ontario 4/4 5 5 1493   Metcalfe et al. (2003b) 
 Ontario 16/16 10 20 540   Lee et al. (2003) 
 Ontario 17/39 77  436 255 246 Lishman et al. (2006) 
 Ontario 11/11 6    52 ± 31 Hua et al. (2006) 
 Ontario 8/8 3.1 19 206   Tabe et al. (2009) 
 Alberta 7/7 ≤25 410 813   Sosiak et al. (2005) 
 Atlantic 
Canada 
15/16 30 110 1400 550 591 ± 401 Brun et al. 2006 
 Canada 1/18 50  1300   Metcalfe et al. (2003a) 
 
Note: If the study reported only one concentration of the analyte, it is reported as maximum detected concentration in the above table. 
Legends:   
Min  Minimum    Max  Maximum  
SD  Standard Deviation   VS  Various Sources 
Det. Freq.  Detection Frequency    
RL  Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
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Table 2.24 Occurrence of lipid regulators in MWWE in other countries 
Compound Country Det. Freq. DL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Bezafibrate Austria 3/5 20 692 4800   Clara et al. (2005b) 
 Austria 3/3 20 1500 1600 1500  Schaar et al. (2010) 
 Finland 12/13 5 < 5 840 150 240 Vieno et al. (2007) 
 Germany 48/49 250  4600 2200  Ternes et al. (1998) 
 Germany NA/10     340 ± 170 Bahr et al. (2007) 
 Spain NA/8 4.35 495 2309  982 Radjenovic et al. (2007) 
 Spain >4/12 8 33 280  128 Rosal et al. (2010) 
 Spain 13/13 1 100 510 283 273 ± 105 Pedrouza et al. (2011) 
 Switzerland 11/11 65 37 133 67 77 ± 28 Hollender et al. (2009) 
 Australia 9/9  <0.5 10   Reungoat et al. (2012) 
 China 4/4 0.3 2 7   Sui et al. (2010) 
 Japan 12/12 15 26 1100   Okuda et al. (2008) 
 Brazil NA/10 50  1190 1077  Stumpf et al. (1999) 
Clofibric Acid USA 0/2 0.8     Boyd et al. (2003) 
 Germany 47/49 50  1600 360  Ternes et al. (1998) 
 Germany NA/6 50    120 ± 20 Ternes et al. (2003) 
 Germany NA/10     90 ± 70 Bahr et al. (2007) 
 Greece 1/11 5  5   Koutsouba et al. (2003) 
 Spain NA/8 3.75 18 156  80 Radjenovic et al. (2007) 
 Spain >4/12 6 <6 91  12 Rosal et al. (2010) 
 Spain 0/13 2     Pedrouza et al. (2011) 
 Sweden NA/3 1.1    24 ± 1 Zorita et al. (2009) 
 Switzerland 6/11 5 11 44 15 20 ± 13 Hollender et al. (2009) 
 China 4/4 5.4 8 20   Sui et al. (2010) 
 Korea NA/5 0.74 0 6  2 Behera et al. (2011) 
Gemfibrozil USA 2/2 10 16 567   Snyder et al. (2006) 
 USA 3/3  35 1600 1400  Wert et al. (2009) 
 USA 3/3 0.25 850 960  890 ± 61 Gerrity et al. (2011) 
 USA 1/4 13  318   Barber et al. (2011) 
 USA 10/12 5    360 Oppenheimer et al. (2011) 
 France NA/6 0.5-2    1500 ± 1700 Ruel et al. (2011) 
 Germany 39/49 50  1500 400  Ternes et al. (1998) 
 Spain NA/8 2.2 1368 3359  2468 Radjenovic et al. (2007) 
 Spain NA/17     6800 Muñoz et al. (2010) 
 Spain NA/17     8200 Muñoz et al. (2010) 
 Spain >4/12 0.1 3 5233  845 Rosal et al. (2010) 
 Australia NA/4 10 140 200 170  Reungoat et al. (2010) 
 Australia NA/16  37 155   Reungoat et al. (2011) 
 Australia 9/9  36 191   Reungoat et al. (2012) 
 China 4/4 4.2 8 50   Sui et al. (2010) 
 Korea 3/7 1 3.9 17  11.2 Kim et al. (2007) 
 Korea 10/11 1 <0.25 8 2.7 3.3 Ryu et al. (2011) 
 Korea 5/5 1.5 6 26  17 Behera et al. (2011) 
 Brazil NA/10 50  1725 400  Stumpf et al. (1999) 
Note: If only one value was detected, it is reported as maximum value in the above table. 
Legends:  RL = Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, 
or limit of quantification – LOQ) 
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2.4.4 Occurrence of EDCs in MWWE 
The USEPA definition of endocrine disruptive chemicals is “an exogenous agent 
that interferes with the production, release, transport, metabolism, binding, action, or 
elimination of natural hormones in the body responsible for the maintenance of 
homeostasis and the regulation of development process.” (Kavlock et al., 1996).  
Estrogen replacement agents, ovulation inhibitors, and reproductive hormones are 
some of the groups of potential EDCs based on their application. Perfluorosurfactants and 
bisphenol-A are also potential EDCs. 
 
Use and consumption 
The 17-α-ethinylestradiol (EE2) and 19-norethersterone drugs have a use as oral 
contraceptive drugs. The 19-norethersterone drug can also treat abnormal uterine 
bleeding and premenstrual pain when used in estrogen replacement therapy (Anderson et 
al., 2002). 17-β-Estradiol (E2) is a female sex hormone, and is the most potent among all 
the naturally occurring estrogens (Bennink, 2004). It is used to treat postmenopausal 
symptoms, osteoporosis, uterine bleeding and in menopausal hormone therapy. Estrone 
and estriol are used in menopausal hormone treatments (Ebadi, 2008). Bisphenol-A 
(BPA) is the mainly used in the production of polycarbonates and epoxy resins. The 
polycarbonates and the resins have a wide industrial use. They are also used to 
manufacture food and beverage containers (Environment Canada and Health Canada, 
2008). 
Of the potential EDCs listed in Table 2.25, the maximum production is of BPA. 
As per Environment Canada and Health Canada (2008), the worldwide production of this 
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compound was 4 billion kg in 2006. In Canada, the annual consumption decreased to less 
than 1,000 tonnes in 2006 from about 12,000 tonnes in 1986. The annual consumption of 
EE2 in most of the countries is less than 100 kg. 
 
Table 2.25 Sale of potential EDCs 
Compound Country Year Sale 
(tonne/yr) 
Reference 
Estrogen Replacement Agents    
Bisphenol-A (BPA) Canada 1986 12,000 Environment. Canada (2008) 
 Canada 2006 100 to 1,000 Environment. Canada (2008) 
 Worldwide 2006 4,000,000 Environment. Canada (2008) 
Reproductive Hormones     
17β-Estradiol Denmark 1996 0.045 Christensen (1998) 
Progesterone UK  2004 0.75 Monteiro et al (2010) 
 France 2004 9.86  Besse and Garric (2009) 
Ovulation Inhibitors    
17α-Ethinylestradiol (EE2) Canada 2001 0.057 Metcalfe et al. (2004) 
United States 2007 0.088 Hannah et al. (2009) 
 Belgium 2007 0.008 Hannah et al. (2009) 
 Denmark 1996 0.0036 Christensen (1998) 
 France 2007 0.034 Hannah et al. (2009) 
 Germany 2007 0.051 Hannah et al. (2009) 
 Italy 2007 0.020 Hannah et al. (2009) 
 Netherland 2007 0.015 Hannah et al. (2009) 
 UK 2007 0.026 Hannah et al. (2009) 
Norethisterone France 2004 0.101  Besse and Garric (2009) 
  
 
Abatement in conventional MWWTP 
The physicochemical properties of the EDCs affect their removal in the 
MWWTP. Some of these properties are their solubility in water, volatilization rate, 
biological and chemical degradation rate, and adsorption (Langford and Jason, 2002). 
Most of the EDCs are nonpolar and hydrophobic in nature and are removed mainly by 
sorption to the solids (Auriol et al., 2006). The octanol-water partition coefficient (Kow) 
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value of the chemicals can give an indication of their sorption potential and 
hydrophobicity. In general, log Kow < 2.5 indicates low sorption potential, 
2.5 < log Kow < 4.0 indicates medium sorption potential while log Kow > 4.0 indicates 
high sorption potential (Jones-Lepp and Stevens, 2007).  Langford and Jason (2002) 
indicate that chemicals with large log Kow value have large hydrophobic molecules that 
bind with solid organic matter, while chemicals with low log Kow value have small 
hydrophilic molecules. In addition, the main process of removal of chemicals with 
log Kow greater than 4 during secondary treatment is by sorption to settled sludge. 
However, as indicated earlier, the removal also depends on other factors besides Kow 
value. Table 2.26 provides the log octanol-water partition coefficient of few potential 
EDCs. 
 
Table 2.26 Log octanol/water partition coefficient of few potential EDCs 
Compound Log Kow Reference 
17-α-Ethinylestradiol (EE2) 3.67 – 4.15 Various, ref.  Auriol et al. (2006) 
17- α-Estradiol 3.94  Almeida and Nogueira (2006) 
17-β-Estradiol (E2) 3.94 – 4.01 Various, ref.  Auriol et al. (2006) 
19-Norethisterone 2.99  Almeida and Nogueira (2006) 
BPA 3.32, 3.43  Auriol et al. (2006) 
Estrone (E1) 2.45 – 3.43 Various, ref.  Auriol et al. (2006) 
Estriol (E3) 2.55 – 2.81 Various, ref.  Auriol et al. (2006) 
Progesterone 3.67  Almeida and Nogueira (2006) 
 
 Johnson and Sumpter (2001) indicate that the main mechanism of removal of the 
EDCs in the MWWTPs can be sorption and biodegradation. As per them, the removal of 
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weak hydrophobic estrogens such as E1, E2, and E3 may be due to the sorption and 
biodegradation. In addition, sorption to the sludge may be the most likely mechanism of 
removal of synthetic estrogen 17-α-ethinylestradiol (EE2), which is recalcitrant and up to 
10 times more hydrophobic than E2. However, in batch experiments conducted by  
Ternes et al. (1999a), the concentration of EE2 did not reduce substantially in conditions 
similar to an activated sludge process even though it has high log Kow value of 4.2. The 
sorption effect did not seem to affect the removal of EE2.   
Many studies have noted negative removal of estrogens in MWWTPs, i.e. the 
concentration of estrogens in treated water is higher than that in the raw sewage. The 
microorganisms present in the activated sludge can cleave the inactive polar conjugates 
of the estrogens, which results in release of active estrogens and increase in their 
concentration (Ternes et al., 1999a). In the aerobic batch experiments with activated 
sludge effluent,  Ternes et al. (1999a) have shown that 17-β-estradiol-17 
(β-D-glucuronide) and 17-β-estradiol-3 (β-D-glucuronide) converts to 17-β-estradiol in 
approximately 15 minutes. More than 95% of 17-β-estradiol oxidizes to estrone in a 
period of 1 to 3 hours (Figure 2.4). Hence, the concentration of some estrogens in the 
sewage effluent may increase after biological treatment due to the deconjugation process. 
D'Ascenzo et al. (2003) have shown that the production of estrone in the sewage 
treatment plants is most probably due to the oxidation of estradiol and deconjugation of 
the glucuronated and sulfated estrogens.  
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Figure 2.4 Conversion of 17-β-estradiol to estrone during biological sewage treatment  
(Adapted from Ternes et al. 1999 a) 
 
 Ternes et al. (1999b) have reported 64 to 78% reduction in concentration of EE2, 
above 99.9% reduction in 17-β-estradiol (E2), and 83% reduction of estrone in MWWE 
in Brazil. However, in their sampling at German MWWTPs, the reduction in E1 and EE2 
in MWWE was not substantial while reduction in E2 was close to 64%. They inform that 
low temperatures (-2 
o
C) during the German sampling event may be a reason for the low 
removal efficiency.  Behera et al. (2011) have reported 87 to 100% reduction of estrone, 
estriol, and estradiol in MWWTPs. D'Ascenzo et al. (2003) have observed high removal 
of estradiol (85%) and estriol (97%) but low removal of estrone (61%) in the sewage 
treatment plant. They have concluded estrone to be the most important EDC in the 
aquatic environment due to its high concentration (nearly 10 times of estradiol) and its 
estrogenic potency (which is approximately half of estradiol).  Clara et al. (2005b) and 
Nakada et al. (2006) have observed > 90% reduction in the concentration of BPA in 
MWWTPs having an activated sludge process. 
While the activated sludge process can achieve high removal of EDCs, the 
concentration of the EDCs present in the effluent is still high enough to produce 
estrogenic activity in fish and aquatic organisms (Auriol et al., 2006). BPA, E2, EE2, and 
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estrone contribute significantly to the estrogenicity of the effluent (Johnson and Sumpter, 
2001; D'Ascenzo et al., 2003). 
 
Occurrence in the MWWE 
Table 2.27 summarizes the occurrence and concentration data of potential EDCs 
in Canadian MWWE from some of the studies. The data show that studies frequently 
detect most of these EDCs. Fernandez et al. (2007) have reported the highest maximum 
concentration for all the EDCs. They have reported the highest maximum concentration 
of 19-norethisterone, E1, E2 and EE2 in the range of 147 ng/L to 178 ng/L. Viglino et al. 
(2008) and  Tabe et al. (2009) did not detect progesterone in any of their sampling events. 
Table 2.28 compiles the data related to the occurrence and concentration of EDCs 
in MWWE in other countries. The data indicate frequent detection of the EDCs in 
MWWE in various countries. Ternes et al. (1999b) have reported the highest maximum 
concentration of 15 ng/L of EE2. Conversely, studies have reported concentrations up to 
3,480 ng/L of BPA, and 282 ng/L of E1 and 275 ng/L of E3. Comparison of data in Table 
2.27 and Table 2.28  indicates higher occurrence and concentration of EE2 in MWWE in 
Canada than in other countries. 
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Table 2.27 Occurrence of potential EDCs in MWWE in Canada 
Compound Region Det.  
Freq. 
DL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Estrogen Replacement Agents       
Bisphenol-A (BPA) Ontario 4/8 114.9 7 42   Tabe et al. (2009) 
 Alberta 7/8  1.3 195   Sosiak et al. (2005) 
 BC 5/5 3.2 2.9 76 45 41 ± 30 Nelson et al. (2007) 
 Canada 28/29 2.1 33 1054 305 386 ± 296 Fernandez et al. (2007) 
Diethylstilbestrol Ontario 0/8 159     Tabe et al. (2009) 
Equilin BC 0/5 8.9     Nelson et al. (2007) 
 Canada 2/29 18 83 207   Fernandez et al. (2007) 
Ovulation Inhibitors        
17-α-Ethinylestradiol  
(EE2) 
Ontario 0/8 118.8     Tabe et al. (2009) 
Alberta 1/8   8.5   Sosiak et al. (2005) 
BC 0/5 6.9     Nelson et al. (2007) 
Manitoba NA/6     14.5 Lee et al. (2004) 
Quebec 0/1 7     Viglino et al. (2008) 
Canada 9/10 1  42 9  Ternes et al. (1999) 
 Canada 6/29 7.1 131 178 177 169 ± 19 Fernandez et al. (2007) 
19-Norethisterone Ontario 0/8 159.1     Tabe et al. (2009) 
BC 5/5 11.1 10.4 23 14 14 ± 5 Nelson et al. (2007) 
Quebec 1/1 7  53   Viglino et al. (2008) 
Canada 1/29 38  159   Fernandez et al. (2007) 
Reproductive Hormones        
17- α-Estradiol Ontario 0/8 101.3     Tabe et al. (2009) 
 Alberta 1/8   1.8   Sosiak et al. (2005) 
 BC 0/5 5.3     Nelson et al. (2007) 
 Canada 4/29 6.9 37 38 37 37 ± 1 Fernandez et al. (2007) 
17-β-Estradiol (E2) Ontario 0/34 5     Lishman et al. (2006) 
Ontario 0/8 158.3     Tabe et al. (2009) 
 Alberta 4/8 3 0.2 2.7   Sosiak et al. (2005) 
 BC 5/5 4.9 0.1 11 2 3 ± 5 Nelson et al. (2007) 
 Manitoba NA/6     0.39 Lee et al. (2004) 
 Quebec 1/1   90   Viglino et al. (2008) 
 Canada 8/10 1  64 6  Ternes et al. (1999) 
 Canada >27/35 0.8 0.2 14.7  1.8 Servos et al. (2005) 
 Canada 14/29 7.1 10 158 25 37 ± 39 Fernandez et al. (2007) 
Estrone (E1) Ontario 17/34 5  38 13 7.6 Lishman et al. (2006) 
 Ontario 7/8 140.6 0.4 12   Tabe et al. (2009) 
 Alberta 6/8  0.3 10.3   Sosiak et al. (2005) 
 BC 5/5 5.4 1.3 27 9 13 ± 12 Nelson et al. (2007) 
 Manitoba NA/6     5.3 Lee et al. (2004) 
 Quebec 0/1 10     Viglino et al. (2008) 
 Canada 8/10 1  48 3  Terrnes et al. (1999) 
 Canada >27/36 0.7 1 96  17 Servos et al. (2005) 
 Canada 18/29 7.6 10 147 43 48 ± 31 Fernandez et al. (2007) 
 Table 2.27 continued (Occurrence of potential EDCs in MWWE in Canada) 
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Compound Region Det.  
Freq. 
DL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Estriol (E3) Ontario 0/8 137.4     Tabe et al. (2009) 
 Alberta 4/8  2.2 4   Sosiak et al. (2005) 
 BC 5/5 5.9 4.9 9 5 6 ± 2 Nelson et al. (2007) 
 Quebec 0/1 50     Viglino et al. (2008) 
 Canada 12/29 1 4 29 29 23 ± 9 Fernandez et al. (2007) 
Progesterone Ontario 0/8 135.7     Tabe et al. (2009) 
 Quebec 0/1 3     Viglino et al. (2008) 
 
Legends: BC = British Columbia   Atl Canada = Atlantic Canada  
RL = Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
 
Note:  
1)  If only one value was detected, it is reported as maximum value in the above table. 
2) Only municipal plant data is considered from Fernandez et al. (2007). In addition, while calculating mean and median from 
this study, the values below MDL were not considered. 
 
 
 
 
Table 2.28 Occurrence of potential EDCs in MWWE in other countries 
Compound Country Det. 
 Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Estrogen Replacement Agents       
Bisphenol-A USA 0/2 0.1     Boyd et al. (2003) 
 USA 2/3 5 50 91   Wert et al. (2009) 
 USA 3/6   270  117 ± 32 Sowers et al. (2009) 
 USA 2/2 5 13 72   Geritty et al. (2011) 
 Austria 6/6 20 26 1530 101 419 ± 605 Clara et al. (2005a)  
 Austria 3/3 15 36 400 73  Schaar et al. (2010) 
 Australia 1/3 1  1.1   Reungoat et al. (2010) 
 China 23/23 1-7.5 28.9 56.8 39.8  Jin et al. (2008) 
 China 2/2 0.9    86 Zhou et al. (2010) 
 Japan 11/11 5 11 143 16 44 ± 50 Nakada et al. (2006) 
 Japan 4/4 1.2-30 50 3480   Nakada et al. (2007) 
 Korea 2/11 5 <5 26 <5 7.1 Ryu et al. (2011) 
Diethylstilbestrol USA 0/1 1     Barber et al. (2011) 
Spain 0/13 25     Pedrouza et al. (2011) 
China 21/23 1-7.5  6.2 3.8  Jin et al. (2008) 
Equilin USA 0/1 1     Barber et al. (2011) 
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Compound Country Det. 
 Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Ovulation Inhibitors        
17-α-Ethinylestradiol 
(EE2) 
USA 4/5 0.053 0.242 0.759   Synder et al. (1999) 
USA 6/6 0.1 0.2 2.4 0.6  Huang et al. (2001) 
USA 0/3 1     Wert et al. (2009) 
USA 9/9  0.1 0.5  0.21 ± 0.13 Sowers et al. (2009) 
USA 0/3 1     Geritty et al. (2011) 
USA 1/3 1  2   Barber et al. (2011) 
USA 0/102 97     Hope et al. (2012) 
USA 0/12 20    < 20 Yang et al. (2011) 
Austria 3/6 1 3 5 4 4 ± 1 Clara et al. (2005a)  
Austria 2/3 0.7 < 4.3 7.4   Schaar et al. (2010) 
 France NA/6 0.5-2    4 ± 1 Ruel et al. (2011) 
 Germany 9/16 1  15 1  Ternes et al. (1999) 
 Germany NA/10     1 ± 0.2 Bahr et al. (2007) 
 Spain 0/13 70     Pedrouza et al. (2011) 
 Sweden 0/3 10     Zorita et al. (2009) 
 Switzerland NA/15  0.1 0.6   Joss et al. (2005) 
 UK NA/56     0.5 ± 0.3 Ifelebuegu et al. (2011) 
(a)
 
 Australia 0/15 0.1     Braga et al. (2005) 
 Australia 0/3 1     Reungoat et al. (2011) 
 China 2/2 1.5    62 Zhou et al. (2010) 
 Japan 0/20 1.2     Komori et al. (2004) 
 Korea 1/7 1  1.3   Kim et al. (2007) 
 Korea 0/11 1     Ryu et al. (2011) 
19-Norethisterone USA 0/1 1     Barber et al. (2011) 
Reproductive Hormones        
17- α-Estradiol USA 0/3 1     Barber et al. (2011) 
 USA 0/102 20     Hope et al. (2012) 
 France NA/6 0.5-2    < 2 Ruel et al. (2011) 
 Spain 0/13 70     Pedrouza et al. (2011) 
 China 2/2 1.3    50 Zhou et al. (2010) 
 Korea 0/5 1.6     Behera et al. (2011) 
 Various    38   VS, ref. Liu et al. (2009) 
17-β-Estradiol (E2) USA 5/5 0.107 0.477 3.66   Snyder et al. (1999) 
USA 8/8 0.1 0.2 4.1 1.9  Huang et al. (2001) 
USA 1/3 0.5  1.8   Wert et al. (2009) 
USA 4/9   2.6  0.42 ± 85 Sowers et al. (2009) 
USA 1/3 0.5  3   Gerrity et al. (2011) 
USA 2/3 1 2 3   Barber et al. (2011) 
USA 4/102 50 8 90 35 42 Hope et al. (2012) 
 Austria 3/6 5 4 30 8 14 ± 14 Clara et al. (2005a) 
 France NA/6 0.5-2    4 Ruel et al. (2011) 
 Germany NA/10     0.9 ± 0.2 Bahr et al. (2007) 
 Spain 0/13 70     Pedrouza et al. (2011) 
 Sweden NA/3 1.6    2.5 ± 2.7 Zorita et al. (2009) 
 Switzerland NA/15  2 8   Joss et al. (2005) 
 UK NA/70     6.9 ± 6.4 Ifelebuegu et al. (2011) 
(a)
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Compound Country Det. 
 Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
17-β-Estradiol (E2) Australia NA/15 0.1    0.95 ± 0.55 Braga et al. (2005) 
(cont’d) Australia 0/3 1     Reungoat et al. (2010) 
 China 19/23 1-7.5  8.6 4.4  Jin et al. (2008) 
 China 2/2 2.1    30 Zhou et al. (2010) 
 Japan NA/20 0.5 < 0.5 11 < 0.5  Komori et al. (2004) 
 Japan 11/11 0.1 0.49 17 4 6 ± 5 Nakada et al. (2006) 
 Japan 4/4 0.015-
1.5 
1.34 2.3   Nakada et al. (2007) 
 Korea 0/7 1     Kim et al. (2007) 
 Korea 2/11 0.5 < 0.5 9.4 < 0.5 1.6 Ryu et al. (2011) 
 Korea 0/5 2.7     Behera et al. (2011) 
 Various    64   VS, ref. Monteiro et al. 
(2010) 
Estrone (E1) USA 0/2 0.3     Boyd et al. (2003) 
 USA 2/2  5.4 20   Synder et al. (2006) 
 USA 3/3  0.44 12 5.4  Wert et al. (2009) 
 USA 9/9  0.4 15.9  2.74 ± 4.98 Sowers et al. (2009) 
 USA 3/3 0.2 15 140  69 ± 64 Gerrity et al. (2011) 
 USA 1/1 1  130   Barber et al. (2011) 
 USA 48/102 20 2 282 45 72 Hope et al. (2012) 
 Austria 4/6 1 2 72 6 22 ± 34 Clara et al. (2005a) 
 Austria 3/3 1.5 <1.1 2 1.6  Schaar et al. (2010) 
 France NA/6 0.5-2    20 ± 30 Ruel et al. (2011) 
 Germany NA/6 3    15 ± 2 Ternes et al. (2003) 
 Germany NA/10     8.7 ± 7.3 Bahr et al. (2007) 
 Spain 1/1 1  4.4   Carballa et al. (2004) 
 Spain 0/13 25     Pedrouza et al. (2011) 
 Sweden NA/3 3    70 ± 10 Zorita et al. (2009) 
 UK NA/70     39 ± 20 Ifelebuegu et al. (2011) 
(a)
 
 Australia NA/15 0.1    8.1 ± 4.2 Braga et al. (2005) 
 Australia 0/3 1     Reungoat et al. (2010) 
 China 23/23 1-7.5 7.2 31.5 12.6  Jin et al. (2008) 
 China 2/2 4.9    123 Zhou et al. (2010) 
 Japan NA/20 0.8 < 0.8 180 12  Komori et al. (2004) 
 Japan 11/11 0.6 3 110 42 47  ± 32 Nakada et al. (2006) 
 Japan 4/4 0.027-
2.1 
20 41   Nakada et al. (2007) 
 Korea 5/7 1 2.2 36  14 Kim et al. (2007) 
 Korea 7/11 5 < 5 120 21 34 Ryu et al. (2011) 
 Korea NA/5 0.84 0 24  6 Behera et al. (2011) 
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Compound Country Det. 
 Freq. 
RL 
ng/L 
Concentration, ng/L Reference 
Min Max Median Mean ± SD  
Estriol (E3) USA 2/2  < 5 5.7   Synder et al. (2006) 
 USA 0/9      Sowers et al. (2009) 
 USA 0/3 1     Barber et al. (2011) 
 USA 0/102 240     Hope et al. (2012) 
 Austria 3/6 1 1 275 17 98 ± 154 Clara et al. (2005a) 
 France NA/6 0.5-2    < 2 Ruel et al. (2011) 
 Spain 0/13 25     Pedrouza et al. (2011) 
 Australia 0/3 1     Reungoat et al. (2010) 
 China 1/23   8.4   Jin et al. (2008) 
 China 2/2 0.9    18 Zhou et al. (2010) 
 Japan NA/20 1.4 < 1.4 5.8 1.5  Komori et al. (2004) 
 Japan 7/8 0.2 0.31 0.84 0.46 0.51 ± 0.18 Nakada et al. (2006) 
 Japan 4/4 0.024-
0.6 
0.11 0.72   Nakada et al. (2007) 
 Korea 3/7 5 8.9 25  16 Kim et al. (2007) 
 Korea 0/5 6     Behera et al. (2011) 
Progesterone USA 0/3 0.5     Wert et al. (2009) 
 USA 1/9   2.6  0.29 ± 0.87 Sowers et al. (2009) 
 USA 0/3 0.5     Gerrity et al. (2011) 
 USA 0/1 1     Barber et al. (2011) 
 Korea 0/11 0.5     Ryu et al. (2011) 
 
Notes:  
a)  The data taken from Ifelebuegu et al. (2011) is for secondary treated effluent only. 
b) If only one value was detected, it is reported as maximum value in the above table. 
 
Legends:  USA:  United States of America  UK: United Kingdom  
RL = Reported limit (i.e. detection limit – DL, or method detection limit – MDL, or limit of detection – LOD, or limit of 
quantification – LOQ) 
 
 
2.4.5 Removal of PhACs and EDCs from MWWE 
As per the discussion in the earlier sections, the municipal effluent contains a 
complex cocktail of various chemicals, PhACs and EDCs. The anthropogenic activities 
have resulted in the omnipresence of these compounds in municipal sewage. The 
conventional MWWTPs cannot effectively remove these micropollutants and hence are a 
major contributor for many of the PhACs and EDCs. The concentrations of the 
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micropollutants are in the range of ng/L to ug/L, and are high enough to produce 
estrogenic activity in fish and aquatic organisms (Auriol et al., 2006). Studies have linked 
them to feminization or masculinization of vertebrates such as fish (Ternes et al., 2004). 
The micropollutants affect the reproduction and growth of fish, amphibians, reptiles, 
birds, and mammals (Bloetscher and Plummer, 2011). The long-term effect of the 
micropollutants on human health is still not clear. However, their negative impacts on 
various aquatic species and mammals are a cause of concern. This concern prompts 
preventive and precautionary measures to reduce the amount of the micropollutants 
released into the environment. To protect public health, it is easier to treat the MWWE to 
remove the micropollutants and address the pollution at source, rather than treating the 
potable water in which these pollutants have been diluted several orders of magnitude. In 
addition, removing of the micropollutants from MWWE will have positive effects on the 
aquatic species in the receiving water bodies. 
The molecular size of most of the PhACs and EDCs is in the range of 150 to 500 
Daltons (Snyder et al., 2003).  Shon et al. (2006) have provided the size range of effluent 
organic matter (EfOM) removed by various MWWE treatment processes. Figure 2.5 
reproduces this data. This figure shows that membrane filtration (reverse osmosis and 
nanofiltration), activated carbon adsorption, ion exchange, and advanced oxidation are 
the treatment processes that can remove 150 to 500 Daltons size EfOM. 
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Figure 2.5 Size range of effluent organic matter removed by various treatment processes 
 (Adapted from Shon et al. 2006) 
 
Reverse osmosis and nanofiltration membrane processes are effective in the 
removal of the micropollutants from MWWE (Sedlak and Pinkston, 2001; Yoon et al., 
2007; Liu et al., 2009; Lee et al., 2012). Membrane filtration is a physical method of 
micropollutant removal, and does not produce by-products or metabolites (Liu et al., 
2009). However, operation cost and membrane fouling can limit their potential use 
(Petala et al., 2006). These processes are very energy intensive. In addition, the waste 
stream can be 15 to 25% of the feed and can have high concentrations of regulated 
contaminants as well as micropollutants that can make their disposal difficult and 
expensive (Lee et al., 2012). 
Adsorption of micropollutants by activated carbon can be by granular activated 
carbon (GAC) bed or by adding powdered activated carbon (PAC) to the (Snyder et al., 
2003).  Ternes et al. (2002) have shown that activated carbon can effectively remove the 
majority of the micropollutants. However, competition for adsorption by the organic 
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matter present in MWWE and blockage of the pores of carbon can decrease the 
adsorption capacity of the target compounds (Koh et al., 2008). In addition, the GAC can 
release the adsorbed compounds and replace it by more strongly adsorbable compounds 
(Snyder et al., 2003).When the adsorption capacity is exhausted, the activated carbon in 
GAC bed needs replacement or regeneration, which is a costly process (Koh et al., 2008).  
The ion exchange process is effective in removing the majority of the 
micropollutants and dissolved organic carbon, and can be less expensive than activated 
carbon in removing of EfOM (Shon et al., 2006). While this process can produce high 
quality effluent, it is a costly process when compared to other treatment processes. The 
waste stream generated during backwash and regeneration can contain high concentration 
of the micropollutants that can make it difficult and costly to dispose. 
Some of the oxidation processes for the transformation of the micropollutants are 
chlorination, chlorine dioxide oxidation, UV irradiation, and ozonation (Snyder et al., 
2003; Koh et al., 2008). The concerns related to the formation of carcinogenic 
by-products on treatment of MWWE with chlorine-based oxidants makes chlorination 
and chlorine dioxide oxidation the less sought treatment methods for oxidation of 
micropollutants. In addition, the ammonia present in the MWWE can react and reduce 
the reactivity of chlorine (Snyder et al., 2003).    
UV radiation disinfects MWWE at reasonable cost (Rice, 1999) and is widely 
used (Snyder et al., 2003). The typical UV dose for disinfection is from <5 up to 
140 mJ/cm
2
 (Snyder et al., 2003; Kim et al., 2009). Studies have attempted to use the UV 
radiation technology to remove pharmaceuticals from MWWE.  Kim et al. (2009) found 
over 90% reductions of some pharmaceuticals at a UV dose of 923 mJ/cm
2
 and 5 minutes 
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of contact time. Out of the 41 pharmaceuticals monitored by them, 29 showed low 
removal even at high UV dose of 2768 mJ/cm
2
 and 15 minutes of contact time. The 
experimental results show that the removal of the pharmaceuticals will be low at a UV 
disinfection dose. 
As discussed earlier, ozone is a powerful oxidant. It decomposes to form oxidants 
such as the hydroxyl radical, which is more powerful oxidant than ozone (Hoigné and 
Bader, 1976). Oxidation reactions directly with ozone are highly selective and slow while 
those with hydroxyl radicals are nonselective and fast (Hoigné and Bader, 1976; Huber et 
al., 2003). The second-order reaction rate constant of the pharmaceuticals with ozone is 
in the range of <1 to 10
6
 M
-1
 s
-1
 and with hydroxyl radical is around 10
9
 M
-1
 s
-1
 (Huber et 
al., 2003; Huber et al., 2005; Dodd et al., 2006). Studies have shown that ozonation can 
effectively mineralize or transform the pharmaceuticals and other chemicals present in 
water and wastewater matrices (Ternes et al., 2003; Huber et al., 2005; Nakada et al., 
2007).  
 
2.4.6 Oxidation of CECs in MWWE by ozonation 
The number of studies that have investigated the transformation of CECs present 
in MWWE by ozonation is limited. The results from these studies indicate that ozonation 
is effective in transforming antiphlogistics, antibiotics, lipid regulators, antidepressants, 
estrogen replacement agents, ovulation inhibitors, and natural and synthetic hormones 
found in the MWWE. Table 2.29 represents the data from some studies that have 
examined the transformation of antiphlogistics on ozonation of MWWE.  
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Table 2.29 Transformation of antiphlogistics present in MWWE by ozonation 
Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated 
 effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/ mg C ng/L ng/L ng/L   
Acetaminophen 4 10.9 – 11.4 5 ~ 0.5 10 > 100 < RL > 96 RG1 
 1 3.2 2   ( 2 – 402)  > 99 KM 
 1 4.5 – 4.7 2 ~ 0.5 5 18 < RL 86 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 5 62.5 < RL 96 LE1, LE2 
Diclofenac 2 23 5 ~ 0.2 50 1300 ± 100 < RL > 96 TN 
 1 12  0.2  4380 4380 0 BH 
 1 12  0.4  4380 2 100 BH 
  7.7 ± 0.5 1     93 HU 
  7.7 ± 0.5 2     99 HU 
 2 7.2 2.1  1 71 – 73  > 99 SN 
 1 6.84 7 1  73 < 1 > 98 DS 
 4 4.7 – 6.0  0.36 – 0.55 10 501 – 1731 < RL – 15 97 – 100  (99) HO 
 4 5.4  0.6 – 0.67 10 855 – 1236 < RL 98 – 100  (99) HO 
 3 6.6 – 10.3  0.2  47 – 150  25 to > 95 WT 
 3 6.6 – 10.3  0.6  47 – 150  > 95 WT 
  6.9 < 2.4 < 0.4 1 433 < RL > 99 RS 
 4 10.9 – 11.4 5 ~ 0.5 10 > 100 < RL > 94 RG1 
 3 6.5 – 8.1  0.6 – 0.8  194 – 240   > 98 RG2 
 3 5.8 – 6.6   0.4 – 0.5   140 – 206   > 98 RG2 
 3 4.2 – 5.8   0.2 – 0.3  162 – 316   97 ± 4 RG2 
 3 2.7 – 3.4 2   ( 2 – 402)  97 to > 99 KM 
 2 5.8 & 7.4 4.6 & 5  20 970 & 200 < RL > 99 SC 
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Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated 
 effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/ mg C ng/L ng/L ng/L   
Ibuprofen 2 23 5 ~ 0.2 50 130 ± 30 67 48 TN 
 2 23 10/15  50 130 ± 30 < RL > 62 TN 
 1 12  0.2  30 26 13 BH 
 1 12  0.4  30 16 47 BH 
 1 12  0.8  30 3 90 BH 
 1 12  1.0  30 4 87 BH 
 2 7.2 2.1  1 5.6 – 15  < 1 SN 
 2 7.2 3.6  1 5.6 – 15  > 82 SN 
 3 3.4 – 4.4  3  0.03-1.2 0.4-2.98 0.26-1.07 -156 to > 76 (36) NK 
 1 6.84 7 1  5.6 < 1 > 82 DS 
 2 4.7 – 6.0  0.36 – 0.55 20 56 – 86 < RL – 80 -43 & 88 HO 
 1 5.4  0.67 20 80 < RL 50 HO 
 3 6.6 – 10.3  0.2  5 – 85   10 to 30 WT 
 3 6.6 – 10.3  0.6  5 – 85   60 to > 95 WT 
 3 6.6 – 10.3  1.0  5 – 85   95 to > 95 WT 
 1 7.4 5  20 31 < RL > 35 SC 
Indomethacin 2 23 5 ~ 0.2 50 100 ± 40 < RL > 50 TN 
 1 12  0.2  124 29 77 BH 
 1 12  0.4  124 20 84 BH 
 1 12  0.8  124 7 94 BH 
  6.9 < 2.4 < 0.4 2 37 < RL > 97 RS 
Ketoprofen 4 3.4 – 4.4  3  0.03-15 76 – 333 20 – 139  52 – 93 (73) NK 
 1 12  0.2  122 114 7 BH 
 1 12  0.4  122 84 31 BH 
 1 12  0.8  122 22 82 BH 
 1 12  1.0  122 15 88 BH 
 1 12  1.2  122 2 98 BH 
  6.9 16.3 ~ 2.4 2 162 3 98 RS 
 3 2.7 – 3.4 2   ( 2 – 402)  31 – 71 KM 
 1 2.7 – 3.4 4   ( 2 – 402)  91 KM 
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Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated 
 effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/ mg C ng/L ng/L ng/L   
Ketoprofen (cont’d) 1 4.5 – 4.7 2 ~ 0.5 5 62 55 11 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 5 6 < RL 58 LE1, LE2 
Naproxen 2 23 5 ~ 0.2 50 100 ± 10 < RL > 50 TN 
 1 12  0.2  157 78 50 BH 
 1 12  0.4  157 3 98 BH 
 1 12  0.6  157 4 97 BH 
 2 7.2 2.1  1 25 – 71  > 96 SN 
 4 3.4 – 4.4  3  0.24-27 28 – 99  < RL – 0.79 > 68 to > 99.5 NK 
 1 6.84 7 1  25 < 1 > 96 DS 
 4 4.7 – 6.0  0.36 – 0.55 10 194 – 292 < RL 70 – 98  (98) HO 
 4 5.4  0.6 – 0.67 10 215 – 329 < RL – 5 59 – 98  (98) HO 
 3 4.2 – 4.6  0.77 – 1.16 10 181 – 291 < RL 70 – 97   (97) HO 
 3 6.6 – 10.3  0.2  23 – 51   20 to > 95 WT 
 3 6.6 – 10.3  0.6  23 – 51  > 95 WT 
  6.9 < 2.4 < 0.4 12 109 < RL > 92 RS 
 3 6.5 – 8.1  0.6 – 0.8  188 – 587  > 90 RG2 
 3 5.8 – 6.6   0.4 – 0.5   189 – 346  > 98 RG2 
 3 4.2 – 5.8   0.2 – 0.3  83 – 142   93 ± 9 RG2 
 3 2.7 – 3.4 2   ( 2 – 402)  43 to > 99 KM 
 1 2.7 – 3.4 4   ( 2 – 402)  83 KM 
 1 4.5 – 4.7 2 ~ 0.5 10 68 < RL 93 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 10 160 < RL 97 LE1, LE2 
 1 4.1 – 4.3  8 ~ 2 10 260 < RL 98 LE1, LE2 
 
Legends: TOC: Total Organic Carbon  DOC: Dissolved Organic Carbon   O3: Ozone   RL: Reported Limit 
 
Note: For Reference Legends, refer to page 112. 
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The data in Table 2.29 indicates that some of the CECs such as acetaminophen, 
diclofenac, indomethacin, and naproxen are transformed by over 80% at an ozone dose of 
around 0.5 mg O3/mg DOC. CECs such as ibuprofen and ketoprofen require an ozone 
dose of around 0.8 mg O3/mg DOC or higher for similar transformation. 
Table 2.30 shows the data from the literature on the transformation of antibiotics 
on ozone treatment of MWWE. Studies have reported more than 80% reduction in 
concentration of erythromycin, lincomycin, roxithromycin, sulfadiazine, 
sulfamethoxazole, and sulfathiazole. There is limited data regarding transformation of 
some CECs such as ciprofloxacin and norfloxacin that are consumed in notable quantity. 
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Table 2.30 Transformation of antibiotics present in MWWE by ozonation 
Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Carbadox 1 4.5 – 4.7 2 ~ 0.5 5 27 < RL 91 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 5 6.1 < RL 59 LE1, LE2 
Chloramphenicol 2 2.7 – 3.4 2   ( 2 – 402)  63 – 68 KM 
Ciprofloxacin  6.9 < 6.2 < 1 5 522 < RL > 99 RS 
 3 2.7 – 3.4 2   ( 2 – 402)  67 to > 99 KM 
 12 4.5 1  10 19 – 30 (23) <10 – 16  YG 
Norfloxacin  6.9 < 4.3 ~ 0.6 8 38 < RL > 89 RS 
Erythromycin 2 23 5 ~ 0.2 50 620 ± 240 < RL > 92 TN 
  7.7 ± 0.5 1     75 HU 
  7.7 ± 0.5 2     98 HU 
 2 7.2 2.1  1 149 – 162   98 SN 
 1 3.4 – 4.4  3  0.0012 103 11.7 89 NK 
 1 6.84 7 1  162 < 1 > 99 DS 
 2 4.7 – 6.0  0.36 – 0.55 20 15 – 17 < RL – 73 -387 & 41 HO 
 3 5.4  0.6 – 0.67 20 19 – 49 < RL 47 – 80   (69) HO 
 2 4.2 – 4.6  0.77 – 1.16 20 48 – 73 < RL 22 & 86 HO 
  6.9 < 4.3 ~ 0.6 10 72 < RL > 99 RS 
 4 10.9 – 11.4 5 ~ 0.5 10 > 100 < RL 95 RG1 
 2 6.5 – 8.1  0.6 – 0.8  153 – 167  97 ± 0.5 RG2 
 3 5.8 – 6.6   0.4 – 0.5   250 – 324   86 ± 11 RG2 
 3 4.2 – 5.8   0.2 – 0.3  20 – 32   83 ± 13 RG2 
 2 2.7 – 3.4 2   ( 2 – 402)  95 to > 99 KM 
 2 5.8 & 7.4 4.6 & 5  20 170 & 210 < RL > 88 SC 
 1 7 7.5  20 170  76 SC 
 12 4.5 1  10 13 – 50 (28) <10 – 15  YG 
 1 4.1 – 4.4 4 ~ 1 10 18.5 < RL 73 LE1, LE2 
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Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Lincomycin  6.9 < 2.4 < 0.4 3 12 < RL > 88 RS 
 3 2.7 – 3.4 2   ( 2 – 402)  88 to > 99 KM 
Roxithromycin 2 23 5 ~ 0.2 50 540 ± 40 < RL > 91 TN 
  7.7 ± 0.5 1     56 HU 
  7.7 ± 0.5 2     97 HU 
  7.7 ± 0.5 3.5     99 HU 
 1 3.4 – 4.4  3  < 0.001 20.9 1.9 91 NK 
 3 4.7 – 6.0  0.36 – 0.55 3 6 – 26 < LOQ 76 – 94   (79) HO 
 3 5.4  0.6 – 0.67 3 4 – 7 < LOQ – 1 70 – 80   (75) HO 
 4 10.9 – 11.4 5 ~ 0.5 10 > 100  79 – 91 (84) RG1 
 3 6.5 – 8.1  0.6 – 0.8  77 – 154   92 ± 5 RG2 
 3 5.8 – 6.6   0.4 – 0.5   456 – 703   86 ± 10 RG2 
 3 4.2 – 5.8   0.2 – 0.3  60 – 187   85 ± 15 RG2 
 3 2.7 – 3.4 2   ( 2 – 402)  76 to > 99 KM 
 1 7.4 5  10 27 < RL > 63 SC 
 1 7 7.5  10 160 < RL > 94 SC 
Sulfadiazine  7.7 ± 0.5 1     84 HU 
  7.7 ± 0.5 2     > 99 HU 
 1 6.0  0.47 35 127 50 61 HO 
 2 4.2 – 4.6  0.77 – 1.16 35 17 – 127 < RL -5 & 86 HO 
 1 4.5 – 4.7 2 ~ 0.5 5 19 < RL 87 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 5 9.2 < RL 73 LE1, LE2 
 1 4.1 – 4.3  8 ~ 2 5 16 < RL 84 LE1, LE2 
Sulfadimethoxine 3 2.7 – 3.4 2   ( 2 – 402)  98 to > 99 KM 
Sulfamerazine 1 3.2 2   ( 2 – 402)  > 99 KM 
Sulfamethazine 2 5.4  0.6 – 0.67 5 7 – 20 < RL 64 – 88 HO 
 2 4.2 – 4.6  0.77 – 1.16 5 7 – 9 < RL 72 – 100 HO 
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Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Sulfamethoxazole 2 23 5 ~ 0.2 50 620 ± 50 < RL > 92 TN 
  7.7 ± 0.5 1     67 HU 
  7.7 ± 0.5 2     97 HU 
  7.7 ± 0.5 3.5     > 99 HU 
 2 7.2 2.1  1 669 – 695  93 SN 
 2 7.2 3.6  1 669 – 695  > 99 SN 
 1 5.6 1 0.2  251 3.2 > 99 DS 
 1 6.84 7 1  669 < 1 > 99 DS 
 4 4.7 – 6.0  0.36 – 0.55 7 84 – 434 < RL – 29 80 – 99   (86) HO 
 4 5.4  0.6 – 0.67 7 99 – 274 < RL 95 – 98   (97) HO 
 3 4.2 – 4.6  0.77 – 1.16 7 96 – 282 < RL 88 – 98   (97) HO 
 3 6.6 – 10.3  0.2  330 – 1200    30 to ~ 95 WT 
 3 6.6 – 10.3  0.6  330 – 1200    95 to > 95 WT 
 3 6.6 – 10.3  1.0  330 – 1200    > 95 WT 
  6.9 < 10.6 ~ 1.5 8 95 < RL > 96 RS 
 4 10.9 – 11.4 5 ~ 0.5 10 > 100 < RL > 93  RG1 
 3 6.5 – 8.1  0.6 – 0.8  160 – 272   94 ± 3 RG2 
 3 5.8 – 6.6   0.4 – 0.5   39 – 229   96 ± 2 RG2 
 3 4.2 – 5.8   0.2 – 0.3  278 – 1701   97 ± 3 RG2 
 3 2.7 – 3.4 2   ( 2 – 402)  94 to 97 KM 
 2 5.8 & 7.4 4.6 & 5  10 73 & 100 < RL > 86 SC 
 1 7 7.5  10 140 < RL > 93 SC 
 12 4.5 1  10 210–1200 (670) 35-140 (80) 88 YG 
 1 4.5 – 4.7 2 ~ 0.5 10 470 250 47 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 10 1040 12.5 99 LE1, LE2 
 1 4.1 – 4.3  8 ~ 2 10 1600 < RL 100 LE1, LE2 
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Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Sulfathiazole  7.7 ± 0.5 1     94 HU 
  7.7 ± 0.5 2     > 99 HU 
 1 4.5 – 4.7 2 ~ 0.5 5 9.2 < RL 73 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 5 5.4 < RL 54 LE1, LE2 
          
Trimethoprim 2 23 5 ~ 0.2 50 340 ± 40 < RL > 85 TN 
 2 7.2 2.1  1 191 – 229  > 99 SN 
 1 3.4 – 4.4  3  0.027 5.5 0.22 96 NK 
 1 5.6 1 0.2  4.4 < 0.25 > 94 DS 
 1 6.84 7 1  191 < 1 > 99 DS 
 4 4.7 – 6.0  0.36 – 0.55 5 71 – 234 < RL 93 – 98   (97) HO 
 4 5.4  0.6 – 0.67 5 76 – 165 < RL 91 – 98   (97) HO 
 3 4.2 – 4.6  0.77 – 1.16 5 85 – 125 < RL 88 – 98   (97) HO 
 3 6.6 – 10.3  0.2  36 - 370  55 to ~ 95 WT 
 3 6.6 – 10.3  0.6  36 - 370  > 95 WT 
  6.9 < 4.3 ~ 0.6 2 73 < RL > 99 RS 
 4 10.9 – 11.4 5 ~ 0.5 10 > 100 < RL > 93  RG1 
 3 6.5 – 8.1  0.6 – 0.8  27 – 49   > 97 RG2 
 3 5.8 – 6.6   0.4 – 0.5   48 – 141   97 ± 2 RG2 
 3 4.2 – 5.8   0.2 – 0.3  49 – 94   95 ± 6 RG2 
 3 2.7 – 3.4 2   ( 2 – 402)  94 to > 99 KM 
 2 5.8 & 7.4 4.6 & 5  20 150 & 240 < RL > 93 SC 
 1 7 7.5  20 320 < RL > 97 SC 
 12 4.5 1  10 11 – 32 < 10  YG 
 1 4.1 – 4.4 4 ~ 1 10 79.5 < RL 94 LE1, LE2 
 1 4.1 – 4.3  8 ~ 2 10 60 < RL 92 LE1, LE2 
 
Legends: TOC: Total Organic Carbon  DOC: Dissolved Organic Carbon   O3: Ozone   RL: Reported Limit 
 
Note: For Reference Legends, refer to page 112. 
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The data from some studies related to transformation of antidepressants and lipid 
regulators is summarized in Table 2.31 and Table 2.32. The data indicates that 
carbamazepine and gemfibrozil are transformed by more than 90% even at a low ozone 
dose of around 0.2 mg O3/mg DOC. At similar ozone dose, transformation of bezafibrate 
is close to zero while that of clofibric acid is in the range of -6 to 50%. These two drugs 
are transformed by over 80% at an ozone dose of around 0.8 mg O3/mg DOC.  
Table 2.33 shows the effect of ozonation of MWWE on the transformation of the 
EDCs. Majority of the listed EDCs are transformed by more than 80% at an ozone dose 
of around 0.5 mg O3/mg DOC. 
Since it is difficult to measure the actual transformation of the CECs present in 
MWWE in concentrations close to or below the detection limits, some studies have 
spiked the MWWE with CECs to study their transformation on ozonation. Appendix-A 
summarizes the result from some of these studies. Data from Table 2.29 to Table 2.33 
and Appendix-A indicates that an increase in the ozone dose generally results in an 
increase in transformation of the CECs. However, it also increases the cost of ozonation 
as well as the concentration of harmful disinfection by-products formed (Liberti et al., 
2000; Kim et al., 2007a). Ozonation of water or wastewater containing bromide can form 
potentially toxic bromate (Haag and Hoigné, 1983; von Gunten and Hoigné, 1994). 
Studies by Bahr et al. (2007) and Kim et al. (2007a) have shown that even if the 
secondary effluent contains bromide concentration of up to 500 μg/L, the formation of 
bromate on its ozonation can be limited to around 10 μg/L if the ozone dose is 
< 1 mg O3/mg DOC. This ozone dose is sufficient to transform the majority of the CECs 
by more than 80%. 
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Table 2.31 Transformation of antiepileptic/antidepressant present in MWWE by ozonation 
Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Carbamazepine 2 23 5 ~ 0.2 50 2100 ± 40 < RL > 98 TN 
 1 12  0.2  2000 1000 50 BH 
 1 12  0.4  2000 < 50 99 BH 
 2 7.2 2.1  1 139  > 99 SN 
 3 3.4 – 4.4  3  1.5 – 21  2.9 – 36   < RL – 33 8.3 to > 81 NK 
 1 5.6 1 0.2  48 < 0.5 > 99 DS 
 1 6.84 7 1  139 < 1 > 99 DS 
 4 4.7 – 6.0  0.36 – 0.55 3 186 - 687 < RL – 6 97 – 100   (99) HO 
 4 5.4  0.6 – 0.67 3 76 – 165 < RL 91 – 98  (97) HO 
 3 4.2 – 4.6  0.77 – 1.16 3 384 – 714 < RL 98 – 100   (100) HO 
 3 6.3 – 10.3  0.2  170 – 350  50 to > 95 WT 
 3 6.3 – 10.3  0.6  170 – 350  > 95 WT 
  6.9 < 6.2 < 1 1 106 < RL > 99 RS 
 4 10.9 – 11.4 5 ~ 0.5 10 > 100 < RL > 98 RG1 
 2 6.5 – 8.1  0.6 – 0.8  468 – 631  98 ± 1 RG2 
 3 5.8 – 6.6   0.4 – 0.5   119 – 172  98 ± 1 RG2 
 2 4.2 – 5.8   0.2 – 0.3  727 – 1192   90 ± 13 RG2 
 3 2.7 – 3.4 2   ( 2 – 402)  98 to > 99 KM 
 2 5.8 & 7.4 4.6 & 5  1 500 & 900  > 99 SC 
 12 4.5 1  10 25 – 140 (67) <10 – 12  YG 
 1 4.5 – 4.7 2 ~ 0.5 5 450 17 96 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 5 410 < RL 99 LE1, LE2 
 1 4.1 – 4.3  8 ~ 2 5 440 < RL 99 LE1, LE2 
 
Legends: TOC: Total Organic Carbon  DOC: Dissolved Organic Carbon   O3: Ozone   RL: Reported Limit 
 
Note: For Reference Legends, refer to page 112. 
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Table 2.32 Transformation of lipid regulators present in MWWE by ozonation 
Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Bezafibrate 1 12  0.2  470 470 0 BH 
 1 12  0.4  470 390 17 BH 
 1 12  0.8  470 10 98 BH 
  7.7 ± 0.5 2     49 HU 
  7.7 ± 0.5 3.5     95 HU 
  7.7 ± 0.5 5     > 99 HU 
 4 4.7 – 6.0  0.36 – 0.55 14 48 – 133  9 - 76 8 – 82   (54) HO 
 4 5.4  0.6 – 0.67 14 55 – 108 <LOQ – 21 81 – 91   ( 88) HO 
 3 4.2 – 4.6  0.77 – 1.16 14 37 – 67 < RL 51 – 89   (81) HO 
  6.9 16.3  ~ 2.4 4 115 4 97 RS 
 3 2.7 – 3.4 2   ( 2 – 402)  47 - 82 KM 
 1 2.7 – 3.4 4   ( 2 – 402)  >99 KM 
 2 5.8 & 7.4 4.6 & 5  20 1500 & 1600  76 – 81  SC 
 1 7 7.5  20 1500  87 SC 
          
Clofibric acid 2 23 5 ~ 0.2 50 120 ± 20 60 50 TN 
 2 23 10/15  50 120 ± 20 < RL > 59 TN 
 1 12  0.2  70 74 - 6 BH 
 1 12  0.4  70 55 21 BH 
 1 12  0.8  70 18 74 BH 
 1 12  1  70 11 84 BH 
 1 12  1.2  70 2 97 BH 
 3 5.4  0.6 – 0.67 3 12 – 44 < RL – 15 50 – 79   (66) HO 
 3 4.2 – 4.6  0.77 – 1.16 3 11 – 18 < RL 8 6 – 86  (86) HO 
 2 2.7 – 3.4 2   ( 2 – 402)  57 - 74 KM 
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Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Gemfibrozil 2 7.2 2.1 0.3 10 16 – 567  > 94 SN 
 1 5.6 1 0.2  3.5 < 0.25 > 93 DS 
 1 6.84 7 1  16 < 1 > 94 DS 
 3 6.3 – 10.3  0.2  35 – 1600   30 to > 95 WT 
 3 6.3 – 10.3  0.6  35 – 1600   > 95 WT 
  6.9 16.3 ~ 2.4 1 332 15 95 RS 
 4 10.9 – 11.4 5 ~ 0.5 10 > 100 < RL 91 RG1 
 3 6.5 – 8.1  0.6 – 0.8  84 – 155   97 ± 2 RG2 
 3 5.8 – 6.6   0.4 – 0.5   36 – 60   81 ± 0.5 RG2 
 3 4.2 – 5.8   0.2 – 0.3  83 – 191   76 ± 15 RG2 
 1 4.5 – 4.7 2 ~ 0.5 5 9.3 < RL 72 LE1, LE2 
 1 4.1 – 4.4 4 ~ 1 5 43 < RL 94 LE1, LE2 
 1 4.1 – 4.3  8 ~ 2 5 85 < RL 97 LE1, LE2 
          
 
Legends: TOC: Total Organic Carbon  DOC: Dissolved Organic Carbon   O3: Ozone   RL: Reported Limit 
 
Note: For Reference Legends, refer to page 112. 
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Table 2.33 Transformation of EDCs present in MWWE by ozonation 
Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre ozonated  
effluent 
Post ozonated 
effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/mg C ng/L ng/L ng/L   
Bisphenol-A 4 3.4 – 4.4  3  1.2 – 30  94 – 205  12.2 – 108 47 – 87  NK 
 2 10.3  0.2   50 – 91   62 to 70 WT 
 2 10.3  0.6   50 – 91   > 95 WT 
 2 5.8 & 7.4 4.6 & 5  15 73 & 400 < RL > 87 SC 
17α-ethinylestradiol  7.7 ± 0.5 0.5     63 HU 
 7.7 ± 0.5 1     83 HU 
  7.7 ± 0.5 2     > 97 HU 
 1 7 7.5  0.7 7.4 < RL > 72 SC 
17β-Estradiol  7.7 ± 0.5 0.5     60 HU 
  7.7 ± 0.5 1     82 HU 
  7.7 ± 0.5 2     > 97 HU 
 3 3.4 – 4.4  3  0.015-1.5 1.58 – 2.63 0.15 – 7.8 > 93 to 97 NK 
Estrone (E1) 2 23 5 ~ 0.2 3 15 ± 2 < RL > 80 TN 
  7.7 ± 0.5 0.5     57 HU 
  7.7 ± 0.5 1     84 HU 
  7.7 ± 0.5 2     > 97 HU 
 2 7.2 2.1  1 5.4 – 20  44 SN 
 4 3.4 – 4.4  3  0.027-0.9 16 – 39 0.15 – 7.8 66 – 87 (95) NK 
 1 6.84 7 1  4.3 < 1 > 77 DS 
 1 7.4 5  1.5 1.6 < RL > 50 SC 
 1 7 7.5  1.5 2 < RL > 60 SC 
Estriol 3 3.4 – 4.4  3  0.024-0.6 0.22 – 1.22 0.10 – 0.12 56 to > 77 NK 
 
Legends: TOC: Total Organic Carbon  DOC: Dissolved Organic Carbon   O3: Ozone   RL: Reported Limit 
Note: For Reference Legends, refer to page 112. 
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Reference Legends: 
 
BH  Bahr et al. (2005) 
DS  Dickenson et al. (2009) 
HO  Hollender et al. (2009) 
HU  Huber et al. (2005) 
KM  Kim and Tanaka (2011) Individual concentration of chemicals not provided. All chemicals were in range of 2 – 402 ng/L. 
LE1  Lee et al. (2012)  (while calculating percentage reduction, values < RL is replaced by half of RL values) 
LE2  Lee (2010) 
NK  Nakada et al. (2007) 
RG1  Reungoat et al. (2010) 
RG2  Reungoat et al. (2012) 
RS  Rosal et al. (2010)  (while calculating percentage reduction, values < RL is replaced by half of RL values) 
SC  Schaar et al. (2010) 
SN  Snyder et al. (2006) 
TN  Ternes et al. (2003) 
WT  Wert et al. (2009a) 
YG  Yang et al. (2011) 
 
 
 113 
2.4.7 Oxidation kinetics of CECs in MWWE with ozone 
On ozonation of MWWE, molecular ozone and hydroxyl radicals can oxidize the 
CECs. The oxidant that will dominate the oxidation process will depend on various 
factors as discussed in earlier sections. The oxidation rate equation as per von Gunten 
(2003b) is: 
     •OHCkOCk
dt
dC
OH3O3       (2.13) 
 
C  concentration of compound 
 3O    concentration of ozone 
 •OH   concentration of hydroxyl radicals 
O3k   
second-order reaction rate constant  of compound with ozone 
OHk   
second-order reaction rate constant of compound with OH radical 
t  time 
 
Integrating the Equation 2.13 and substituting the OH radical concentration with 
   3CT O/•OHR   i.e. ratio of hydroxyl and ozone exposure (details in Section 2.3.3), 
the following equation is obtained: 
 






dtO)Rk(k
C
C
ln 3CTOHO3
O
    (2.14) 
Co initial concentration of compound (at time t = 0) 
C concentration of compound at time t 
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This is analogous to the disinfection kinetics earlier (Equation 2.7 and 2.8). From 
the Equation 2.13 and 2.14, the fraction of a compound that reacts with hydroxyl radical 
 COH,f  and molecular ozone (fO3) is: 
)Rk(k
Rk
f
CTOHO3
CTOH
COH,

       (2.15) 
COH,O3 f  - 1    f         (2.16) 
 
In case of ozonation of low pH water or wastewater having high concentration of 
OH radical scavengers, the oxidation by OH radicals will be ineffective (Hoigné and 
Bader, 1983a). In this case, ignoring the terms related to OH radicals in Equation 2.14, it 
can be rewritten as: 
 






dtOk
C
C
ln 3O3
O
      (2.17) 
 
From this equation, the half-life of compound C, due to oxidation with ozone is: 
    O33O33
1/2
kxO
0.69
/ηkxO
0.69
t       (2.18) 
 
In the above equation, 
η   is the short-circuiting factor, and is considered as unity 
for a batch type reactor or a plug flow reactor. If the second-order reaction rate constant 
of the compound is known, equation 2.18 gives an indication if the compounds will 
oxidize by ozonation in typical water or wastewater treatment plant. Consider a typical 
wastewater ozonation unit having a dissolution chamber with 2 minutes of detention 
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time, typical transferred ozone dose of 4 mg/L and a residual ozone concentration at the 
outlet of this chamber of 2 mg/L (approximately 4 x 10
-5
 M). Assuming uniform 
concentration of the compound and ozone in the chamber, ozone concentration drops to 
below detection limit in the first contact column, and the detention time in dissolution 
chamber equal to the half-life of the compound, the reaction-rate constant ( O3k ) of 
140 M
-1
 s
-1
 is calculated. This indicates that only the compounds that have reaction-rate 
constants greater than 140 M
-1
 s
-1
 will oxidize by more than 50% if hydroxyl radicals do 
not contribute significantly in their oxidation. At typical ozone doses for disinfection of 
MWWE, since the exposure of oxidant decreases significantly in the chambers following 
the dissolution chamber, the majority of the oxidation of the compounds will occur in the 
dissolution chamber itself. 
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CHAPTER III 
DESIGN AND METHODOLOGY 
 
3.1  SOURCE AND QUALITY OF MWWE 
A pilot plant was set-up at the Little River Pollution Control Plant (LRPCP), 
Windsor, Ontario, Canada for ozone treatment of secondary treated MWWE. LRPCP has 
a treatment capacity of 73,000 m
3
/day. Figure 3.1 shows the treatment process of LRPCP. 
It consists of preliminary and primary treatment, followed by biological treatment 
(activated sludge process). The treatment process includes the addition of alum after grit 
removal to enhance coagulation and phosphorus removal. In general, the effluent BOD5 
and TSS values are less than 10 mg/L (personal communication with Chris Manzon, 
Plant Manager, LRPCP). The plant discharges the effluent with or without disinfection 
into Little River that leads into the Detroit River. The plant meets the specified 
disinfection requirement of < 200 MPN E. coli/100 mL during the months of April-
October with UV disinfection. In the current study, the municipal wastewater plant 
effluent (MWWE) before disinfection was the feed water (influent) to the pilot unit. 
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Figure 3.1 Treatment process of LRPCP 
 
3.2  PILOT UNIT 
Figure 3.2 shows the schematics while Figure 3.3 shows the picture of the pilot 
unit. Pilot unit consisted of an ozone contactor, ozone generator (Lab2B, Triogen, 
Glasgow, UK), and ozone monitor (Model 454, Teledyne, San Diego, USA). Air was the 
feed gas to generate ozone. The ozone contactor comprised of a dissolution chamber 
(DC) and four reaction chambers (RC#1 to RC#4). The material of the columns was clear 
PVC and that of fittings was ozone resistant stainless steel or Teflon. MWWE was 
collected in a 300 L feed tank, from where it was transferred to the top of the DC by a 
peristaltic pump. A coarse bubble glass diffuser dispersed the air enriched with ozone at 
the bottom of the dissolution chamber. The water flowed counter-current to the rising gas 
bubbles. Ozonated wastewater from the DC entered the first reaction chamber (RC#1) 
from the bottom and flowed upwards. Similarly, the flow entered the column RC#2 from 
the top and the columns RC#3 and RC#4 from the bottom. The column RC#4 provided 
additional contact time to ensure that effluent from the pilot unit did not contain any 
residual ozone. When operated in continuous flow mode at a flow rate of 4 L/min, the 
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hydraulic retention time (HRT) in the DC and in RC#1 to RC#3 was 1.7 minutes in each 
of them. The HRT in RC#4 was 10 minutes. Table 3.1 lists the design parameters of the 
ozone contactor. Sampling ports were provided at the inlet of the dissolution chamber, 
and at the outlet of all the five chambers. 
 
 
 
Figure 3.2 Schematic of the pilot unit 
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Figure 3.3 Picture of the pilot unit installed at LRPCP 
  (inset picture shows the ozone generator and monitor) 
 
Table 3.1 Design parameters of ozone contactor 
Parameter Value 
Column # DC, RC #1, #2, #3 RC#4 
Column internal diameter 88.9 mm (3.5”) 215.9 mm (8.5”) 
Column height (total) 1.8 m 1.8 m 
Water height (average) 1.1 m 1.1 m 
Volume 6.82 L 40.2 L 
Hydraulic retention time @ 
design flow of 4 L/min 
1.7 min 10.0 min 
 
3.3  GRANULAR ACTIVATED CARBON FILTER 
To investigate the mutagenicity of ozone treated MWWE filtered through 
granular activated carbon (GAC), a GAC filter was designed and operated as an 
adsorption column. The internal diameter of the filter was 89 mm (3.5 inch) and the 
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carbon bed depth was 490 mm. Calgon make Filtrasorb
®
 300 activated carbon having 
effective size of 0.8 to 1 mm was used. Ozone treated MWWE was pumped to the top of 
the GAC filter by a peristaltic pump at a flow rate of 200 mL/min. The empty bed contact 
time was around 15 minutes. The filtered MWWE was discharged from the bottom of the 
filter, and samples were collected for mutagenicity test after minimum 45 minutes of 
operation of the filter.  
 
3.4  SELECTION OF VARIABLES 
As discussed earlier, the disinfection efficiency and removal of CECs by 
ozonation is dependent on characteristics of MWWE such as temperature, pH, alkalinity, 
organic carbon content, etc. and transferred ozone dose. In this study conducted with 
actual MWWE, the only parameter controlled was TOD. The remaining parameters were 
monitored. The physicochemical characteristics of the sample that change after 
ozonation, such as turbidity and dissolved oxygen level, were also monitored. Ozonation 
transforms the characteristics of the CECs present in the MWWE and reduces the 
aromaticity. The aromaticity of the MWWE was monitored by measuring its UVA. The 
list of parameters monitored and analyzed in this study is as per Table 3.2. The 
physicochemical parameters were monitored and analyzed either at the site or in the 
Environmental Laboratory of University of Windsor. Ontario MOE laboratory carried out 
the analyses of the CECs. 
  
 121 
Table 3.2 List of parameters monitored and analyzed 
Parameter Sampling Point Purpose 
Water flow rate Outlet of column RC#4 Check system performance 
   
pH Upstream of DC and 
downstream of RC#4 
- As above 
   
Temperature - As above - As above 
   
Dissolved oxygen (DO) - As above - As above 
   
Alkalinity - As above - As above 
   
Turbidity - As above To measure color 
   
UV absorption at 456 nm - As above To measure color 
   
Ozone dose Upstream of DC Calculate ozone exposure, 
ozone consumed Ozone residual Downstream of DC, RC#1, 
2, 3, 4 
   
Total organic carbon, 
Dissolved organic carbon 
Upstream of DC and 
downstream of RC#4 
Check system performance 
   
UV absorption at 254 nm  - As above To measure aromaticity 
   
E. coli and total coliform 
enumeration  
Upstream of DC and 
downstream of RC#2, 4 
To monitor disinfection 
   
CEC analysis Upstream of DC and 
downstream of RC#4 
To determine the 
transformation of CECs 
 
 122 
3.5  SELECTION OF OZONE DOSE 
Two different ozone doses were selected based on the literature review and 
preliminary experiments. The criteria for selection were:  
(a)  Minimum ozone dose that meets Ontario MOE (2008) disinfection target 
of < 200 MPN E. coli /100 mL,  
(b)  Ozone dose that consistently meets the disinfection target as well as it 
produces residual ozone at the outlet of the first reaction chamber (RC#1). 
 
3.6  SAMPLING AND ANALYSIS PROCEDURE 
3.6.1 Ozone concentration in the feed gas and vent gas 
A microprocessor based ozone monitor (Teledyne, model: 454M) measured ozone 
concentration in the feed gas and the vent gas. This monitor quantifies the ozone in the 
air by measuring UV absorption at 254 nm.  
 
3.6.2 Ozone concentration in wastewater 
Reagent and material:  Commercial grade indigo trisulfonate reagent (Sigma-
Aldrich make) 
Instrument: Spectronic 20D+ spectrophotometer 
Procedure: Wastewater samples were collected from the sampling ports for residual 
ozone analysis. The sampling lines were flushed thoroughly by discarding the initial flow 
for a couple of seconds. In addition, while adding the wastewater samples to the flask 
containing reagent, care was taken to ensure that the samples do not run down the side of 
the flask as it could cause ozone off-gassing. The ozone residual in wastewater was 
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measured as per the Standard Methods: 4500-O3 B, indigo colorimetric method. When 
the applied ozone concentration was changed, samples for residual ozone analysis were 
collected only after minimum three hydraulic turnovers in the ozone contactor. 
 
3.6.3 Total organic carbon (TOC) 
Reagent & Material:  100-micron nylon mesh, phosphoric acid 
Instrument:  Shimadzu TOC-VCSH Total Organic Analyzer 
Procedure:  The TOC concentration in wastewater was measured as per the Standard 
Methods (5310-B, Combustion-Infrared Method) by APHA (1998), and Method 415.3 by  
USEPA (2009). The samples were collected in clean amber glass bottles, and 
immediately stored at 4 deg. C. They were processed and analyzed within 48 hours of 
collection. Just before analysis, the samples were filtered with 100-micron nylon mesh 
and acidified to pH ≤ 2 by adding concentrated phosphoric acid (H3PO4). As the 
concentration of organic carbon was low (< 10 mg C/L), the NPOC (non purgeable 
organic carbon) method of the TOC analyzer was selected for analysis. The total 
hydraulic retention time of the treated MWWE from the wastewater treatment plant was 
in the range of 10 to 24 hours. After the conventional treatment, it was assumed that there 
would be a negligible amount of purgeable organic carbon left, hence NPOC method was 
deemed appropriate to use. The samples were analyzed within 24 hours of collection. 
 
3.6.4 Dissolved Organic Carbon (DOC) 
Reagent & Material:  0.45 µm polyethersulfone (PES) filter, phosphoric acid 
Instrument:  Shimadzu TOC-VCSH Total Organic Analyzer 
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Procedure: The procedure for DOC analysis is same as that of TOC. The samples 
were filtered with 0.45 µm PES filter, and acidified to pH ≤ 2 by adding concentrated 
phosphoric acid (H3PO4). The samples were analyzed within 24 hours of collection. 
 
3.6.5 UV absorption at 254 nm (UVA) 
Reagent & Material:  0.45 µm polyethersulfone filter 
Instrument:  Varian Cary 50 UV/Visible Spectrophotometer 
Procedure:  The sample was filtered with 0.45 µm polyethersulfone filter. The filtrate 
was not acidified as it might have interfered with UV absorption at 254 nm (UVA). The 
UVA was measured as per the Standard Methods, Part 5910 B, Ultraviolet Absorption 
Method (APHA, 1998). 
 
3.6.6 Colour 
The colour of municipal wastewater is frequently monitored in the Pt-Co units by 
visually comparing it with Pt-Co standards. To increase accuracy and reduce reliance on 
the judgment of the lab analyst for colour measurement, the colour was measured as per 
the method proposed by  Bennett and Drikas (1993). The true colour was measured 
within 12 hours of collection of the samples. 
Reagent & Material:  0.45 µm polyethersulfone filter 
Instrument:  Varian Cary 50 UV/Visible Spectrophotometer and Turbidity meter (Hach 
make, Model: 2100 AN) 
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Procedure:  The sample was filtered with 0.45 µm polyethersulfone filter. The filtrate 
was not acidified.  The turbidity in NTU and UV absorption at 456 nm was measured. 
Colour (Hazen units) was calculated as per the following formula: 
cε
1
xt•E
L
A
tcC 














       (3.1)
 
Ctc = true colour (Hazen units) 
A = total absorbance due to dissolved coloured species 
L = cell path length (cm) 
E  = coefficient of scattering (NTU
-1
.cm
-1
) 
 = 0.00264 NTU
-1
.cm
-1
 (at 456 nm) 
t = turbidity (NTU) 
εc = colour absorptivity (HU
-1
.cm
-1
) 
 = 0.00027 HU
-1
.cm
-1
 (at 456 nm) 
 
3.6.7 Alkalinity 
The alkalinity was measured as per Standard Methods 2320 (APHA, 1998). 
 
3.6.8 pH, Dissolved Oxygen and Temperature 
The above parameters were measured with Hach portable multi-meter (Model 
HQ40D), and Hach pH and dissolved oxygen probes. 
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3.6.9 Disinfection of wastewater 
 E. coli and total coliform enumeration was carried out by USEPA approved 
Colilert® method. 
Reagent & Material: Colilert
®
- 18, Quanti-Tray
® 
- 2000 
Instrument:  Quanti-Tray
®
 sealer, UV lamp (365 nm) 
Procedure: Samples were collected in sterile bottles containing sodium thiosulphate. 
Samples expected of containing disinfection-indicator microorganism count of more than 
2000 MPN/100mL were diluted with sterilized deionised water. Colilert
®
- 18 reagent by 
Idexx Corp. was added to 100mL samples (or diluted sample). The samples were 
transferred to sterile quantification trays (Quanti-Tray®-2000 by Idexx) and sealed 
mechanically. The sealed trays were incubated at 37 
o
C for 18 to 22 hours. E. coli 
enumeration was performed by counting fluorescent wells under 365-nm UV light. The 
yellow coloured wells were counted to determine the total coliform count. The E. coli and 
total coliform levels were then reported as most probable number (MPN) per 100 mL.  
 
3.6.10 Mutagenicity of secondary and tertiary treated MWWE 
The mutagenicity of the MWWE pre-ozonation, MWWE post-ozonation, and 
MWWE post-ozonation + GAC filtration, was evaluated with the modified Ames 
fluctuation test.  Rao and Lifshitz (1995) describe the detail about this method and the 
reagents. The Muta-Chromo Plate kit by Environmental Bio-Detection Products Inc., 
Canada, was used for this test. The TA 98 and TA 100 strain of Salmonella typhimurium 
were initially tested. TA 100 strain was found to be more sensitive to the MWWE 
samples and was selected for the mutagenicity test. The MWWE samples to be tested 
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were filtered-sterilized with 0.22 μm membrane filter. Based on the required 
concentration of the sample, it was diluted with sterile distilled water to a final volume of 
17.5 mL. A 2.5 mL of reaction mixture and 20 μL of bacteria grown overnight in nutrient 
broth was added to it. The mixture was stirred to mix thoroughly. Using a multi-channel 
pipette, 200 μL of the mixture was dispensed into 96-well micro-titration plate. The plate 
was then sealed to prevent evaporation and was incubated at 37
o
C for six days. The direct 
acting mutagen, sodium azide, was used as positive control for TA 100 and sterile 
distilled water as negative control. The background treatment plate consisted of distilled 
water, reaction mixture, and bacteria.  
The plates were scored visually. All yellow, partially yellow, or turbid wells were 
counted as positive and purple wells were scored negative. The ratio of positive scores of 
the sample plates with background plate was determined and statistical evaluation carried 
out using Chi-square analysis (Gilbert, 1980). The samples were considered mutagenic if 
the positive score of sample plates were significantly higher than the number of positive 
scores of background plate. In the current study, the samples were analyzed in triplicate. 
The results are expressed as mutagenicity ratio (MR) and are the average of the triplicates 
(± standard error). 
 
3.7  CALCULATIONS 
3.7.1 Ozone exposure 
Ozone exposure, also referred to as CT value, was calculated as per the Extended 
Integrated CT10 method (Rakness et al., 2005). Wert et al. (2009a) have calculated a 
short-circuiting factor (SCF) of 0.6 for their ozonation pilot unit with pipe contactors. 
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This SCF was selected in the current study. This value is also in line with the SCF (or 
T10/T) values given as guidance in the USEPA (1999). 
C = concentration of ozone in water (i.e. residual ozone) 
T10  =  time period in which 10% of the water that enters a contactor has passed through  
=  hydraulic detention time of the contactor (volume/flow rate) x short-circuiting 
factor (SCF) 
 
3.7.2 Applied Ozone Dose (AOD) 
The applied ozone dose is the amount of ozone directed from the ozone generator 
to unit volume of water treated. The following equation was used to calculate AOD (in 
mg/L): 
water
gas
feed3
Q
Q
x)(OAOD      (3.2) 
feed3)(O   : ozone concentration in the feed gas, mg/L 
Qgas  : feed gas flow rate, L/min 
Qwater  : wastewater flow rate, L/min 
 
3.7.3 Transfer Efficiency (TE) 
Transfer efficiency is used to define the percentage of the applied ozone dose that 
has been used and dissolved in the aqueous solution and is not lost in the vent gas. It is 
affected by various parameters such as contactor design, operating conditions, wastewater 
characteristics, etc. TE was calculated as under: 
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 
100%x
)(O
)(O)(O
TE
feed3
vent3feed3     (3.3) 
vent3)(O   : ozone concentration in the vent gas, mg/L 
 
3.7.4 Transferred Ozone Dose (TOD) 
This is the amount of ozone added from the gaseous air containing ozone to the 
wastewater. The following formula was used to calculate TOD (in mg/L): 
 
water
gas
vent3feed3
Q
Q
x)(O)(OTOD     (3.4) 
or 
TExAODTOD        (3.5) 
In the above formula, it is assumed that the feed gas flow rate and the vent gas 
flow rate are equal. In addition, there is negligible destruction of ozone in the headspace 
above the water level in dissolution chamber. 
 
3.7.5 Ozone Consumption (Z) 
It is the mass of ozone consumed by the wastewater, and is calculated as: 
  resi3
water
gas
vent3feed3 )(O
Q
Q
x)(O)(OZ 






  (3.6) 
or 
resi3)(OTODZ        (3.7) 
resi3)(O  : residual ozone in the wastewater, mg/L 
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3.7.6 Specific Ozone Consumption (Zspec) 
It is the ratio of the ozone consumption and initial dissolved organic carbon: 
O
spec
DOC
Z
Z         (3.8) 
DOCo  : initial dissolved organic carbon, mg/L 
 
3.7.7 Specific UV Absorbance (SUVA) 
Specific UV absorbance (SUVA) is the ratio of UV absorption at 254 nm to initial 
dissolved organic carbon concentration. This parameter characterizes the effluent organic 
matter (EfOM). SUVA varies with the type of DOC and is highest in the presence of 
long-chain humic acids (Bratby, 2006). As per Edzwald and Tobiason (1999),  
 SUVA > 4 (L/mg.m) indicates that the DOC in the water matrix is highly 
hydrophobic and has high molecular weight (MW);  
 SUVA in the range of 2 to 4 (L/mg.m) indicates the presence of a mixture of 
hydrophobic and hydrophilic organic matter; 
 SUVA < 2 (L/mg.m) indicates that the organic matter is mostly non-humic, has 
low hydrophobicity and has low MW.  
The molecules with lower MW are generally more biodegradable than molecules 
with larger MW (Çeçen and Aktas, 2012). SUVA gives an indirect indication of the 
biodegradability of the raw and ozonated water, and value of < 2 (L/mg.m) indicates that 
the water contains biodegradable organics that can be removed by biofiltration (Çeçen 
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and Aktas, 2012). Hence, the lower the SUVA value, the higher is the biodegradability of 
the organics in the water matrix. 
The formula to calculate SUVA is: 
m
cm100
x
L
mg
DOC
cm
1
UV
mg.m
L
SUVA
O
254


















  (3.9) 
 
3.8  ANALYSIS  OF  CECs  AT  ONTARIO  MOE  LABORATORY 
Samples packed in ice to maintain sample temperature to around 4 
o
C were 
shipped to the Mass Spectroscopy Laboratory of Ontario Ministry of the Environment 
(Toronto, Canada) for the analyses of the target CECs. Solid phase extraction (SPE) was 
used to extract the samples and liquid chromatography/tandem mass spectrometry and 
isotope dilution mass spectrometry were used to analyse the samples. Hao et al. (2008) 
describe details of the methodology and quality control procedure. Table 3.3 shows the 
list of the CECs targeted in the current study and their detection limits (DLs). 
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Table 3.3 List of target CECs (PhACs and EDCs) 
Antibiotics DL, ng/L Antiphlogistics DL, ng/L 
1 Carbadox 10 24 Acetaminophen 2 
2 Chloramphenicol 2 25 Diclofenac 1 
3 Chlortetracycline 10 26 Ibuprofen 0.5 
4 Ciprofloxacin 0.5 27 Indomethacin 5 
5 Doxycycline 5 28 Ketoprofen 2 
6 Enrofloxacin 5 29 Naproxen 2 
7 Erythromycin 10 Antidepressant  
8 Lasalocid A 10 30 Carbamazepine 1 
9 Lincomycin 0.5 Anticoagulant  
10 Meclocycline 10 31 Warfarin 5 
11 Norfloxacin 10 Lipid Regulators  
12 Oxytetracline 5 32 Bezafibrate 0.5 
13 Roxithromycin 2 33 Clofibric acid 1 
14 Sulfachloropyridazine 5 34 Gemfibrozil 1 
15 Sulfadiazine sodium 5 Estrogen Replacement Agents  
16 Sulfadimethoxine 1 35 Bisphenol-A (BPA) 2 
17 Sulfamerazine 1 36 Diethylstilbestrol 10 
18 Sulfamethazine 1 37 Equilin 2 
19 Sulfamethizole 2 Ovulation Inhibitors  
20 Sulfamethoxazole 2 38 19-Norethersterone 5 
21 Sulfathiazole 2 Reproductive Hormones  
22 Tetracycline 10 39 17-α-Estradiol 5 
23 Trimethoprim 10 40 17-β-Estradiol 2 
   41 Estrone 2 
   42 Estriol 5 
   43 Progesterone 20 
   Ionophore  
   44 Monensin sodium 10 
Legend:  DL: Detection limit   
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3.9  SUMMARY OF THE PARAMETERS MONITORED 
Table 3.4 summarizes the parameters monitored and the instruments used in this 
study. 
 
Table 3.4 Summary of the parameters monitored 
Sr. Parameter Instrument and Method 
1 pH Hach pH probe 
2 Temperature Hach pH/DO probe 
3 Dissolved Oxygen Hach DO probe 
4 Alkalinity Standard Methods , Titration, SM-2320 
5 Flow Rate (liquid) Volumetric cylinder and stop-watch 
6 Flow Rate (feed gas) Rotameter 
7 Total  Organic  Carbon (TOC) Shimadzu TOC Analyzer, Standard 
Methods 5310 
8 Dissolved Organic Carbon (DOC) 
9 UV absorption at 254 nm (UVA) UV-Vis Spectrophotometer, SM-5910 
10 Color  
 - UV absorption at 456 nm UV-Vis Spectrophotometer 
 - Turbidity Hach 2100 AN Turbidimeter 
11 Transferred Ozone Dose (TOD)  
 - Ozone concentration in feed gas Ozone analyzer, UV 254 Absorption 
 - Ozone concentration in vent gas Ozone analyzer, UV 254 Absorption 
12 SUVA (Ratio of UVA to DOC) US EPA Method 415.3 
13 Disinfection  
 - Ozone residual in water UV Spectrophotometer (Spectronics), SM 
4500-O
3
 B, Indigo Colorimetric  Method 
 - Exposure (CT
10
) Extended Integrated CT
10
 Method 
 - E. coli enumeration Colilert® method by IDEXX, Standard 
Methods 9223 B 
14 Concentration of CECs Mass Spectrophotometer, Analysis by 
Ontario MOE 
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CHAPTER IV 
ANALYSIS OF RESULTS 
 
This study was conducted to evaluate the effectiveness of ozone treatment on 
disinfection of municipal effluent and transformation of pharmaceuticals and EDCs. The 
results from the study are presented in two parts. Part-I of this chapter consists of results 
from experiments conducted to determine the ozone dose required to achieve the 
disinfection target and to correlate disinfection with probable process control parameters. 
The MWWE was treated with different ozone doses. The disinfection indicator 
microorganisms, total coliform and E. coli, and MWWE characteristics were monitored. 
The Part-II of this chapter consists of results related to the occurrence and concentration 
of the CECs in MWWE, and their transformation when MWWE is treated with ozone.  
 
PART – I  DISINFECTION OF MWWE WITH OZONE 
 
4.1  MWWE CHARACTERISTICS 
Four sets of experiments were conducted to study the effect of different ozone 
dose on disinfection. The characteristics of the MWWE prior to disinfection are 
presented in Table 4.1. 
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Table 4.1 Characteristics of secondary treated MWWE before ozone treatment 
Experiment DOC DO pH Temp. Alkalinity UVA 
 mg/L mg/L  oC mg/L as CaCO3 cm-1 
Trial #1  
 
5.04 1.59 ± 0.04 7.13 ± 0.02 20.5 ± 0.1 230 – 240 0.1160 
Trial #2  
 
5.38 ± 0.11 1.23 ± 0.29 7.11 ± 0.09 20.1 ± 0.2 210 0.1067 ± 0.0015 
Trial #3  
 
6.04 ± 0.09 2.08 ± 0.36 7.13 ± 0.14 21.5 ± 0.3 160 0.1065 ± 0.0020 
Trial #4  
 
5.33 ± 0.14 2.30 ± 0.21 7.12 ± 0.16 18.8 ± 0.2 170 – 180 0.1075 ± 0.0009 
Legends:  
DOC: Dissolved organic carbon   DO: Dissolved oxygen  
Temp. : Temperature    UVA: UV absorption at 254 nm 
 
The total coliform in the MWWE was in the range of 10
4
 to 10
5
 MPN/100 mL, 
which is the typical range for nitrified effluent in North America (USEPA, 1986b). 
E. coli count was in the range of 2,500 to 21,000 MPN/100 mL. 
 
4.2  DISINFECTION OF MWWE WITH OZONE  
The secondary treated MWWE was treated with different ozone doses. The goal 
was to determine the optimum ozone dose required to meet the Ontario MOE disinfection 
target of < 200 MPN E. coli/100 mL for the MWWE of LRPCP. 
Table 4.2 represents the results from four experiments. The data indicates that the 
disinfection criterion was fulfilled sometimes even at low ozone dose of 1.6 to 2.8 mg/L. 
However, the disinfection target was always achieved at TODs between 3.7 to 4.2 mg/L, 
and the E. coli count in the ozonated MWWE was between 5 and 11 MPN E. coli/100 
mL.  
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Table 4.2 Effect of ozone on disinfection 
Experiment DOC TOD Residual Ozone Ozone 
Exposure (CT10) 
mg-min/L 
 UVA  Total Coliform  E coli 
 mg/L mg/L DC RC #1  cm-1 
% 
Reduction 
 
MPN/ 
100 mL 
Log 
Reduction 
 
 
MPN/ 
100 mL 
Log 
Reduction 
Trial #1                
Influent 5.04      0.1160   109,100   21,380  
  1.6 0.10 <0.10 0.04  0.0954 18  365 2.48  48 2.65 
  2.3 0.29 <0.10 0.15  0.0835 28  145 2.88  20 3.03 
  3.9 0.89 0.14 0.53  0.0744 36  73* 3.17  10 3.35 
Trial #2                
Influent 5.38      0.1067   36,940   7,547  
  1.8 <0.10 <0.10 0.02  0.0916 14  > 2420   1613 0.67 
  2.8 0.11 <0.10 0.05  0.0768 28  422 1.95  50 2.19 
  4.2 0.63 0.05 0.37  0.0649 39  79 2.70  11 2.86 
Trial #3               
Influent 6.04      0.1065   46,177   11,403  
  1.4 <0.10 <0.10 0  0.1027 4  > 2420 < 1.28  > 2420 < 0.67 
  1.8 <0.10 <0.10 0.015  0.1019 4  > 2420 < 1.28  > 2420 < 0.67 
  2.7 <0.10 <0.10 0.06  0.0878 18  > 2420 < 1.28  463 1.41 
  3.9 0.24 <0.10 0.07  0.0740 31  56 2.93  10 3.06 
Trial #4               
Influent 5.33      0.1075   10,893   2,513  
  1.4 0.10 <0.10 0.04  0.0960 11  3006 0.57  348 1.01 
  1.8 <0.10 <0.10 0.06  0.0852 21  283 1.60  17 2.20 
  2.6 0.26 <0.10 0.10  0.0764 29  53 2.43  5 2.70 
  3.7 0.82 0.14 0.76  0.0672 38  19 2.77  5 2.79 
  7.3 3.22 1.75 6.54  0.0537 50  10 3.03  1 3.60 
* This data is for sample taken from the outlet of RC#3. All remaining data related to reduction in total coliform and E. coli are for sample from outlet of RC#2. 
Legends:  
DC: Dissolution chamber 
RC #1: First reaction chamber 
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Ozonation of MWWE did not cause a major change in its DOC, pH, and 
alkalinity parameters. However, the increase in ozone dose resulted in increase of 
dissolved oxygen, and reduction in UVA and color of the ozonated MWWE. The DOC to 
TOC ratio was always greater than 0.95.  Table 4.3 represents the data related to the 
effect of ozone dose on dissolved oxygen concentration, UVA, and color of the MWWE. 
 
Table 4.3 Effect of ozone on DO, UVA and color of secondary treated MWWE 
 
TOD  
mg/L 
DO  
mg/L 
UV254 Absorbance  True Color 
cm-1 
%  
decrease 
 
Hazen 
 units 
% 
decrease 
Trial #1        
Influent  1.59 ± 0.04 0.1160   11.89  
 1.6 n.m. 0.0954 18  3.33 72 
 2.3 7.40 0.0835 28  2.90 76 
 3.9 7.95 0.0744 36  1.31 89 
Trial #2        
Influent  1.23 ± 0.29 0.1067 ± 0.0015   15.98  
 1.8 7.28 0.0916 14  10.51 34 
 2.8 7.87 0.0768 28  4.46 72 
 4.2 7.92 0.0649 39  2.35 85 
Trial #3        
Influent  2.08 ± 0.36 0.1065 ± 0.0020   17.28  
 1.4 7.01 0.1027 4  9.21 47 
 1.8 7.18 0.1019 4  7.34 58 
 2.7 7.70 0.0878 18  5.63 67 
 3.9 7.84 0.0740 31  1.38 92 
Trial #4        
Influent  2.30 ± 0.21 0.1075 ± 0.0009   13.91  
 1.4 n.m. 0.0960 11  6.83 51 
 1.8 7.45 0.0852 21  6.13 56 
 2.6 7.92 0.0764 29  4.48 68 
 3.7 8.09 0.0672 38  2.72 80 
 7.3 18.84 0.0537 50  1.35 90 
Legends: TOD: Transferred ozone dose    DO: Dissolved oxygen  n.m.: not measured  
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In three experiments, ozonated MWWE samples were taken from the outlet of the 
dissolution chamber and reaction chambers, to determine the level of disinfection 
achieved at different contact times. The results are presented in Table 4.4. Results 
indicate that disinfection of MWWE with ozone is a fast process. At the transferred 
ozone doses, the level of disinfection did not increase after the first reaction chamber.  
 
Table 4.4 Effect of contact time on disinfection   
Experiments TOD 
 
mg/L 
Column Total Contact 
Time* 
min 
Residual  
ozone 
mg/L 
Total coliform  E. coli 
MPN/ 
100 mL 
Log  
Reduction 
 MPN/ 
100 mL 
Log  
Reduction 
Trial #1          
Influent     109,100   21,380  
 1.6 DC  0.10 488 2.35  59 2.56 
  RC#1 1.7 <0.10 365 2.48  48 2.65 
  RC#2 3.4 <0.10 435 2.40  66 2.51 
  RC#3 5.1 <0.10 365 2.48  61 2.55 
 2.3 DC  0.29 161 2.83  34 2.80 
  RC#1 1.7 <0.10 145 2.88  20 3.03 
  RC#2 3.4 <0.10 173 2.80  26 2.92 
  RC#3 5.1 <0.10 130 2.93  34 2.80 
 3.9 DC  0.89 121 2.95  18 3.07 
  RC#1 1.7 0.14 ND -  10 3.35 
  RC#2 3.4 <0.10 35 3.49  4 3.72 
  RC#3 5.1 <0.10 73 3.17  11 3.30 
Trial #2           
Influent     36,940   7,547  
 1.8 RC#1 1.7 <0.10 > 2420 < 1.18  1613 0.67 
  RC#4 6.8 <0.10 > 2420 < 1.18  1567 0.68 
 2.8 RC#1 1.7 <0.10 422 1.95  50 2.19 
  RC#4 6.8 <0.10 658 1.75  56 2.14 
 4.2 RC#1 1.7 <0.10 79 2.70  11 2.86 
  RC#4 6.8 <0.10 90 2.61  13 2.78 
Trial #3           
Influent     46,177   11,403  
 1.8 RC#1 1.7 <0.10 > 2420 < 1.28  > 2420 < 0.67 
  RC#4 6.8 <0.10 > 2420 < 1.28  > 2420 < 0.67 
 2.7 RC#1 1.7 <0.10 > 2420 < 1.28  463 1.41 
  RC#4 6.8 <0.10 > 2420 < 1.28  558 1.31 
 3.9 RC#1 1.7 <0.10 56 2.93  10 3.06 
  RC#4 6.8 <0.10 85 2.74  11 3.06 
* Total contact time does not include the 1.7 minute of contact time in dissolution chamber 
 139 
4.3  CORRELATION BETWEEN DISINFECTION AND PROBABLE 
PROCESS CONTROL PARAMETERS 
4.3.1 Transferred Ozone Dose 
In the four experiments conducted, at transferred ozone dose of 1.4 to 4.2 mg/L, 
the total coliform log reduction was in range of <1.28 to 3.17, and the E. coli log 
reduction was in the range of <0.67 to 3.35 (Table 4.2) 
Figure 4.1 depicts the graphical presentation of E. coli inactivation at different 
transferred ozone doses.  
 
 
Legends   Pre O3:MWWE before ozonation 
    TOD: Transferred ozone dose (mg/L), eg. TOD 1.6 = transferred ozone dose of 1.6 mg/L 
 
Figure 4.1 Effect of transferred ozone doses on E. coli inactivation 
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The results indicate that the disinfection target of < 200 MPN E. coli/100 mL was 
achieved even at relatively low ozone doses of 1.6 to 2.8 mg/L. However, on some 
occasions this ozone dose did not fulfill the disinfection criterion. At TOD of 3.7 to 
4.2 mg/L, the log reduction of the disinfection indicating microorganisms was always 
greater than 2.7 and the disinfection target was achieved consistently. This level of 
disinfection is similar to the results reported by other studies. 
Table 4.5 compiles the disinfection data reported by some studies. The data 
indicates variation in the disinfection efficiency with ozone, as expected, due to the 
difference in the MWWE characteristics. However, for an ozone dose of 0.2 to 
0.8 mg O3/mg C, the E. coli log reduction is in the range of 1.58 to 4.94. In most cases, 
the E. coli after ozonation is less than 200 MPN/100 mL. The total coliform log reduction 
is in the range of 1.82 to 3.48.  
TOD has been considered the most important parameter in disinfection by ozone 
treatment (Xu et al., 2002; Paraskeva and Graham, 2005). Some researchers have 
proposed TOD as process control parameter for disinfection (Stover and Jarnis, 1981; 
Venosa and Meckes, 1983). The dose/response curve proposed by  USEPA (1986a) 
attempts to correlate the TOD with the reduction of disinfection indicator 
microorganisms. Figure 4.2 and Figure 4.3 present the data related to the dose/response 
curve for E. coli and total coliform as collected in the present study.  
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Table 4.5 Effect of ozone dose on disinfection of secondary/tertiary treated MWWE 
DOC or 
TOC 
mg/L 
O3 dose 
 
mg/L 
Disinfection  
indicator  
microorganism 
MPN or cfu/100 mL Log  
Reduction 
Reference 
Pre O3 Post O3 
23 5 mg/L (TOD) E. coli   2.75 Ternes et al. (2003) 
23 10 mg/L (TOD) E. coli   3.63 Ternes et al. (2003) 
8.3 ± 1 22 mg/L (TOD) E. coli 107.22 7 6.38 Finch et al. (1989) 
8.3 ± 1 12 mg/L (TOD) E. coli 107.22 76 5.34 Finch et al. (1989) 
8.3 ± 1 6 mg/L (TOD) E. coli 107.22 191 4.94 Finch et al. (1989) 
8.3 ± 1 3 mg/L (TOD) E. coli 107.22 105 2.22 Finch et al. (1989) 
7.7 ± 0.5 2 mg/L (TOD) E. coli 5 x 105 2 x 102 3.4 Huber et al. (2005) 
7.7 ± 0.5 5 mg/L (TOD) E. coli 5 x 105 < 102 > 3.7 Huber et al. (2005) 
19.6 ± 1.27 5 mg/L (AOD) E. coli 210,000 16 x 103 1.12 Tripathi et al. (2011)  
19.6 ± 1.27 10 mg/L (AOD) E. coli 210,000 6 x 102 2.54 Tripathi et al. (2011) 
8.8 – 10.1 2 – 6 mg/L (TOD) E. coli 4x104-2.5x105 102 2.6 – 3.4 Paraskeva et al. (2005) 
3.4 0.8 mg/L (TOD) E. coli 20,000 6935 0.46 Zimmermann et al. (2011) 
2.4 1.2 mg/L (TOD) E. coli 5,000 50 2.0 Zimmermann et al. (2011) 
4.4 2.6 mg/L (TOD) E. coli 6,000 158 1.58 Zimmermann et al. (2011) 
4.7 3.8 mg/L (TOD) E. coli 5,000 50 2.0 Zimmermann et al. (2011) 
4.1 5.2 mg/L (TOD) E. coli 4,000 57 1.85 Zimmermann et al. (2011) 
12 ~ 2.4 (TOD) T.C. 46,000 24,000 0.28 Bahr et al. (2005) 
12 ~ 4.8 (TOD) T.C. 46,000 36 3.1 Bahr et al. (2005) 
11.4 ~ 5.7 (TOD) T.C. 104.38 – 105.04  1.82 Bahr et al. (2007) 
11.4 ~ 11.4 (TOD) T.C. 104.38 – 105.04  2.86 Bahr et al. (2007) 
7.2 2.1 mg/L (TOD) T.C. > 1600 30 > 1.73 Wert et al. (2007) 
7.2 3.6 mg/L (TOD) T.C. > 1600 < 2 > 2.9 Wert et al. (2007) 
7.2 4.9 mg/L (TOD) T.C. 6000 < 2 > 3.48 Wert et al. (2007) 
~ 19 3.4 mg/L (AOD) T.C.   2 Lazarova et al. (1998) 
~ 19 10 mg/L (AOD) T.C.   3.3 Lazarova et al. (1998) 
19.6 ± 1.27 5 mg/L (AOD) T.C. 254,000 19,000 1.12 Tripathi et al. (2011) 
19.6 ± 1.27 10 mg/L (AOD) T.C. 254,000 9 x 102 2.45 Tripathi et al. (2011) 
8.8 – 10.1 7 – 10 mg/L 
(TOD) 
T.C. 4x104-2.5x105 10 3.6 – 4.4 Paraskeva et al. (2005) 
5.0 – 8.3 5 mg/L (TOD) T.C. 104.28 – 106.86 102.7 ~ 1.6 – 4.2 Venosa et al. (1983) 
5.0 – 8.3 10 mg/L (TOD) T.C. 104.28 – 106.86 101.6 ~ 2.7 – 5.3 Venosa et al. (1983) 
Legends:  
DOC: Dissolved organic carbon   TOC: Total organic carbon 
TOD: Transferred ozone dose   AOD: Applied ozone dose 
T.C.: Total coliform    O3:     Ozone 
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Figure 4.2 Dose response curve for E. coli  
 
 
 
 
Figure 4.3 Dose response curve for total coliform 
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Table 4.6 compiles the data from the dose/response curve from the current study 
and from other studies for effluents with initial ozone demand less than 1 mg/L. In the 
current study, the initial ozone demand of the MWWE was less than 0.5 mg/L, and can 
be considered as a good quality secondary treated MWWE as the initial ozone demand is 
less than 1 mg/L (USEPA, 1986b). The data shows that although the TOD is correlated 
with the reduction in total coliform and E. coli, the correlation is not very strong (R
2
 
value of 0.53 and 0.53).  Paraskeva and Graham (2005) have also found a weak 
correlation between the TOD and level of disinfection (R
2
 value of 0.50 to 0.63). This is 
contrary to the strong correlation (R
2
 value of 0.76) reported by USEPA (1986b). As the 
correlation between the TOD and disinfection is not always strong, it can be concluded 
that TOD is not be the best process control parameter for disinfection. 
 
Table 4.6 Slope of Dose/Response Curve and Intercept for Ozone Disinfection 
Parameter Slope Intercept* Correlation Reference 
E. coli -3.20 0.49 0.53 Current study 
E. coli -3.44 to  
- 3.65 
0.71 to 
0.77 
0.54 to 
0.63 
Paraskeva et al. (2005) 
Total Coliform -2.63 0.35 0.53 Current study 
Total Coliform - 3.04 0.61 0.50 Paraskeva et al. (2005) 
Total Coliform -2.51 0.50 0.76  USEPA (1986b) 
* Intercept represents the calculated initial ozone demand. 
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4.3.2 Residual ozone 
In the experiments conducted in this study, different ozone doses were applied 
and the residual ozone concentrations in effluent leaving the dissolution chamber (DC) 
and the reaction chambers (RC#1 to RC#4) were measured. Figure 4.4 shows the residual 
ozone concentration at different time intervals for the four trials. The microbial indicators 
were also monitored to determine the disinfection achieved. The results are presented 
earlier in Table 4.2. 
 
 
Figure 4.4 Residual ozone concentration at outlet of DC, RC#1, RC#2 and RC#3 
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Residual ozone at the end of dissolution chamber (DC) 
In some of the experiments conducted, the TOD was not sufficient to produce 
residual ozone in the effluent leaving the dissolution chamber. This can indicate that the 
TOD was lower than or just equal to the immediate ozone demand (ImOD) of the 
wastewater matrix. In such cases, the reduction of the microbial indicators was less than 
1-log, and the disinfection target of E. coli count less than 200 MPN/100mL was not 
achieved. In most of the cases when the residual ozone at the outlet of the dissolution 
chamber was greater than 0.1 mg/L, greater than 2-two log reduction of the microbial 
indicators was observed. At TOD of 3.7 to 4.2 mg/L, the residual ozone was between 
0.24 to 0.89 mg/L. Figure 4.5 and Figure 4.6 show the plot of disinfection and 
corresponding residual ozone in the dissolution chamber. 
 
Residual ozone at the outlet of first reaction chamber (RC#1) 
For transferred ozone dose of less than 3 mg/L (approximately 0.5 mg O3/mg C) 
or less, the residual ozone at the outlet of the first reaction column (RC#1) was close to 
zero. The resulting total coliform log reduction was between 0.57 and 2.88 while E. coli 
log reduction was in the range of 0.67 to 3.06. Figure 4.5 and Figure 4.6 show the visual 
representation of the results. As per the figures, up to 3-log reduction in disinfection 
parameter was observed at almost zero ozone residual. This result is in line with the 
findings of other studies (Paraskeva et al., 1999; Xu et al., 2002; Gehr et al., 2003) that 
have reported greater than 2-log reduction in disinfection parameters at residual ozone 
concentrations close to zero. At residual ozone concentration close to zero, the ozone 
exposure (CT value) is almost zero. Hence, the conventional method of correlating ozone 
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exposure to reduction in disinfection parameter does not apply for wastewater 
disinfection.  
The residual ozone concentration at the outlet of RC#1 was between 0.01 to 0.14 
mg/L at transferred ozone dose of approximately 4 mg/L (0.8 mg O3/mg C). The total 
coliform log reduction was between 2.7 and 3.13, while E. coli log reduction was in the 
range of 2.79 to 3.35. In all the experiments, the disinfection target was met and total 
coliform was less than 100 MPN/100 mL while E. coli count was less than 15 MPN/100 
mL. Ozone exposures for ozone doses from 3.7 to 4.2 mg/L as per the Extended 
Integrated CT10 method were between 0.06 and 0.8 mg-min/L (Table 4.2). 
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Figure 4.5 Relationship between residual ozone and total coliform inactivation 
 
 
Figure 4.6 Relationship between residual ozone and E. coli inactivation 
  
R² = 0.49R² = 0.28
0
1
2
3
4
0 1 2 3 4
T
o
ta
l 
C
o
li
fo
rm
 L
o
g
 R
ed
u
ct
io
n
Residual ozone, mg/L
DC
RC1
0
1
2
3
4
0.0 0.1 0.2
R² = 0.72R² = 0.36
0
1
2
3
4
0 1 2 3 4
E
. 
co
li
L
o
g
 R
ed
u
ct
io
n
Residual ozone, mg/L
DC
RC1
0
1
2
3
4
0.0 0.1 0.2
 148 
As per Figure 4.5 and Figure 4.6, the correlation between residual ozone and 
inactivation of disinfection indicator microorganisms is not strong. The R
2
 value for 
correlation between reduction of microorganisms and residual ozone at outlet of DC is 
0.49 and 0.72, while the value is 0.28 and 0.36 for correlation between reduction in 
microorganisms and residual ozone at outlet of RC#1. It was observed that greater than 
2.5 log reduction in disinfection parameter was achieved when the residual ozone at the 
outlet of RC#1 was greater than 0.1 mg/L.  
From the above, it can be concluded that residual ozone in effluent is not a good 
disinfection process control parameter. However, residual ozone at the outlet of 
dissolution chamber and first contact chamber can be monitored to determine if ImOD is 
fulfilled, and to calculate specific ozone consumption (Zspec). Minimum residual ozone of 
0.1 mg/L at the outlet of the first reaction chamber can indicate that a minimum level of 
disinfection has been achieved. This minimum level of disinfection achieved will depend 
on the MWWE characteristics. In this study, a minimum of 2.5 log reduction was 
observed when the residual ozone concentration was 0.1 mg/L. 
 
4.3.3 UV absorption at 254 nm  
Studies have shown that the UV absorption at 254 nm (UVA) of MWWE 
decreases after ozone treatment.  Bahr et al. (2007) have attempted to correlate the 
inactivation of disinfection indicator microorganisms with reduction in UVA. In large-
scale ozonation applications, they proposed UVA as a process control parameter for 
disinfection as well as removal of micropollutants (pharmaceuticals and EDCs) and 
bromate formation, mainly because of the ease in its analysis and continuous monitoring. 
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During the literature review, no other study was found that had attempted to correlate 
disinfection with reduction in UVA. In the current study, an attempt was made to 
determine the strength of correlation between reduction in UVA and level of disinfection 
due to ozonation. Figure 4.7 and Figure 4.8 show the results.  
For the TOD up to 0.8 mg O3/mg C, a linear correlation was found to exist 
between the log reduction in UVA and the log reduction in the microbial indicators. The 
R
2
 values were 0.71 and 0.80 for correlation between reduction in UVA and total 
coliform, and UVA and E. coli. The coefficient of determination (R
2
) values from the 
current study and previous study by Bahr et al. (2007) is presented in Table 4.7.   
 
Table 4.7 Coefficient of determination (R
2
) values for correlation between reduction in UVA 
and inactivation of disinfection indicator microorganisms 
Disinfection indicator 
microorganism 
Coefficient of 
determination (R
2
) 
Reference 
E. coli 0.795 Current study 
Total coliform 0.714 Current study 
Total coliform 0.764 Bahr et al. (2007) 
Fecal coliform 0.572 Bahr et al. (2007) 
Intestinal enterococci 0.787 Bahr et al. (2007) 
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Figure 4.7 Correlation between reduction in UVA and Total Coliform inactivation 
 
 
Figure 4.8 Correlation between reduction in UVA and E. coli inactivation  
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4.3.4 SUVA 
The SUVA was calculated and an attempt was made to correlate disinfection with 
SUVA (Figure 4.9 and Figure 4.10). The correlation coefficient of 0.58 and 0.77 for 
correlation between SUVA and total coliform, and SUVA and E. coli was obtained. 
Hence, the correlation of disinfection with SUVA is not as strong as with UVA.  
 
 
Figure 4.9 Correlation between reduction in SUVA and Total Coliform inactivation 
 
 
Figure 4.10 Correlation between reduction in SUVA and E. coli inactivation  
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4.3.5 Color 
In this study, the reduction in color was measured at the different transferred 
ozone doses. The results are presented in Table 4.3. At TOD of 1.4 to 2.8 mg/L, the true 
color reduced by 34 to 76%. At relative higher ozone doses of 3.7 to 4.2 mg/L, the 
reduction in color was in the range of 80 to 92%. When compared with UVA reduction at 
similar ozone doses, the reduction in color was comparatively higher. This can indicate 
that the compounds that contribute to color have higher reaction rate with the oxidants, 
and oxidation reaction to remove color is favoured over removal of aromatic compounds. 
Strong correlation (R
2
 value of 0.86 and 0.80) was observed between the true 
color reduction and inactivation of disinfection indicator microorganisms (Figure 4.11 
and Figure 4.12). This is an interesting finding, and the results indicate that the color 
parameter can be applied as a surrogate parameter to assess disinfection. However, more 
study is required to confirm the results.  
  
 153 
 
Figure 4.11 Correlation between reduction in color and Total Coliform inactivation 
 
 
Figure 4.12 Correlation between reduction in color and E. coli inactivation   
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4.4  OTHER OBSERVATIONS 
The relationship between TOD and reduction in UVA, and TOD and reduction in 
color was non-linear. Figure 4.13 and Figure 4.14 show the respective plots for both the 
cases. At TOD of 1.4 to 7.3 mg/L, the reduction in UVA was in the range of 4 to 50%, 
while reduction in color was in the range of 34 to 92%. The color was reduced by 34% 
even at the lowest transferred ozone dose, while there was almost zero reduction in the 
UVA if the ozone dose did not fulfill the initial ozone demand. From the plots, the 
correlation between TOD and reduction in UVA (R
2
 = 0.85) is stronger than the 
correlation between TOD and color reduction (R
2
 = 0.69). If the results of each 
experiment are plotted separately as shown in Appendix B and C, then excellent 
correlation (R
2
 > 0.94) is observed in all cases. For individual experiments,  Wert et al. 
(2009b) have also found a strong correlation (R
2
 > 0.95) between the ozone dose and 
reduction in UVA as well as color measured at 455 nm. As shown in Table 4.8, the 
reduction in UVA and color observed in the current study is in line with the results 
reported from other studies.  
 
Table 4.8 Reduction in UVA and color of secondary treated MWWE on ozone treatment 
TOC/DOC UV254A Color* Ozone dose % Reduction post ozonation Reference 
mg/L cm-1 Color units mg/L UV254A Color  
5.04 – 6.04 0.1065 to 0.1160 11.9 to 17.3 (456 nm) 1.4 to 7.3 4 to 50 34 to 92 Current study 
< 10 – 14 0.174 to 0.208 NA (400 nm) 2 – 13 24 to 56 62 to 92 Xu et al. (2002) 
< 11 – 30 0.260 to 0.509 NA (400 nm) 4 – 30 14 to 52 NA Xu et al. (2002) 
11.4 ± 0.9 0.278 ± 0.027 NA (436 nm) ~ 2 to 11.5 20 to 55 60 to 92 Bahr et al. (2007) 
6.6  0.14 Not analyzed 1.7 to 6.6 27 to 55 - Wert et al. (2009) 
10.3 0.26 42 (455 nm) 2.5 to 11.6 15 to 61 21 to 91 Wert et al. (2009) 
10.3 0.171 33 (455 nm) 2.5 to 10.6 16 to 58 51 to 96 Wert et al. (2009) 
* The values in bracket are the wavelengths at which the absorbance was measured. 
Legends:  NA: Not available  
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Figure 4.13 Correlation between TOD and reduction in UVA 
  
 
 
Figure 4.14 Correlation between TOD and reduction in color 
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The SUVA values of MWWE before ozonation were in the range of 1.76 to 
2.3 (L/mg.m). After ozonation with TOD of around 0.72 mg O3/mg DOC, the SUVA 
values decreased and were in the range of 1.16 to 1.35 (L/mg.m). The reduction was in 
the range of 34 to 42%. Since the SUVA values decreased and were < 2 (L/mg.m) after 
ozonation, this indicates that the biodegradability of the organics present in MWWE 
increased. 
 
4.5  DISCUSSION 
There is a disagreement between researchers on the mechanism responsible for 
inactivation of disinfection indicator microorganisms by ozone. The researchers either 
support the direct pathway (attack by ozone on the microorganisms) or the indirect 
pathway (the hydroxyl radicals formed on decomposition of ozone are responsible for 
inactivation of the disinfection indicator microorganisms) mechanism. If direct pathway 
is the main mechanism for disinfection, then the level of disinfection should keep on 
increasing until there is sufficient residual ozone in the effluent. In the current study, at 
TOD of 0.8 mg O3/ mg C or less, the residual ozone concentration dropped to below 
0.2 mg/L at the outlet of the first reaction chamber (3.4 minute contact time including the 
contact time in dissolution chamber). Comparing disinfection data from the end of the 
first and the subsequent three reaction chambers, i.e. between 3.4 minutes and 17 minutes 
of contact time, no further reduction in disinfection parameters was observed, even in 
cases where some residual ozone was observed at the end of the first reaction chamber. 
Tyrrell et al. (1995) and Zimmermann et al. (2011) have also made similar observations. 
In experiments by Tyrrell et al. (1995), even when 0.22 to 0.45 mg/L of residual ozone 
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was present at the end of two minutes of ozonation, they did not observe further major 
reduction in the count of the microorganisms. Hence, the low concentrations of residual 
ozone are not adequate for further major inactivation of microorganisms. This can be 
explained by the hypothesis by Xu et al. (2002) and Huber et al. (2005) that the 
microorganisms in the activated sludge flocs may be shielded from the oxidants and the 
low ozone residual is not sufficient for their inactivation. From this, it can be concluded 
that the major portion of the disinfection occurs before the residual ozone in the effluent 
reduces to low concentration, approximately 0.5 mg/L. In this experiment, at an ozone 
dose of 0.8 mg O3/mg DOC or lower, the residual ozone concentration decreased to less 
than 0.2 mg/L in approximately 3.4 minutes of total contact time (1.7 minute in 
dissolution chamber and 1.7 minutes in the first contact chamber). 
 Buffle et al. (2006b) have observed that the concentration of hydroxyl radical 
decreases by more than two orders of magnitude during the first few seconds of 
ozonation. Hence, even if indirect pathway were mainly responsible for disinfection, the 
majority of disinfection would occur during the initial few seconds of the effluent coming 
in contact with oxidants.  
From the results of this study and above discussion, it can be concluded that 
irrespective of the main mechanism responsible for inactivation of the microorganisms, 
disinfection with ozone is a fast process. At a typical disinfection dose applied in this 
study, an increase in disinfection level was not observed after the initial 200 seconds of 
MWWE being exposed to ozone. Since significant decrease in the count of disinfection 
indicator microorganism does not occur with an increase in the contact time, ozone 
contactors with long contact time do not provide any benefit. However, as aqueous ozone 
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is harmful to some aquatic animals even at low ozone dose (Arthur et al., 1975; Ward and 
DeGraeve, 1978; Summerfelt, 2003), the contact time should be sufficient to ensure that 
there is no residual ozone in the effluent before it is discharged to the receiving water 
body. In the current study, at TOD close to 0.8 mg O3/mg C, the residual ozone in 
MWWE at the outlet of the pilot unit having 17 minutes of total contact time was always 
below quantification level. 
Of the probable disinfection control parameters discussed, i.e. transferred ozone 
dose, residual ozone, UVA, SUVA, and color, correlation was not strong between TOD 
and disinfection, and residual ozone and disinfection. Nevertheless, TOD is an important 
parameter for disinfection. The TOD should be sufficient to fulfill the immediate ozone 
demand of the MWWE. The residual ozone concentration in the effluent leaving the 
dissolution chamber or first reaction chamber can be monitored as a surrogate parameter 
to ensure that the minimum level of disinfection is achieved. The correlation of 
inactivation of disinfection indicator microorganisms with UVA and color was strong, 
while it was not as strong with SUVA. Besides, to calculate SUVA, online monitoring of 
DOC is also required, which can be challenging. Hence, UVA and color can be used as a 
process control parameter to monitor and control disinfection process. The UVA of 
effluent can be continuously monitored due to the advancements in instrumentation 
technology (Ried et al., 2009). In addition, recent studies have proposed UVA and color 
as possible process control parameters for monitoring the transformation of PhACs and 
EDCs (Bahr et al., 2007; Dickenson et al., 2009; Wert et al., 2009b; Hansen et al., 2010; 
Nanaboina and Korshin, 2010). 
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The results indicate that TOD of around 4 mg/L (0.72 mg O3/mg DOC) was 
sufficient to achieve consistently the disinfection target of < 200 MPN E. coli/100mL for 
the secondary treated effluent of LRPCP. This ozone dose was selected to study the 
transformation of the CECs in the secondary treated effluent by ozonation.  
 160 
PART – II OCCURRENCE OF CECs IN MWWE AND THEIR 
TRANSFORMATION BY OZONATION 
 
4.6  OCCURRENCE OF CECs IN SECONDARY TREATED MWWE 
In this study, eight sets of MWWE samples were analyzed to determine the 
occurrence of target CECs in MWWE. These CECs consisted of 35 pharmaceutically 
active compounds (PhACs) and 9 endocrine disruptive chemicals (EDCs). 
For reporting the results, the PhACs were categorized into groups such as 
Antibiotics, Antiphlogistics, Antiepileptic/Antidepressant, Ionophore, and Lipid 
Regulators. Out of the 35 PhACs targeted, six were not detected in any of the MWWE 
samples. Table 4.9 contains the list of these PhACs and their detection limits. Table 4.10 
represents the results related to the occurrence of the remaining PhACs. 
 
Table 4.9 List of PhACs not detected during the study 
Pharmaceutical Group DL (ng/L) 
Carbadox Antibiotics 10 
Chloramphenicol Antibiotics 2 
Lasalocid A Antibiotics 10 
Monensin sodium Ionophore 10 
Sulfachloropyridazine Antibiotics 5 
Warfarin Anticoagulant 5 
Legend:  DL   Detection limit 
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Table 4.10 Occurrence of PhACs in MWWE (LRPCP) 
Compound Detection 
Frequency 
DL 
ng/L 
Concentration, ng/L 
Minimum Maximum Median Mean ± SD 
Antibiotics - Tetracyclines      
Chlortetracycline 4/8 10 33 188 52 81 ± 70 
Doxycycline 7/8 5 20 304 57 91 ± 96 
Meclocycline 5/8 10 28 319 63 130 ± 120 
Oxytetracycline 7/8 5 8 78 32 37 ± 27 
Tetracycline 6/8 10 23 402 103 145 ± 141 
Antibiotics – Macrolides      
Erythromycin 8/8 10 11 87 29 36 ± 25 
Lincomycin 4/8 0.5 4 89 72 60 ± 42 
Roxithromycin 8/8 2 3 32 10 12 ± 10 
Antibiotics – Sulfonamides      
Sulfadiazine sodium 3/8 5 13 22 14 16 ± 7 
Sulfadimethoxine 2/8 1 1 3   
Sulfamerazine 3/8 1 1 5 3 3 ± 2 
Sulfamethazine 4/8 1 6 69 46 42 ± 30 
Sulfamethizole 4/8 2 3 7 3 4 ± 2 
Sulfamethoxazole 8/8 2 3 2554 107 470 ± 826 
Sulfathiazole 3/8 2 2 8 7 6 ± 3 
Antibiotics – Fluoroquinolones      
Ciprofloxacin 6/8 0.5 52 2652 777 1082 ± 1119 
Enrofloxacin 7/8 5 6 127 57 58 ± 45 
Norfloxacin 7/8 10 15 11581 154 2601 ± 4014 
Antibiotics – Miscellaneous      
Trimethoprim 5/8 1 4 435 59 132 ± 169 
Antiphlogistics       
Acetaminophen 5/8 2 10 416 293 219 ± 193 
Diclofenac 7/8 1 17 1198 156 323 ± 399 
Ibuprofen 1/8 0.5  15638   
Indomethacin 3/8 5 11 43 13 22 ± 17 
Ketoprofen 7/8 2 2 51 15 20 ± 18 
Naproxen 8/8 2 9 261 109 119 ± 93 
Antiepileptic/antidepressant      
Carbamazepine 3/8 1 85 381 303 256 ± 179 
Lipid Regulators       
Bezafibrate 8/8 0.5 6 154 23 48 ± 52 
Clofibric Acid 4/8 1 1 64 30 31 ± 33 
Gemfibrozil 7/8 1 3 717 34 227 ± 273 
Note: Values below DL were not included in calculating median and mean concentration. 
Legends: DL   Detection Limit  SD   Standard Deviation 
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4.6.1 Antibiotics 
Out of the 23 antibiotics targeted, four were not detected in any of the eight 
sampling events. Four antibiotics had less than 50 % occurrence and the remaining had 
50 % or greater occurrence. Table 4.10 includes the results related to the occurrence of 
the antibiotics. 
The concentrations of tetracyclines group PhACs were in the range of 8 ng/L to 
402 ng/L. Tetracycline had the highest median concentration of 103 ng/L, and the highest 
maximum concentration of 402 ng/L. The occurrence was 75%. The detection frequency 
and concentration of this compound is in line with previous studies by  Miao et al. 
(2004), Sosiak et al. (2005), and Tabe et al. (2009). The median concentrations of the 
chlortetracycline, doxycycline, meclocycline, and oxytetracycline in the current study 
were less than 100 ng/L. The occurrence of these four drugs was at least 50%. In earlier 
studies conducted in Canada and abroad (Miao et al., 2004; Sosiak et al., 2005; 
Karthikeyan and Meyer, 2006; Tabe et al., 2009; Barber et al., 2011; Reungoat et al., 
2011), most of these drugs were not detected in MWWE or their detection frequency 
were less than 25%. 
Out of the three drugs in the macrolides group, erythromycin and roxithromycin 
were detected in all eight samples. The occurrence of lincomycin was 50%. It had the 
highest median and maximum concentration of 72 ng/L, and 89 ng/L, respectively. 
Sulfachloropyridazine was the only drug of the sulfonamides group PhACs that 
was not detected in any of the samples. The frequency of detection of sulfamethoxazole 
in MWWE was 100%. In its group, it had the highest maximum concentration of 
2554 ng/L. The concentrations of sulfadimethoxine, sulfamerazine, sulfamethizole, and 
sulfathiazole were less than 10 ng/L. The occurrence as well as concentration of 
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sulfonamides in the current study is in line with the results from previous studies by Miao 
et al. (2004), Sosiak et al. (2005), and Tabe et al. (2009). 
In the fluoroquinolones group PhACs consisting of ciprofloxacin, enrofloxacin, 
and norfloxacin, the average concentration of ciprofloxacin and norfloxacin was greater 
than 1000 ng/L. Ciprofloxacin was detected twice in concentrations exceeding 
2000 ng/L, the highest being 2652 ng/L. In Canada, the highest reported concentration of 
this drug in effluent until now is 888 ng/L by Sosiak et al. (2005). Rosal et al. (2010) 
from Spain have reported up to 5692 ng/L concentration of this drug. The concentration 
of norfloxacin exceeded 3000 ng/L in three samples. Its average and maximum 
concentration was 2601 ng/L and 11581 ng/L, respectively. This concentration is high 
when compared to the literature. Sosiak et al. (2005) have reported a maximum 
concentration of 821 ng/L in a Canadian MWWE. Hence, concentrations of ciprofloxacin 
and norfloxacin detected in the current study are high when compared to results reported 
from other studies from Canada. 
 
4.6.2 Antiphlogistics 
This study targeted six PhACs of this group. Ibuprofen was detected in only one 
MWWE sample, but in a high concentration of 15638 ng/L. Metcalfe et al. (2003a) and 
Brun et al. (2006) have detected ibuprofen in concentrations exceeding 20,000 ng/L. In 
the current study, the maximum concentration of diclofenac was 1198 ng/L. The 
concentrations of the remaining four PhACs were in range of 2 to 416 ng/L. This is in the 
range of values reported by other studies from Canada and abroad. 
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4.6.3 Antiepileptic/anti-depressant 
Carbamazepine was the only compound targeted in this category. It was detected 
in three of the eight sampling events. The concentrations were between 85 and 381 ng/L, 
and the median concentration was 303 ng/L. These concentrations are in the range 
reported by studies from Canada (Metcalfe et al., 2003a; Metcalfe et al., 2003b; Sosiak et 
al., 2005; Tabe et al., 2009). 
 
4.6.4 Lipid Regulators 
The PhACs covered in this group were bezafibrate, clofibric acid, and 
gemfibrozil. The occurrence of bezafibrate was 100%. Its concentration was in the range 
of 6 to 154 ng/L. Clofibric acid was detected in 50% while its concentration was in the 
range of 1 to 64 ng/L. Occurrence of gemfibrozil was close to 90% and its concentrations 
were up to717 ng/L. The concentrations of these PhACs are in the range reported by 
studies from Canada (Metcalfe et al., 2003a; Metcalfe et al., 2003b; Sosiak et al., 2005; 
Brun et al., 2006; Tabe et al., 2009). 
 
4.6.5 Endocrine Disrupting Chemicals 
Table 4.11 compiles the results related to the occurrence of the nine EDCs 
targeted. The occurrence of diethylstilbestrol and equilin was less than 25% while their 
concentrations were up to 14 ng/L. Bisphenol-A was detected in five out of eight samples 
in the concentration range of 9 ng/L to 15341 ng/L. In two samples, its concentration 
exceeded 9000 ng/L. When compared to the published literature, the concentrations of 
bisphenol-A observed in current study are high.  
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Table 4.11 Occurrence of EDCs in MWWE (LRPCP)  
Compound Detection  
Frequency 
Detection 
Limit, ng/L 
Concentration, ng/L 
Min Max Median Mean ± SD 
Estrogen Replacement Agents      
Bisphenol-A (BPA) 5/8 2 9 15341 144 4943 ± 6578 
Diethylstilbestrol 1/8 10  14 14 14 
Equilin 2/8 2 7 7 7 7 
Reproductive Hormones      
17-α-Estradiol 4/8 5 9 4167 20 1054 ± 1858 
17-β-Estradiol (E2) 5/8 2 5 52 12 22 ± 19 
Estrone (E1) 6/8 2 3 24 13 12 ± 9 
Estriol (E3) 4/8 5 27 541 79 181 ± 223 
Progesterone 2/8 20 60 121 90 90 ± 51 
Ovulation Inhibitors      
19-Norethisterone 3/8 5 5 41 23 23 ± 17 
 
The occurrence of 17-α-estradiol was 50%. While its median concentration was 
20 ng/L, in one sample it was detected in high concentration of 4167 ng/L. The highest 
concentration of eight other PhACs and EDCs also occurred during the same sampling 
event. This can indicate release of highly concentrated waste from source(s) other than 
households. The concentrations of E1 and E2 were in the ranges of 3 to 24 ng/L and 5 to 
52 ng/L, respectively. These concentrations are in line with values reported by earlier 
studies. The maximum concentration of E3 detected during the study was 541 ng/L. This 
concentration is high when compared to results from other studies from Canada. 
However, E3 has been detected in MWWE in concentrations up to 275 ng/L in Austria 
(Clara et al., 2005a). In the current study, progesterone was detected in only two of the 
eight sampling events in concentrations of 60 ng/L and 121 ng/L. The ovulation inhibitor 
19-norethisterone was detected in nearly 40% of the samples in the concentration range 
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of 5 to 41 ng/L. Fernandez et al. (2007) have detected this compound in concentrations 
up to 159 ng/L in Canadian MWWE. 
 
4.7  TRANSFORMATION OF CECs IN MWWE BY OZONATION 
The MWWE samples before and after ozone treatment from two sets of 
experiment were analyzed to study the transformation of the CECs. The results are 
presented in this section.  
 
4.7.1 Data Processing 
To get a better understanding of the actual transformation taking place, the 
transformation efficiencies of CECs having concentration below their detection limit 
(DL) in ozone treated MWWE were calculated only if their concentrations in MWWE 
before ozone treatment were equal to or greater than five times their DL. In addition, for 
CECs having concentration below their DL in the ozonated MWWE, a value equal to half 
their DL was used to calculate their transformation efficiencies.  
 
4.7.2 Transformation of CECs at TOD of 4.4 mg/L (0.72 mg O3/mg DOC) 
In two experiments, the average initial dissolved organic carbon (DOC) of water 
was 6.1 mg/L. The average applied ozone dose was 8.8 mg/L that resulted in transferred 
ozone dose (TOD) of 4.4 mg/L or 0.72 mg O3/mg DOC. The specific ozone consumption 
(Zspec), i.e. the ratio of ozone consumption to the initial DOC was calculated to be 
0.6 mg O3/mg DOC. The pH of the water was in the range of 6.9 to 7.1, temperature was 
in the range of 18 to 21 
o
C, while alkalinity was in the range of 95 to 180 mg/L as 
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CaCO3. Out of the 41 CECs targeted, the following eight CECs were not detected in both 
the experiments: carbadox, chloramphenicol, diethylstilbestrol, lasalocid A, monensin 
sodium, sulfachloropyridazine, sulfadimethoxine, and warfarin. Table 4.12 presents the 
data related to the concentration of the detected CECs, and their transformation on 
reaction with ozone.  
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Table 4.12 Transformation of CECs at TOD of 0.72 mg O3/mg DOC 
Compound DL, 
ng/L 
Concentration 
Pre Ozonation, 
ng/L 
 Concentration 
Post Ozonation, 
ng/L 
 Transformation 
% 
  Exp 1 Exp 2  Exp 1 Exp 2  Exp 1 Exp 2 
Antiphlogistics          
Acetaminophen 2 293 9.7  ND ND  99.7  
Diclofenac 1 17.4 302  ND 21.6  97.1 92.8 
Ibuprofen 0.5 15638 ND  7.5 ND  99.9  
Indomethacin 5 ND 43.3  ND ND   94.2 
Ketoprofen 2 51.2 15  7.4 3.2  85.6 79 
Naproxen 2 261 113  ND 2.2  99.6 98.1 
Antibiotic - Fluoroquinolones          
Ciprofloxacin 0.5 1398 156  ND 33.1  99.9 78.8 
Enrofloxacin 5 5.9 101  ND 77.6   22.8 
Norfloxacin 10 3248 154  ND 45  99.8 70.7 
Antibiotic - Macrolides          
Erythromycin 10 12 86.5  ND 42.9   50.4 
Lincomycin 0.5 79.2 4.3  1.3 ND  98.3 94.1 
Roxithromycin 2 2.5 31.5  ND 30.4   3.5 
Antibiotic - Tetracyclines          
Chlortetracycline 10 ND 56.2  ND 45.9   18.4 
Doxycycline 5 304 54.7  ND 28  99.2 48.8 
Meclocycline 10 319 ND  ND ND  98.4  
Oxytetracycline 5 64.6 32.2  40.1 29.3  38 8.8 
Tetracycline 10 402 104  42 30.8  89.6 70.2 
Antibiotic - Sulfonamides          
Sulfamerazine 1 5 ND  1.6 ND  68.5  
Sulfamethazine 1 69 ND  ND ND  99.3  
Sulfamethoxazole 2 2554 581  8.8 ND  99.7 99.8 
Antibiotic - Miscellaneous          
Trimethoprim 1 12.7 435  ND ND  96.1 99.9 
Antiepileptic, antidepressant          
Carbamazepine 1 ND 381  ND ND   99.9 
Lipid regulators          
Bezafibrate 0.5 11.5 154  2.1 ND  81.9 99.8 
Clofibric acid 1 1.9 57.3  ND ND   99.1 
Gemfibrozil 1 386 3.4  ND 1.1  99.9 67.3 
Estrogen replacement agents          
Bisphenol-A (BPA) 2 ND 122  3.8 ND   99 
Equilin 2 6.6 ND  3.7 ND  43.9%  
Ovulation Inhibitors          
19-Norethersterone 5 23.2 ND  2.5 ND  89  
Reproductive Hormones          
17-α-Estradiol 5 9.5 20.6  ND 13.8   33 
17-β-Estradiol (E2) 2 11.6 11.5  4.3 10  63 14 
Estrone (E1) 2 14.3 2.7  ND ND  93  
Estriol(E3) 5 83.1 ND  ND ND  97  
Progesterone 20 59.9 ND  ND ND    
Legends: DL Detection Limit  Exp Experiment  ND   Not detected  
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The results show that ozonation is effective in transforming the majority of the 
investigated compounds. The sum of the concentration of all the targeted CECs in the pre 
ozonated MWWE in the experiment #1 and #2 was 25,346 ng/L and 3,033 ng/L, which 
decreased to 173 ng/L and 423 ng/L in the ozonated MWWE, respectively. The 
concentrations of the individual CECs in the pre ozonated MWWE were up to 
15,638 ng/L, while their concentrations in the ozone treated MWWE were below 
78 ng/L. 
The transformations of the drugs in the antiphlogistics group were above 90% 
except for ketoprofen. Transformation of ketoprofen was still high but comparatively 
lower at 79 and 86%. Studies have reported above 90% reduction of acetaminophen, 
diclofenac, indomethacin, and naproxen at ozone doses up to 0.5 mg O3/mg DOC (Bahr 
et al., 2005; Reungoat et al., 2010; Rosal et al., 2010; Reungoat et al., 2012). For 
ibuprofen, studies have reported less than 50% removal up to an ozone dose of 0.5 mg 
O3/mg DOC and above 90% transformation at an ozone dose of 0.8 mg O3/mg DOC or 
higher (Ternes et al., 2003; Bahr et al., 2005; Snyder et al., 2006; Wert et al., 2009a). For 
ketoprofen, the data vary in the literature. In experiments conducted with TOD/DOC 
ratios ranging between 0.2 and 1.2,  Bahr et al. (2005) have reported transformation 
efficiencies ranging between 7 and 98%. At TOD/DOC ratio of 0.8, ketoprofen 
transformation was reported to be 82%, which is similar to the current study. Kim and 
Tanaka (2011) have reported 31 to 71% transformation of this drug at TOD/DOC ratio of 
0.6 to 0.75.  
In the fluoroquinolones subgroup of antibiotics, transformations of ciprofloxacin 
and norfloxacin were in the range of 71 to >99%. Rosal et al. (2010) and  Kim and 
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Tanaka (2011) have reported 67 to >99% transformation of these drugs at ozone doses of 
0.6 to 0.9 mg O3/mg C. The transformation of enrofloxacin in the present study was only 
23%. In the only study found that has reported the transformation of this chemical on 
ozonation of MWWE, Dodd et al. (2006) have reported >99% transformation at 
TOD/DOC ratio of around 0.6. 
In the macrolides subgroup, the transformation efficiency of the antibiotic 
lincomycin was close to 99%. This is consistent with the finding by Rosal et al. (2010) 
and Kim and Tanaka (2011). However, the transformation of erythromycin and 
roxithromycin was only 50% and 3.5%. Transformations > 90 % has been previously 
reported for these two compounds at similar ozone doses (Reungoat et al., 2010; Rosal et 
al., 2010; Schaar et al., 2010; Reungoat et al., 2012). 
The removal of chlortetracycline and oxytetracycline of the tetracyclines group of 
antibiotics was between 9 and 38%. Mean transformation of doxycycline, meclocycline, 
and tetracycline was in the range of 75 to 98%.  Dodd et al. (2006) have reported >99% 
reduction of tetracycline from wastewater at a TOD/TOC ratio of around 0.3. No data 
regarding transformation of doxycycline and meclocycline on ozonation of MWWE was 
available in the published literature. 
Ozonation reduced the concentration of sulfamethazine and sulfamethoxazole 
drugs of the sulfonamide group of antibiotics by over 99% and their concentrations 
decreased to below detection limit or close to the detection limit after ozone treatment. 
These results are consistent with the findings of other studies (Huber et al., 2005; Snyder 
et al., 2006; Hollender et al., 2009; Reungoat et al., 2012). Studies have reported over 
90% transformation of sulfamethoxazole even at low ozone doses of around 0.2 mg 
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O3/mg DOC (Ternes et al., 2003; Dickenson et al., 2009; Reungoat et al., 2012). Hence, 
this compound seems to transform readily on reaction with ozone. 
The transformation of antidepressant and lipid regulator drugs such as 
carbamazepine, bezafibrate, clofibric acid, and gemfibrozil was above 90%. Bahr et al. 
(2005) have reported low removal of these drugs up to an ozone dose of 
0.4 mg O3/mg DOC. They observed 74 to 98% reduction at a comparatively higher ozone 
dose of 0.8 mg O3/mg DOC. Hollender et al. (2009) have also reported average 88% and 
66% removal of bezafibrate and clofibric acid at ozone doses of 0.6 to 0.67 mg O3/mg 
DOC. 
The data in Table 4.12 indicate that ozone was effective in transforming potential 
EDCs such as 19-norethisterone, estrone (E1), estriol (E3), and bisphenol A (BPA). Their 
transformation was in the range of 89 to 97%. The transformation of E2 was 14 and 63%. 
Equilin and 17-α-estradiol were detected at low concentrations and their transformation 
was 44% and 33%. Progesterone was detected at a concentration of 60 ng/L in the pre 
ozonated MWWE and below its detection limit in the ozonated MWWE in one 
experiment. Its transformation efficiency was not calculated because of the data 
processing rules described earlier. 
Few studies have probed the effect of ozonation of MWWE on transformation of 
19-norethisterone and progesterone. Snyder et al. (2006) have observed more than 80% 
reduction of progesterone present in surface water by ozonation at an ozone dose of 
2.4 mg/L. Baig et al. (2008) have treated MWWE spiked with EDCs with ozone, and 
have reported 56% and > 84% reduction in concentration of norethisterone at ozone 
doses of ~ 0.3 and ~ 0.5 mg O3/mg DOC. Studies have reported high removal of E1, E3 
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and BPA at ozone doses similar to or less than that of current study (Ternes et al., 2003; 
Huber et al., 2005; Nakada et al., 2007; Wert et al., 2009a). The structures of E1, E2, E3, 
equilin and BPA consist of phenolic moieties (Deborde et al., 2005; Westerhoff et al., 
2005; Nakada et al., 2007) and the reaction between ozone and phenols is faster at neutral 
or basic pH (Deborde et al., 2005; Huber et al., 2005). The kO3 values of E1, E2, E3, and 
BPA are in the order of 10
5
 – 106 M-1 · s-1 as per the published literature. Hence, high 
transformation of these compounds by ozonation is expected. The transformation 
efficiencies of E1, E3, and BPA in the current study were as per the expectation and in 
line with the earlier reported studies, but the transformation of E2 was contrary to the 
expectations and not consistent with its structural characteristics. 
Figure 4.15 is a visual presentation of the data in Table 4.12. Out of 31 CECs for 
which transformation efficiencies could be calculated, average transformation efficiency 
of 21 CECs exceeded 80%. The average transformation of 17-α-estradiol, 17-β-estradiol, 
erythromycin, sulfamerazine, doxycycline, and tetracycline was between 30 – 80%. For 
the remaining four CECs (roxithromycin, chlortetracycline, enrofloxacin, and 
oxytetracycline; all antibiotics), the average transformation was less than 30%. 
Transformation of enrofloxacin, erythromycin, roxithromycin, and E2 was lower than 
expected. One of the reasons for the low transformation efficiency can be the analytical 
uncertainties and challenges while analyzing compounds in low ng/L concentrations. 
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Figure 4.15 Transformation of CECs at TOD of 4.4 mg/L (0.72 mg O3/mg DOC) 
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4.7.3 Comparison of transformation of CECs at TOD of 2.8 mg/L 
(0.46 mg O3/mg DOC) and TOD of 4.4 mg/L (0.72 mg O3/mg DOC) 
In order to study the effect of different ozone doses on the transformation of the 
CECs, in one experiment the MWWE was treated with two different ozone doses. Table 
4.13 shows the characteristics of the MWWE before ozone treatment. At transferred 
ozone doses of 2.8 mg/L and 4.4 mg/L, the UVA of the effluent reduced to 0.0817 and 
0.0747 cm
-1
, i.e. a reduction of 29 and 35% compared to the UVA value of the pre-
ozonated effluent. The Zspec was calculated to be 0.43 and 0.6 mg O3/mg DOC. Table 
4.14 and Figure 4.16 summarize the transformations of detected CECs at the two ozone 
doses. 
 
Table 4.13 Characteristics of MWWE before ozone treatment 
Parameter Value  
DOC 6.12 mg/L 
pH 6.92  
Temperature 20.5 – 20.8 oC 
Alkalinity 95 mg/L as CaCO3 
UV absorption at 254 nm (UVA) 0.1152 cm
-1
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Table 4.14 Transformation of CECs at TOD of 2.8 and 4.4 mg/L 
Compound DL, 
ng/L 
Concentration 
pre 
ozonation, 
ng/L 
Concentration 
post ozonation, 
ng/L 
 Transformation, % 
TOD  
2.8 mg/L 
TOD  
4.4 mg/L 
 TOD  
2.8 mg/L 
TOD  
4.4 mg/L 
Antiphlogistics        
Diclofenac 1 302.4 22.5 21.6  92.6 92.8 
Indomethacin 5 43.3 < 5 < 5  94.2 94.2 
Ketoprofen 2 15 5.0 3.2  66.7 79.0 
Naproxen 2 113 81.9 2.2  27.5 98.1 
Antibiotics – Fluoroquinolones        
Ciprofloxacin 0.5 156.2 78.9 33.1  49.5 78.8 
Enrofloxacin 5 100.6 107.1 77.6  -6.5 22.8 
Norfloxacin 10 153.6 73.8 45.0  52.0 70.7 
Antibiotics – Macrolides        
Erythromycin 10 86.5 52 42.9  39.9 50.4 
Lincomycin 0.5 4.3 < 0.5 < 0.5  94.1 94.1 
Roxithromycin 2 31.5 31.4 30.4  0.4 3.5 
Antibiotics - Tetracyclines        
Chlortetracycline 10 56.2 49.4 45.9  12.2 18.4 
Doxycycline 5 54.7 32.4 28.0  40.8 48.8 
Oxytetracycline 5 32.2 31.8 29.3  1.0 8.8 
Tetracycline 10 103.5 44.1 30.8  57.4 70.2 
Antibiotics – Sulfonamides        
Sulfamethoxazole 2 580.6 109 1.0  81.2 99.8 
Antibiotics - Miscellaneous        
Trimethoprim 1 435.2 3.6 <1  99.2 99.9 
Antiepileptic/antidepressant        
Carbamazepine 1 381.2 24.7 < 1  93.5 99.9 
Lipid Regulators        
Bezafibrate 0.5 153.7 48.2 < 0.5  68.6 99.8 
Clofibric Acid 1 57.3 34.9 < 1  39.0 99.1 
Gemfibrozil 1 3.4 1.2 1.1  64.9 67.3 
EDCs        
17-α-Estradiol 5 20.6 12.4 13.8  39.7 32.7 
17-β-Estradiol (E2) 2 11.5 16.2 10  -40.6 13.6 
Bisphenol-A (BPA) 2 122.4 < 2 < 2  99.2 99.2 
Legends: DL   Detection limit  TOD Transferred ozone dose 
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Figure 4.16 Transformation of CECs at TOD of 2.8 and 4.4 mg/L 
 
Result shows that the number of CECs detected in the pre-ozonated MWWE but 
not in the ozone treated MWWE increased from three at the lower TOD of 2.8 mg/L to 
seven at the higher TOD of 4.4 mg/L. In general, the transformation of CECs was higher 
at the higher ozone dose. There was a noticeable increase in the transformation of 
naproxen, ciprofloxacin, bezafibrate, and clofibric acid from 27 - 67% at lower ozone 
dose to 79 - >99% at higher ozone dose. The transformation of BPA, carbamazepine, 
diclofenac, indomethacin, lincomycin, sulfamethoxazole, and trimethoprim was more 
than 80% at both ozone doses. For these drugs, the percentage transformation at both 
ozone doses was almost identical. Transformations of enrofloxacin, roxithromycin, 
oxytetracycline, and chlortetracycline were below 30% at both ozone doses.  
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4.7.4 Oxidation pathway and transformation 
The oxidation pathway can dictate the type of by-products formed, and hence 
knowledge of it is important. On ozonation, transformation of a compound can be 
through the direct pathway (oxidation by molecular ozone) or indirect pathway (oxidation 
by hydroxyl radicals). The fraction of compound transformed by hydroxyl radical  COH,f  
and molecular ozone (fO3) can be calculated with Equation 2.14, 2.15, and 2.16, repeated 
as follows:  
 






dtO)Rk(k
C
C
ln 3CTOHO3
O
    (2.14) 
)Rk(k
Rk
f
CTOHO3
CTOH
COH,

       (2.15) 
COH,O3 f  - 1    f         (2.16) 
 
The ozone exposure value is required to calculate the RCT value as per the 
Equation 2.14. The Extended Integrated CT10 method used to calculate ozone exposure 
for microorganism-inactivation credit calculations does not include the considerable 
ozone exposure in the dissolution chamber. While this is desirable for inactivation credit 
calculations as a safety factor, it will give lower than actual ozone exposure value for 
micropollutant kinetic calculations and hence the calculations will not be accurate. For 
micropollutant kinetic calculations in this study, the ozone exposure in the dissolution 
chamber was also included. Considering the dissolution chamber as a continuously stirred 
tank reactor (CSTR), the ozone exposure in it was considered equal to the product of 
residual ozone concentration measured in MWWE at its outlet and hydraulic retention 
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time of MWWE in the chamber. Total ozone exposure was the sum of the ozone 
exposure as per the Extended Integrated CT10 method and ozone exposure in the 
dissolution chamber.  
If the ozone exposure is known, the RCT value can be calculated from the 
transformation measured of a compound that has low reactivity with molecular ozone and 
high reactivity with hydroxyl radicals. The second-order reaction rate constant of 
ketoprofen with ozone is 0.4 M
-1
 · s-1 and with hydroxyl radicals is 8.4 x 109 M-1 · s-1 
(Table 4.15). Hence, transformation measured of this compound was used to calculate 
RCT value. 
At experiment conducted with ozone doses of around 0.72 mg O3/mg DOC, the 
total ozone exposure was 2.04 mg-min/L (2.55 x 10
-3
 M.s). Using this value, and 
transformation measured of ketoprofen, an average RCT value of 8.12 x 10
-8
 was 
calculated. This value is in agreement with the RCT values of 0.6-4.1 x 10
-8
 reported by 
Hollender et al. (2009) , 4.78-6.31 x 10
-8
 reported by Gonzales et al. (2012), and 
4.94 x 10
-8
 reported by  Launer et al. (2012). 
Table 4.16 presents the results of the theoretical transformation calculations of 
CECs and their fraction transformation by hydroxyl radical and molecular ozone  
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Table 4.15 Rate constants for reaction of target compounds with ozone and hydroxyl radicals 
Compound kO3 kOH References  
 M
-1 s-1 M-1 s-1 kO3 kOH  
Antiphlogistics      
Acetaminophen 2.7 x 105 1.7 x 109  Rivas et al. (2011)  Yang et al. (2009)  
Diclofenac ~1 x 106 7.5 x 109  Huber et al. (2003)   
Ibuprofen 9.1 7.4 x 109  Huber et al. (2005)   
Indomethacin      
Ketoprofen 0.4 8.4 x 109  Real et al. (2009)   
Naproxen 2 x 105 9.6 x 109  Huber et al. (2005)   
Antibiotic - Fluoroquinolones      
Ciprofloxacin 1.9 x 104 4.1 x 109  Dodd et al. (2006)  
Enrofloxacin 1.5 x 105 4.5 x 109  Dodd et al. (2006)  
Norfloxacin 1.1 x 104 1 x 109  Rivas et al. (2011)  Rivas et al. (2010)  
Antibiotic - Macrolides      
Erythromycin 6.93 x 104   Huang (2011)   
Lincomycin 6.7 x 105 8.5 x 109  Dodd et al. (2006)  
Roxithromycin 6.3 x 104 5.4 x 109  Dodd et al. (2006)  
Antibiotic - Tetracyclines      
Chlortetracycline 1.7 x 107 5.2 x 109  Ben et al. (2012)  Jeong et al. (2010)  
Doxycycline 8 x 105 7.6 x 109  Rivas et al. (2011)  Jeong et al. (2010)  
Meclocycline      
Oxytetracycline 6.9 x 106 5.6 x 109  Ben et al. (2012)  Jeong et al. (2010)  
Tetracycline 1.9 x 106 7.7 x 109  Dodd et al. (2006)  
Antibiotic - Sulfonamides      
Sulfamerazine  7.8 x 109   Mezyk et al. (2007)  
Sulfamethazine 2.9 x 106 8.3 x 109  Ben et al. (2012)  Mezyk et al. (2007)  
Sulfamethoxazole 2.5 x 106 5.5 x 109  Huber et al. (2005)   
Antibiotic - Miscellaneous      
Trimethoprim 2.7 x 105 6.9 x 109  Dodd et al. (2006)  
Antiepileptic, antidepressant      
Carbamazepine 3 x 105 8.8 x 109  Huber et al. (2005)   
Lipid regulators      
Bezafibrate 590 7.4 x 109  Huber et al. (2003)   
Clofibric acid < 20 4.7 x 109  Huber et al. (2005)   
Gemfibrozil 2 x 104 8.0 x 109  Wert et al. (2011)  Razavi et al. (2009)  
Estrogen replacement agents      
Bisphenol-A (BPA) 1.7 x 104 1 x 1010  Deborde et al. (2005) Rosenfeldt et al. (2004)  
Equilin      
Ovulation Inhibitors      
19-Norethersterone 2215   Brosèus et al. (2009)   
Reproductive Hormones      
17-α-Estradiol      
17-β-Estradiol (E2) 2.2 x 105 1.4 x 1010  Deborde et al. (2005) Rosenfeldt et al. (2004)  
Estrone (E1) 9.4 x 105 2.6 x 1010  Nakonechny et al. (2008)  
Estriol (E3) 1.0 x 105   Deborde et al. (2005)   
Progesterone 480 8.5 x 108  Barron et al. (2006)  Mezyk et al. (2010)  
Note: Reaction rate constant are for pH ~7 and temperature ~ 20 oC. Check references for exact pH, temp. 
Legends:  kO3 Second-order reaction rate constant of compound with ozone 
  kOH Second-order reaction rate constant of compound with hydroxyl radical  
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Table 4.16 Dominant oxidation pathway, and comparison of theoretical and actual 
transformation of CECs 
Compound kOH kO3 Theoretical Calculations Measured  
% transf.  M
-1 s-1 M-1 s-1 fOH,C fO3 % transf. 
Antiphlogistics       
Acetaminophen 1.7 x 109 2.7 x 105 <0.01 >0.99 > 99.9 99.7 
Diclofenac 7.5 x 109 ~1 x 106 <0.01 >0.99 > 99.9 95 
Ibuprofen 7.4 x 109 9.1 0.99 0.01 78.9 99.9 
Ketoprofen 8.4 x 109 0.4 >0.99 <0.01 82.4 82.3 
Naproxen 9.6 x 109 2 x 105 <0.01 >0.99 > 99.9 98.9 
Antibiotic - Fluoroquinolones       
Ciprofloxacin 4.1 x 109 1.9 x 104 0.02 0.98 > 99.9 89.4 
Enrofloxacin 4.5 x 109 1.5 x 105 <0.01 >0.99 > 99.9 22.8 
Norfloxacin 1 x 109 1.1 x 104 0.01 0.99 > 99.9 85.3 
Antibiotic - Macrolides       
Erythromycin  6.93 x 104   > 99.9* 50.4 
Lincomycin 8.5 x 109 6.7 x 105 <0.01 >0.99 > 99.9 96.2 
Roxithromycin 5.4 x 109 6.3 x 104 0.01 0.99 > 99.9 3.5 
Antibiotic – Tetracyclines       
Chlortetracycline 5.2 x 109 1.7 x 107 <0.01 >0.99 > 99.9 18.4 
Doxycycline 7.6 x 109 8 x 105 <0.01 >0.99 > 99.9 48.8 
Oxytetracycline 5.6 x 109 6.9 x 106 <0.01 >0.99 > 99.9 98.4 
Tetracycline 7.7 x 109 1.9 x 106 <0.01 >0.99 > 99.9 23.4 
Antibiotic - Sulfonamides       
Sulfamerazine 7.8 x 109    80.1** 68.5 
Sulfamethazine 8.3 x 109 2.9 x 106 <0.01 >0.99 > 99.9 99.3 
Sulfamethoxazole 5.5 x 109 2.5 x 106 <0.01 >0.99 > 99.9 99.8 
Antibiotic - Miscellaneous       
Trimethoprim 6.9 x 109 2.7 x 105 <0.01 >0.99 > 99.9 98 
Antiepileptic, antidepressant       
Carbamazepine 8.8 x 109 3 x 105 <0.01 >99.99 > 99.9 99.9 
Lipid regulators       
Bezafibrate 7.4 x 109 590 0.50 0.50 95.2 90.9 
Clofibric acid 4.7 x 109 < 20 0.95 0.05 64.1 99.1 
Gemfibrozil 8.0 x 109 2 x 104 0.03 0.97 > 99.9 83.6 
Estrogen replacement agents       
Bisphenol-A (BPA) 1 x 1010 1.7 x 104 0.05 0.95 > 99.9 99 
Ovulation Inhibitors       
19-Norethersterone  2215   99.7* 89 
Reproductive Hormones       
17-β-Estradiol (E2) 1.4 x 1010 2.2 x 105 0.01 0.99 > 99.9 39 
Estrone (E1) 2.6 x 1010 9.4 x 105 <0.01 >99.99 > 99.9 93 
Estriol (E3)  1.0 x 105   > 99.9* 97 
Progesterone 8.5 x 108 480 0.13 0.87 75.3 > 67 
Notes:  * Theoretical percentage transformation is based on transformation with molecular ozone only. 
** Theoretical percentage transformation is based on transformation with hydroxyl radicals only. 
Legends:  kO3 Second-order reaction rate constant of compound with ozone 
kOH Second-order reaction rate constant of compound with hydroxyl radicals 
  fOH,C fraction transformation of compound with hydroxyl radicals 
  fO3 fraction transformation of compound with molecular ozone 
transf. transformation  
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The second-order reaction rate constant of most of the CECs with hydroxyl 
radical is > 10
9
 M
-1
 · s-1 (Table 4.15). However, the results in Table 4.16 indicate that the 
oxidation pathway with hydroxyl radicals only dominates the transformation of 
compounds that are ozone recalcitrant and have low reactivity with ozone (less than ~ 
600 M
-1
 · s-1). Bezafibrate has low reactivity with ozone (kO3 value 590 M
-1
 · s-1) and high 
reactivity with hydroxyl radicals (kOH value of 7.4 x 10
9
 M
-1
 · s-1). As per the 
calculations, its fraction of transformation is 0.50 by hydroxyl radicals and 0.50 by 
ozone. Progesterone also has low reactivity with ozone. Its reactivity with hydroxyl 
radicals is one to two magnitudes lower compared to most of the other CECs. In this case, 
the fraction of removal by ozone is 0.87 while that due to hydroxyl radicals is 0.13. For 
CECs with kO3 value > 10
4
 M
-1
 · s-1, their fraction transformation due to reaction with 
ozone is > 0.99. At the operating conditions in this study, the direct pathway dictates the 
transformation of more than 80% of the CECs targeted. 
  Acero and von Gunten (2001) have shown that ozone-based AOPs, such as 
ozone + hydrogen peroxide, can increase the RCT value by three to ten times. If the RCT 
value determined in the current study is increased by 10 times and the new value is 
applied to the oxidation kinetic study, there is significant increase in the transformation of 
ozone-recalcitrant CECs by hydroxyl radicals. However, the direct pathway still 
dominates the transformation of majority of the CECs. Studies have shown that ozone-
based AOP process that increase the hydroxyl radical concentration by decreasing the 
residual ozone concentration are not as effective as ozonation alone in disinfection of 
MWWE. Hence, ozone-based AOP processes for treatment of MWWE may adversely 
affect disinfection and might not improve significantly the transformation of CECs. 
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Results from Table 4.16 indicate that, in general, the actual average 
transformation values as in Table 4.12 are close to the calculated theoretical 
transformation values. For some CECs such as ibuprofen and clofibric acid, the actual 
transformation is higher than that theoretically calculated. On the other side, actual 
transformations of CECs such as enrofloxacin, erythromycin, roxithromycin, 
doxycycline, chlortetracycline, and tetracycline, were less than 60% while their 
theoretically calculated transformation were close to 100%. These CECs have high 
reactivity with ozone (kO3 value 10
4
 to 10
5
 M
-1
 · s-1) as well as hydroxyl radicals (kOH 
value around 10
9
 M
-1
 · s-1). Hence, their low transformation was contrary to the 
expectation. Similarly, the transformation of E2 was lower than expected. The analytical 
difficulties and challenges related to analysis of CECs in MWWE matrix that have 
concentrations less than 100 ng/L can be a reason for the low measured transformation. 
 
4.8  Mutagenicity of secondary and tertiary treated effluent 
Table 4.17 summarizes the results from the modified Ames fluctuation test 
conducted to determine mutagenicity of MWWE pre-ozonation (FE), MWWE post-
ozonation (OZ), and MWWE post ozonation + GAC filtration (OZGAC). Four of the 
eighteen samples (i.e. 22% of samples) tested positive for mutagenic activity. Based on 
the test results, the FE and the OZ samples exhibited mutagenic effect. The FE and OZ 
samples with 50% dilution tested positive in two of the three trials. Their 10% 
concentration samples always tested negative. As per the classification suggested by 
Jolibois and Guerbet (2005) and reproduced in Table 4.18, the FE and OZ samples were 
moderately mutagenic. As their mutagenicity response intensities were similar, it shows 
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that ozone treatment did not increase the mutagenicity of ozonated MWWE. None of the 
GAC filtered MWWE samples tested positive. This indicates that ozonation plus GAC 
filtration reduced the mutagenic activity of the effluent. 
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Table 4.17 Mutagenicity of secondary and tertiary treated MWWE samples 
Sample Mutagenicity ratio (average ± standard error) 
 Trial #1 Trial #2 Trial #3 
Background 1.00 ± 0.15 1.00 ± 0.10 1.00 ± 0.04 
50% FE 1.44 ± 0.48 2.57
c
 ± 0.27 5.96
c
 ± 0.24 
10% FE 0.85 ± 0.24 0.34 ± 0.06 0.62 ± 0.06 
50% OZ 0.85 ± 0.15 2.32
c
 ± 0.26 4.62
c
 ± 0.37 
10% OZ 0.97 ± 0.20 0.27 ± 0.06 0.84 ± 0.12 
50% OZGAC 0.91 ± 0.18 0.40 ± 0.04 1.02 ± 0.37 
10% OZGAC 0.74 ± 0.12 0.38 ± 0.05 0.67 ± 0.17 
Notes: 
1) The statistically significant positive results are highlighted in bold. 
2) Prefix: 10%, 50% indicates the sample concentration in sterile distilled water. 
 
Legends:  
a  p < 0.05 (statistical significance) 
 b  p < 0.01  
 c  p< 0.001 
FE:   MWWE pre ozonation  
OZ:   MWWE post ozonation  
OZGAC: MWWE post ozonation + GAC filtration  
 
 
 
Table 4.18 Mutagenic intensity 
Sample 
concentration 
Statistical significance level 
 p < 0.05 p < 0.01 p < 0.001 
10% Slight Moderate Strong 
50% Slight Slight Moderate 
Note: Table is adapted from Jolibois and Guerbet (2005). 
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CHAPTER V 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1  CONCLUSIONS 
In this study, a pilot-scale ozonation plant was installed at Little River Pollution 
Control Plant, Canada, and experiments were conducted to determine the efficacy of 
ozonation of secondary treated municipal wastewater effluent (MWWE) for disinfection 
and transformation of contaminants of concern. The results of experiments conducted to 
study disinfection reveal the following: 
 The disinfection target of < 200 MPN E. coli/100 mL was consistently 
achieved at transferred ozone dose (TOD) of around 0.72 mg O3/mg DOC 
and sometimes but not always at TOD of 0.46 mg O3/mg DOC. 
 Contact time of 2 minutes at TOD of around 0.72 mg O3/mg DOC was 
sufficient to meet the disinfection target.  
 Residual ozone concentration reduced to less than quantifiable concentration 
of 0.01 mg/L within a contact time of 8 minutes or less.  
 Disinfection efficiency (measured as reduction in E. coli count) showed 
correlation with TOD, residual ozone, UV absorption at 254 nm (UVA), 
SUVA, and color. The correlation coefficient (R
2
 value) was in the range of 
0.53 to 0.80. A strong correlation was observed between disinfection 
efficiency and reduction in the UVA as well as color (R
2
 value of 0.80 in both 
cases).  
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 There was a positive change in the physicochemical properties of MWWE 
after ozonation. Ozonation improved the aesthetics of MWWE by removing 
color, increasing the dissolved oxygen (DO) concentration, and decreasing 
the aromaticity (measured as UVA). At TOD of around 0.72 mg O3/mg DOC, 
the DO increased from < 2.5 mg/L to around 8 mg/L. UVA reduction was 
between 31 and 39% while color reduction was between 80 and 92%. 
 Mineralization of the organics did not occur at TOD of around 
0.72 mg O3/mg DOC since no change was observed in bulk organic 
concentration (TOC) after ozonation. However, SUVA decreased by 34 to 
42% and its value after ozonation was in the range of 1.16 to 1.35 (L/mg.m). 
This indicates that ozonation of MWWE resulted in breaking of organic 
molecules into molecules with lower molecular weight, and there was an 
increase in the biodegradability of the organics.  
 
The result of experiments conducted to study the occurrence of CECs in MWWE 
and their transformation on ozonation reveal the following: 
 CECs were present in the MWWE in ng/L to μg/L concentrations. 
 At TOD of 0.72 mg O3/mg DOC, the sum of concentration of all the CECs 
targeted reduced by 86 to 99%. Out of 31 CECs for which the transformation 
efficiency could be calculated, transformation of 21 CECs exceeded 80%. 
The concentrations of 11 CECs were reduced to less than their detection 
limit. 
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 The transformation of the CECs was lower at TOD of 0.46 mg O3/mg DOC 
than at TOD of 0.72 mg O3/mg DOC. The difference between transformation 
at the two ozone doses was significantly higher for compounds having low 
reactivity with ozone, example: bezafibrate and clofibric acid. The 
transformation of CECs such as BPA, carbamazepine, diclofenac, 
indomethacin, lincomycin, sulfamethoxazole, and trimethoprim was more 
than 80% at both ozone doses.   
 The direct pathway dominated transformation of more than 80% of the CECs 
targeted. The indirect pathway dictated the transformation of CECs that are 
less reactive with ozone (second-order reaction rate constant with ozone less 
than ~ 600 M
-1
 · s-1). 
 The mutagenicity of MWWE did not increase after ozonation. 
 
The results indicate that for a properly treated secondary or tertiary MWWE, a 
transferred ozone dose of < 1 mg O3/mg DOC should suffice to achieve the dual purpose 
of disinfection as well as transformation of CECs. 
 
5.2  RECOMMENDATIONS 
 Testing methods should be developed for inline measurement of disinfection 
of MWWE. 
 Results of current study indicate that UV absorption at 254 nm and color has 
strong correlation with inactivation of disinfection indicator microorganism. 
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More studies should be conducted with MWWE of different municipal 
wastewater treatment plants to confirm the finding. 
 Surrogate parameters to indirectly measure transformation of CECs on 
ozonation should be developed. 
 By-products formed on ozonation of MWWE can be more mutagenic than 
their parent compound. Test results of current study with modified Ames test 
indicate that the mutagenicity of the effluent did not increase after ozonation 
at the operating conditions. The finding should be confirmed with a battery of 
genotoxicity tests. 
 The MWWE before ozonation and after ozonation tested positive for 
mutagenicity in the current study. The effect of biofiltration of ozonated 
MWWE on reduction of genotoxicity and mutagenicity of the MWWE should 
be investigated. 
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APPENDIX A 
Effect of ozonation of MWWE spiked with PhACs and EDCs  
Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre Ozonated 
effluent 
Post Ozonated 
Effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/ mgC ng/L ng/L ng/L   
          
Ciprofloxacin  5.3 1 ~ 0.2  331,340  41 DD 
  5.3 1.5 ~ 0.3  331,340  66 DD 
  5.3 3 ~ 0.6  331,340  > 99 DD 
          
Enrofloxacin  5.3 1 ~ 0.2  359,390  62 DD 
  5.3 1.5 ~ 0.3  359,390  90 DD 
  5.3 3 ~ 0.6  359,390  > 99 DD 
          
Lincomycin  5.3 1 ~ 0.2  406,540  70 DD 
          
Penicillin G  5.3 1 ~ 0.2  334,390  20 DD 
  5.3 1.5 ~ 0.3  334,390  40 ± 15 DD 
  5.3 3 ~ 0.6  334,390  70 DD 
  5.3 5 ~ 1  334,390  > 99 DD 
Roxithromycin  5.3 1 ~ 0.2  837,050  55 ± 10 DD 
          
Sulfamethoxazole  5.3 1 ~ 0.2  253,280  66 DD 
  5.3 1.5 ~ 0.3  253,280  93 DD 
  5.3 3 ~ 0.6  253,280  > 99 DD 
          
Tetracycline  5.3 1 ~ 0.2  444,430  85 DD 
  5.3 1.5 ~ 0.3  444,430  > 99 DD 
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Compound No. of 
sample 
TOC  or DOC O3 dose O3 dose RL O3 
samples 
Pre Ozonated 
effluent 
Post Ozonated 
Effluent 
% Reduction 
Range  (Median) 
Reference 
  mg/L mg/L mg O3/ mgC ng/L ng/L ng/L   
          
Trimethoprim  5.3 1 ~ 0.2  290,320  59 DD 
  5.3 1.5 ~ 0.3  290,320  87 DD 
  5.3 3 ~ 0.6  290,320  > 99 DD 
          
17β-Estradiol  1.6 1   50,000  80 BL 
  1.6 5   50,000  >99 BL 
  1.6 10   50,000  99.6 BL 
  COD: 59  4.3   40  90 HS 
  COD: 44 1.9   40  90 HS 
  BOD: 2.5-4 3  0.7 200  > 90 HM 
          
Estrone  COD: 59  6.1   40  90 HS 
  BOD: 2.5-4 1  0.7 200  > 90 HM 
  BOD: 2.5-4 3  0.7 200 > RL > 99 HM 
          
17α-Ethinyl Estradiol  COD: 59  6.2   40  90 HS 
 COD: 44 2.5   40  90 HS 
  BOD: 2.5-4 1  0.7 200  > 90 HM 
  BOD: 2.5-4 3  0.7 200 ~ 10 ~ 95 HM 
 
Legends: TOC: Total Organic Carbon  DOC: Dissolved Organic Carbon  O3: Ozone  RL: Reported Limit 
Reference Legends: 
 
DD  Dodd et al. (2006) 
BL  Bila et al. (2007) 
HS  Hansen et al. (2010) 
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APPENDIX B 
Correlation between TOD and reduction in color (for each trial) 
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APPENDIX C 
Correlation between TOD and reduction in UVA (for each trial) 
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APPENDIX D 
Details of the CECs targeted 
Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Analgesic/Anti-inflammatory Agents 
Diclofenac 15307-86-5 C14H11Cl2NO2 296.15 2-(2,6-dichloranilino) phenylacetic acid 
 
Ibuprofen 15687-27-1 C13H18O2 206.28 2-[4-(2-methylpropyl)phenyl]propanoic acid 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Indomethacin (6259) 53-86-1 C19H16ClNO4 357.79 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-
indol-3-yl)acetic acid 
 
Ketoprofen 22071-15-4 C16H14O3 254.28 (2R)-2-(3-benzoylphenyl)propanoic acid 
 
Naproxen (7997) 22204-53-1 C14H14O3 230.26 (2S)-2-(6-methoxynaphthalen-2-yl)propanoic 
acid 
 
Antibiotics 
Carbadox 6804-07-5 C11H10N4O4 262.22 methyl-N-[(1-hydroxy-4-oxidoquinoxalin-4-ium-
2-ylidene)methylimino]carbamate 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Chloramphenicol 56-75-7 C11H12Cl2N2O5 323.13 2,2-dichloro-N-((1R,2R)-1,3-dihydroxy-1-(4-
nitrophenyl)propan-2-yl)acetamide 
 
Chlortetracycline 57-62-5 C22H23ClN2O8 478.88 (4S,4aS,5aS,12aR)-7-chloro-4-(dimethylamino)-
1,6,10,11,12a-pentahydroxy-6-methyl-3,12-
dioxo-4,4a,5,5a-tetrahydrotetracene-2-
carboxamide 
 
Ciprofloxacin 85721-33-1 C17H18FN3O3 331.34 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-
ylquinoline-3-carboxylic acid 
 
Doxycycline 564-25-0 C22H24N2O8 444.43 (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-
1,5,10,11,12a-pentahydroxy-6-methyl-3,12-
dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-
carboxamide 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Enrofloxacin 93106-60-6 C19H22FN3O3 359.39 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-
4-oxoquinoline-3-carboxylic acid 
 
Erythromycin 114-07-8 C37H67NO13 733.93 (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-
[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-
methyloxan-2-yl]oxy-14-ethyl-7,12,13-
trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-
methoxy-4,6-dimethyloxan-2-yl]oxy-
3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-
2,10-dione 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Lasalocid A 25999-31-9 C34H54O8 590.79 6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-
[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-
yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-
dimethyl-6-oxononyl]-2-hydroxy-3-
methylbenzoic acid 
 
Lincomycin 154-21-2 C18H34N2O6S 406.54 (2S,4R)-N-[(1S)-2-hydroxy-1-[(3R,4S,5R,6R)-
3,4,5-trihydroxy-6-methylsulfanyloxan-2-
yl]propyl]-1-methyl-4-propylpyrrolidine-2-
carboxamide 
 
Meclocycline 2013-58-3 C22H21ClN2O8 476.86 (4S,4aR,5S,5aR,12aR)-7-chloro-4-
(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-
methylidene-3,12-dioxo-4,4a,5,5a-
tetrahydrotetracene-2-carboxamide 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Norfloxacin 70458-96-7 C16H18FN3O3 319.33 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-
ylquinoline-3-carboxylic acid 
 
Oxytetracycline 79-57-2 C22H24N2O9 460.43 (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-
1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-
dioxo-4,4a,5,5a-tetrahydrotetracene-2-
carboxamide 
 
Penicillin G 61-33-6 C16H18N2O4S 334.39 (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-
phenylacetyl)amino]-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylic acid 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Roxithromycin 80214-83-1 C41H76N2O15 837.05 (3R,4S,5S,6R,7R,9R,10Z,11S,12R,13S,14R)-6-
[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-
methyloxan-2-yl]oxy-14-ethyl-7,12,13-
trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-
methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-
methoxyethoxymethoxyimino)-3,5,7,9,11,13-
hexamethyl-oxacyclotetradecan-2-one 
 
Sulfachloropyridazine 80-32-0 C10H9ClN4O2S 284.72 4-amino-N-(6-chloropyridazin-3-
yl)benzenesulfonamide 
 
Sulfadiazine sodium 547-32-0 C10H9N4NaO2S 272.26 sodium (4-aminophenyl)sulfonyl-pyrimidin-2-
ylazanide 
 
Sulfadimethoxine 122-11-2 C12H14N4O4S 310.33 4-amino-N-(2,6-dimethoxypyrimidin-4-
yl)benzenesulfonamide 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Sulfamerazine 127-79-7 C11H12N4O2S 264.30 4-amino-N-(4-methylpyrimidin-2-
yl)benzenesulfonamide 
 
Sulfamethazine 57-68-1 C12H14N4O2S 278.33 4-amino-N-(4,6-dimethylpyrimidin-2-
yl)benzenesulfonamide 
  
Sulfamethizole 144-82-1 C9H10N4O2S2 270.33 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-
yl)benzenesulfonamide 
 
Sulfamethoxazole 723-46-6 C10H11N3O3S 253.28 4-amino-N-(5-methyl-1,2-oxazol-3-
yl)benzenesulfonamide 
 
Sulfathiazole 72-14-0 C9H9N3O2S2 255.32 4-amino-N-(1,3-thiazol-2-yl)benzenesulfonamide 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Tetracycline 60-54-8 C22H24N2O8 444.43 (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-
1,6,10,11,12a-pentahydroxy-6-methyl-3,12-
dioxo-4,4a,5,5a-tetrahydrotetracene-2-
carboxamide 
 
Trimethoprim 738-70-5 C14H18N4O3 290.32 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-
2,4-diamine 
 
Tylosin 1401-69-0 C46H77NO17 916.10 2-[(4R,5S,6S,7S,9R,11E,13E,15R,16R)-6-
[(3R,5S)-5-[(2S,5S,6S)-4,5-dihydroxy-4,6-
dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-
hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-
hydroxy-15-[[(2R,3S,5R,6R)-5-hydroxy-3,4-
dimethoxy-6-methyloxan-2-yl]oxymethyl]-
5,9,13-trimethyl-2,10-dioxo-1-
oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde 
 
Virginiamycin M1 
 
21411-53-0 C28H35N3O7 525.59 8,9,14,15,24,25-Hexahydro-14-hydroxy-4,12-
dimethyl-3-(1-methylethyl)-3H-21,18-nitrilo-
1H,22H-pyrrolo[2,1-
C][1,8,4,19]dioxadiazacyclotetracosine-
1,7,16,22(4H,17H)-tetrone 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Estrogen Replacement Agents 
Bisphenol A 80-05-7 C15H16O2 228.29 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol 
 
Diethylstilbestrol 56-53-1 C18H20O2 268.35 4-[(E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol 
 
Equilin 474-86-2 C18H20O2 268.35 (9S,13S,14S)-3-hydroxy-13-methyl-
9,11,12,14,15,16-hexahydro-6H-
cyclopenta[a]phenanthren-17-one 
 
Lipid regulators 
Bezafibrate 41859-67-0 C19H20ClNO4 361.82 2-[4-[2-[(4-
chlorobenzoyl)amino]ethyl]phenoxy]-2-
methylpropanoic acid 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Clofibric acid 882-09-7 C10H11ClO3 214.65 2-(4-chlorophenoxy)-2-methylpropanoic acid 
 
Gemfibrozil 25812-30-0 C15H22O3 250.33 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic 
acid 
 
Ovulation Inhibitors 
17-α-Ethynyl Estradiol 57-63-6 C20H24O2 296.40 (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenanthrene-3,17-diol 
 
19-Norethisterone 68-22-4 C20H26O2 298.42 (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-
hydroxy-13-methyl-
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-
1H-cyclopenta[a]phenanthren-3(2H)-one  
Reproductive Hormones 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
17-α-Estradiol 57-91-0 C18H24O2 272.38 (8R,9S,13S,14S,17R)-13-methyl-
6,7,8,9,11,12,14,15,16,17-
decahydrocyclopenta[a]phenanthrene-3,17-diol 
 
17-β-Estradiol 57-91-0 C18H24O2 272.38 (8R,9S,13S,14S,17S)-13-methyl-
6,7,8,9,11,12,14,15,16,17-
decahydrocyclopenta[a]phenanthrene-3,17-diol 
 
Estrone 53-16-7 C18H22O2 270.37 (8R,9S,13S,14S)-3-hydroxy-13-methyl-
7,8,9,11,12,14,15,16-octahydro-6H-
cyclopenta[a]phenanthren-17-one 
 
Estriol 50-27-1 C18H24O3 288.38 (8R,9S,13S,14S,16R,17R)-13-methyl-
6,7,8,9,11,12,14,15,16,17-
decahydrocyclopenta[a]phenanthrene-3,16,17-
triol 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Progesterone 57-83-0 C21H30O2 314.46 (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-
dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-
dodecahydrocyclopenta[a]phenanthren-3-one 
 
Anitcoagulant 
Warfarin 81-81-2 C19H16O4 308.33 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-
one 
 
Antiepileptic, antidepressant 
Carbamazepine 298-46-4 C15H12N2O 236.27 5H-Dibenzo[b,f]azepine-5-carboxamide 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Antipyretic 
Acetaminophen 103-90-2 C8H9NO2 151.16 N-(4-hydroxyphenyl)acetamide 
 
Ionophore 
Monensin sodium 17090-79-8 C36H61NaO11 692.85 sodium(2R,3S,4R)-4-[(2R,6R,7S,8R,9S)-2-
[(2R,5S)-5-ethyl-5-[(2S,3R,5S)-5-
[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-
3,5-dimethyloxan-2-yl]-3-methyloxolan-2-
yl]oxolan-2-yl]-9-hydroxy-2, 
8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-
methoxy-2-methylpentanoate 
 
Perfluorosurfactants 
Perfluorobutanesulfonic acid 
(PFBS) 
375-73-5 C4HF9O3S 300.10 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonic 
acid 
 
Perfluorooctanoic acid 
(PFOA) 
335-67-1 C8HF15O2 414.07 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-
pentadecafluorooctanoic acid 
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Compound CAS-RN Molecular formula Mol Wt. 
g/mol 
Chemical Name Structure 
Perfluorooctanesulfonic acid 
(PFOS) 
 
1763-23-1 C8HF17O3S 500.13 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-
heptadecafluorooctane-1-sulfonic acid 
 
 
References: 
(1) Chemical name: http://www.ncbi.nlm.nih.gov/pccompound,  Accessed on: Jan 02, 2012 
(2) CAS number: http://www.chemicalbook.com Accessed on: Jan 02, 2012 
(3) Drawings: Chemdraw 
 
 
 209 
REFERENCES 
Absi, F., Gamache, F., Gehr, R., Liechti, P. and Nicell, J. (1993) Pilot plant investigation 
of ozone disinfection of a physico-chemically treated municipal wastewater, San 
Francisco, California. 
Acero, J.L. and von Gunten, U. (2001) Characterization of oxidation processes: ozonation 
and the AOP O-3/H2O2. Journal American Water Works Association 93(10), 90-
100. 
Aga, D.S. (2008) Fate of pharmaceuticals in the environment and in water treatment 
systems, CRC Press, Boca Raton. 
Almeida, C. and Nogueira, J.M.F. (2006) Determination of steroid sex hormones in water 
and urine matrices by stir bar sorptive extraction and liquid chromatography with 
diode array detection. Journal of Pharmaceutical and Biomedical Analysis 41(4), 
1303-1311. 
Alvares, A.B.C., Diaper, C. and Parsons, S.A. (2001) Partial oxidation by ozone to 
remove recalcitrance from wastewaters - A review. Environmental Technology 
22(4), 409-427. 
Anderson, P.O., Knoben, J.E. and Troutman, W.G. (2002) Handbook of clinical drug 
data, McGraw-Hill Medical Pub. Division, New York. 
Andreasen, F., Elsborg, L., Husted, S. and Thomsen, O. (1978) Pharmacokinetics of 
Sulfadiazine and Trimethoprim in Man. European Journal of Clinical 
Pharmacology 14(1), 57-67. 
Andreozzi, R., Marotta, R., Pinto, G. and Pollio, A. (2002) Carbamazepine in water: 
persistence in the environment, ozonation treatment and preliminary assessment 
on algal toxicity. Water Research 36(11), 2869-2877. 
APHA (1998) Standard methods for the examination of water and wastewater, 20th 
Edition. Clesceri, L.S., Greenberg, A.E. and Eaton, A.D. (eds), American Public 
Health Association/American Water Works Association/Water Environment 
Federation, Washington, DC. 
Arthur, J.W., Andrew, R.W., Mattson, V.R., Olson, D.T., Glass, G.E., Halligan, B.J. and 
Walbridge, C.T. (1975) Comparative toxicity of sewage-effluent disinfection to 
freshwater aquatic life, U.S. Environmental Protection Agency, Office of 
Research and Development, Environmental Research Laboratory, Duluth. 
Auriol, M., Filali-Meknassi, Y., Tyagi, R.D., Adams, C.D. and Surampalli, R.Y. (2006) 
Endocrine disrupting compounds removal from wastewater, a new challenge. 
Process Biochemistry 41(3), 525-539. 
Bahr, C., Ernst, M., Reemtsma, T., Heinzmann, B., Luck, F. and Jekel, M. (2005) Pilot 
scale ozonation of treated municipal effluents for removal of pharmaceutical 
compounds and pathogens – The Berlin study, IOA, Strasbourg. 
Bahr, C., Schumacher, J., Ernst, M., Luck, F., Heinzmann, B. and Jekel, M. (2007) 
SUVA as control parameter for the effective ozonation of organic pollutants in 
secondary effluent. Water Science and Technology 55(12), 267-274. 
Baig, S., Hansmann, G. and Paolini, B. (2008) Ozone oxidation of oestrogenic active 
substances in wastewater and drinking water. Water Science and Technology 
58(2), 451-458. 
 210 
Baker, J.C. (1925) Chlorine in Sewage and Waste Disposal. Industrial & Engineering 
Chemistry 17(10), 1059-1060. 
Baldwin, R.T. (1927) Chlorine research. Journal of Chemical Education 4(5). 
Bancroft, K., Chrostowski, P., Wright, R.L. and Suffet, I.H. (1984) Ozonation and 
Oxidation Competition Values - Relationship to Disinfection and Microorganisms 
Regrowth. Water Research 18(4), 473-478. 
Barber, L.B., Keefe, S.H., Kolpin, D.W., Schnoebelen, D.J., Flynn, J.L., Brown, G.K., 
Furlong, E.T., Glassmeyer, S.T., Gray, J.L., Meyer, M.T., Sandstrom, M.W., 
Taylor, H.E. and Zaugg, S.D. (2011) Lagrangian sampling of wastewater 
treatment plant effluent in Boulder Creek, Colorado, and Fourmile Creek, Iowa, 
during the summer of 2003 and spring of 2005—Hydrological and Water-Quality 
data, p. 84, U.S. Geological Survey, Reston, Virginia. 
Barron, E., Deborde, M., Rabouan, S., Mazellier, P. and Legube, B. (2006) Kinetic and 
mechanistic investigations of progesterone reaction with ozone. Water Research 
40(11), 2181-2189. 
Batt, A.L., Kim, S. and Aga, D.S. (2007) Comparison of the occurrence of antibiotics in 
four full-scale wastewater treatment plants with varying designs and operations. 
Chemosphere 68(3), 428-435. 
Behera, S.K., Kim, H.W., Oh, J.E. and Park, H.S. (2011) Occurrence and removal of 
antibiotics, hormones and several other pharmaceuticals in wastewater treatment 
plants of the largest industrial city of Korea. Science of the Total Environment 
409(20), 4351-4360. 
Ben, W., Qiang, Z., Pan, X. and Nie, Y. (2012) Degradation of Veterinary Antibiotics by 
Ozone in Swine Wastewater Pretreated with Sequencing Batch Reactor. Journal 
of Environmental Engineering-Asce 138(3), 272-277. 
Bennett, L.E. and Drikas, M. (1993) The Evaluation of Color in Natural-Waters. Water 
Research 27(7), 1209-1218. 
Bennink, H.J.T.C. (2004) Are all estrogens the same? Maturitas 47(4), 269-275. 
Benotti, M.J., Trenholm, R.A., Vanderford, B.J., Holady, J.C., Stanford, B.D. and 
Snyder, S.A. (2009) Pharmaceuticals and Endocrine Disrupting Compounds in 
US Drinking Water. Environmental Science & Technology 43(3), 597-603. 
Bertanza, G., Papa, M., Pedrazzani, R., Repice, C. and Dal Grande, M. (2012) Tertiary 
ozonation of industrial wastewater for the removal of estrogenic compounds (NP 
and BPA): a full scale case study, International Water Association, Goslar, 
Germany. 
Besse, J.P. and Garric, J. (2009) Progestagens for human use, exposure and hazard 
assessment for the aquatic environment. Environmental Pollution 157(12), 3485-
3494. 
Besse, J.P., Kausch-Barreto, C. and Garric, J. (2008) Exposure assessment of 
pharmaceuticals and their metabolites in the aquatic environment: Application to 
the French situation and preliminary prioritization. Human and Ecological Risk 
Assessment 14(4), 665-695. 
Bhandari, A., Environmental Council of the States (U.S.) Emerging Contaminants of 
Concern Task Committee and Environmental and Water Resources Institute 
(U.S.) (2009) Contaminants of Emerging Environmental Concern, American 
Society of Civil Engineers, Reston, Va. 
 211 
Bila, D., Montalvao, A.F., Azevedo, D.D. and Dezotti, M. (2007) Estrogenic activity 
removal of 17 beta-estradiol by ozonation and identification of by-products. 
Chemosphere 69(5), 736-746. 
Black & Veatch, C. (2010) White's Handbook of Chlorination and Alternative 
Disinfectants (5th Edition), John Wiley & Sons, Hoboken, NJ. 
Bloetscher, F. and Plummer, J.D. (2011) Environmental Review & Case Study: 
Evaluating the Significance of Certain Pharmaceuticals and Emerging Pathogens 
in Raw Water Supplies. Environmental Practice 13(03), 198-215. 
Boyd, G.R., Reemtsma, H., Grimm, D.A. and Mitra, S. (2003) Pharmaceuticals and 
personal care products (PPCPs) in surface and treated waters of Louisiana, USA 
and Ontario, Canada. Science of the Total Environment 311(1-3), 135-149. 
Braga, O., Smythe, G.A., Schafer, A.I. and Feitz, A.J. (2005) Fate of steroid estrogens in 
Australian inland and coastal wastewater treatment plants. Environmental Science 
& Technology 39(9), 3351-3358. 
Bratby, J. (2006) Coagulation and flocculation in water and wastewater treatment, IWA 
Publishing, London; Seattle. 
Brosèus, R., Vincent, S., Aboulfadl, K., Daneshvar, A., Sauvé, S., Barbeau, B. and 
Prévost, M. (2009) Ozone oxidation of pharmaceuticals, endocrine disruptors and 
pesticides during drinking water treatment. Water Research 43(18), 4707-4717. 
Brun, G.L., Bernier, M., Losier, R., Doe, K., Jackman, P. and Lee, H.B. (2006) 
Pharmaceutically active compounds in Atlantic Canadian sewage treatment plant 
effluents and receiving waters, and potential for environmental effects as 
measured by acute and chronic aquatic toxicity. Environmental Toxicology and 
Chemistry 25(8), 2163-2176. 
Buffle, M.O., Schumacher, J., Meylan, S., Jekel, M. and von Gunten, U. (2006a) 
Ozonation and advanced oxidation of wastewater: Effect of O3 dose, pH, DOM 
and HO•-scavengers on ozone decomposition and HO• generation. Ozone-Science 
& Engineering 28(4), 247-259. 
Buffle, M.O., Schumacher, J., Salhi, E., Jekel, M. and von Gunten, U. (2006b) 
Measurement of the initial phase of ozone decomposition in water and wastewater 
by means of a continuous quench-flow system: Application to disinfection and 
pharmaceutical oxidation. Water Research 40(9), 1884-1894. 
Buxton, G.V. and Elliot, A.J. (1986) Rate Constant for Reaction of Hydroxyl Radicals 
with Bicarbonate Ions. Radiation Physics and Chemistry 27(3), 241-243. 
Buxton, G.V., Greenstock, C.L., Helman, W.P. and Ross, A.B. (1988) Critical Review of 
Rate Constants for Reactions of Hydrated Electrons, Hydrogen Atoms and 
Hydroxyl Radicals (·Oh/·O-) in Aqueous Solution. Journal of Physical and 
Chemical Reference Data 17(2), 513-886. 
Can, Z.S. and Çakir, E. (2010) Treatability of Organic Constituents in the Paşaköy 
Wastewater Treatment Plant Effluent by O3 and O3/H2O2. Ozone-Science & 
Engineering 32(3), 209-214. 
Carballa, M., Omil, F., Lema, J.M., Llompart, M., García-Jares, C., Rodríguez, I., 
Gómez, M. and Ternes, T. (2004) Behavior of pharmaceuticals, cosmetics and 
hormones in a sewage treatment plant. Water Research 38(12), 2918-2926. 
 212 
Castiglioni, S., Bagnati, R., Fanelli, R., Pomati, F., Calamari, D. and Zuccato, E. (2006) 
Removal of pharmaceuticals in sewage treatment plants in Italy. Environmental 
Science & Technology 40(1), 357-363. 
Çeçen, F. and Aktas, Ö. (2012) Activated carbon for water and wastewater treatment : 
integration of adsorption and biological treatment, Wiley-VCH, Weinheim, 
Germany. 
Cermola, M., DellaGreca, M., Iesce, M.R., Previtera, L., Rubino, M., Temussi, F. and 
Brigante, M. (2005) Phototransformation of fibrate drugs in aqueous media. 
Environmental Chemistry Letters 3(1), 43-47. 
Chambers, P.A., Allard, M., Walker, S.L., Marsalek, J., Lawrence, J., Servos, M., 
Busnarda, J., Munger, K.S., Adare, K., Jefferson, C., Kent, R.A. and Wong, M.P. 
(1997) The Impacts of Municipal Wastewater Effluents on Canadian Waters: A 
Review. Water Quality Research Journal of Canada 32(4), 659-713. 
Cho, M., Kim, J., Kim, J.Y., Yoon, J. and Kim, J.H. (2010) Mechanisms of Escherichia 
coli inactivation by several disinfectants. Water Research 44(11), 3410-3418. 
Choi, K., Kim, Y., Park, J., Park, C.K., Kim, M., Kim, H.S. and Kim, P. (2008) Seasonal 
variations of several pharmaceutical residues in surface water and sewage 
treatment plants of Han River, Korea. Science of the Total Environment 405(1-3), 
120-128. 
Christensen, F.M. (1998) Pharmaceuticals in the environment - A human risk? 
Regulatory Toxicology and Pharmacology 28(3), 212-221. 
Clara, M., Kreuzinger, N., Strenn, B., Gans, O. and Kroiss, H. (2005a) The solids 
retention time - a suitable design parameter to evaluate the capacity of wastewater 
treatment plants to remove micropollutants. Water Research 39(1), 97-106. 
Clara, M., Strenn, B., Gans, O., Martinez, E., Kreuzinger, N. and Kroiss, H. (2005b) 
Removal of selected pharmaceuticals, fragrances and endocrine disrupting 
compounds in a membrane bioreactor and conventional wastewater treatment 
plants. Water Research 39(19), 4797-4807. 
Comeau, F., Surette, C., Brun, G.L. and Losier, R. (2008) The occurrence of acidic drugs 
and caffeine in sewage effluents and receiving waters from three coastal 
watersheds in Atlantic Canada. Science of the Total Environment 396(2-3), 132-
146. 
Crouse, B.A., Ghoshdastidar, A.J. and Tong, A.Z. (2012) The presence of acidic and 
neutral drugs in treated sewage effluents and receiving waters in the Cornwallis 
and Annapolis River watersheds and the Mill CoveSewage Treatment Plant in 
Nova Scotia, Canada. Environmental Research 112(0), 92-99. 
D'Ascenzo, G., Di Corcia, A., Gentili, A., Mancini, R., Mastropasqua, R., Nazzari, M. 
and Samperi, R. (2003) Fate of natural estrogen conjugates in municipal sewage 
transport and treatment facilities. Science of the Total Environment 302(1-3), 199-
209. 
Dahi, E. (1976) Physicochemical Aspects of Disinfection of Water by Means of 
Ultrasound and Ozone. Water Research 10(8), 677-684. 
Daughton, C.G. and Ternes, T.A. (1999) Pharmaceuticals and personal care products in 
the environment: Agents of subtle change? Environmental Health Perspectives 
107, 907-938. 
 213 
Deborde, M., Rabouan, S., Duguet, J.P. and Legube, B. (2005) Kinetics of aqueous 
ozone-induced oxidation of some endocrine disruptors. Environmental Science & 
Technology 39(16), 6086-6092. 
Dhar, N.R. (1934) Formation of hydroxyl radical from the photolysis of water and the 
generation of formaldehyde. Trans. Faraday Soc. Transactions of the Faraday 
Society 30. 
Dickenson, E.R.V., Drewes, J.E., Sedlak, D.L., Wert, E.C. and Snyder, S.A. (2009) 
Applying Surrogates and Indicators to Assess Removal Efficiency of Trace 
Organic Chemicals during Chemical Oxidation of Wastewaters. Environmental 
Science & Technology 43(16), 6242-6247. 
Dodd, M.C., Buffle, M.O. and von Gunten, U. (2006) Oxidation of antibacterial 
molecules by aqueous ozone: Moiety-specific reaction kinetics and application to 
ozone-based wastewater treatment. Environmental Science & Technology 40(6), 
1969-1977. 
Dong, M.M., Mezyk, S.P. and Rosario-Ortiz, F.L. (2010) Reactivity of Effluent Organic 
Matter (Ef0M) with Hydroxyl Radical as a Function of Molecular Weight. 
Environmental Science & Technology 44(15), 5714-5720. 
Drury, D.D., Snyder, S.A. and Wert, E.C. (2006) Using Ozone Disinfection for EDC 
Removal. Proceedings of the Water Environment Federation 2006(12), 1249-
1258. 
Dufour, A.P. (1977) Bacterial Indicators / Health Hazards Associated With Water. 
Hoadley, A.W. and Dutka, B.J. (eds), pp. 48-58, American Society for Testing 
and Materials, Philadelphia, PA. 
Ebadi, M.S. (2008) Desk reference of clinical pharmacology, CRC Press, Boca Raton. 
Edzwald, J.K. and Tobiason, J.E. (1999) Enhanced coagulation: US requirements and a 
broader view. Water Science and Technology 40(9), 63-70. 
Elmund, G.K., Allen, M.J. and Rice, E.W. (1999) Comparison of Escherichia coli, total 
coliform, and fecal coliform populations as indicators of wastewater treatment 
efficiency. Water Environment Research 71(3), 332-339. 
Elovitz, M.S. and von Gunten, U. (1999) Hydroxyl radical/ozone ratios during ozonation 
processes. I.The Rct concept. Ozone-Science & Engineering 21(3), 239-260. 
Elovitz, M.S., von Gunten, U. and Kaiser, H.P. (2000) Hydroxyl radical/ozone ratios 
during ozonation processes. II. The effect of temperature, pH, alkalinity, and 
DOM properties. Ozone-Science & Engineering 22(2), 123-150. 
Emblidge, J.P. and DeLorenzo, M.E. (2006) Preliminary risk assessment of the lipid-
regulating pharmaceutical clofibric acid, for three estuarine species. 
Environmental Research 100(2), 216-226. 
EMEA (1998) Lincomycin - Summary Report (1), European Medicines Agency - 
Veterinary Medicines and Inspections, Committe for Veterinary Medicinal 
Products. 
Environment Canada and Health Canada (2008) Screening Assessment for the Challenge 
Phenol, 4,4' -(1-methylethylidene) bis (Bisphenol A), Chemical Abstracts Service 
Registry Number 80-05-7, Environment Canada & Health Canada. 
Fernandez, M.P., Ikonomou, M.G. and Buchanan, I. (2007) An assessment of estrogenic 
organic contaminants in Canadian wastewaters. Science of the Total Environment 
373(1), 250-269. 
 214 
Ferrari, B., Paxéus, N., Lo Giudice, R., Pollio, A. and Garric, J. (2003) Ecotoxicological 
impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, 
clofibric acid, and diclofenac. Ecotoxicology and Environmental Safety 55(3), 
359-370. 
Finch, G.R. and Smith, D.W. (1987) Ozone disinfection of secondary effluent containing 
antibiotic-resistant Escherichia coli. Canadian Journal of Civil Engineering 
14(2), 234-238. 
Finch, G.R. and Smith, D.W. (1989) Ozone Dose-Response of Escherichia Coli in 
Activated Sludge Effluent. Water Research 23(8), 1017-1025. 
Finch, G.R., Yuen, W.C. and Uibel, B.J. (1992) Inactivation of Escherichia Coli Using 
Ozone and Ozone - Hydrogen Peroxide. Environmental Technology 13(6), 571-
578. 
Folmar, L.C., Denslow, N.D., Rao, V., Chow, M., Crain, D.A., Enblom, J., Marcino, J. 
and Guillette Jr., L.J. (1996) Vitellogenin induction and reduced serum 
testosterone concentrations in feral male carp (Cyprinus carpio) captured near a 
major metropolitan sewage treatment plant. Environmental Health Perspectives 
104(10), 1096-1101. 
García-Galán, M.J., Díaz-Cruz, M.S. and Barceló, D. (2008) Identification and 
determination of metabolites and degradation products of sulfonamide antibiotics. 
Trends in Analytical Chemistry 27(11), 1008-1022. 
Gascoigne, G.B. (1931) Chlorination of Sewage and Sewage Effluents. Sewage Works 
Journal 3(1), 38-49. 
Gehr, R. and Nicell, J. (1996) Pilot Studies and Assessment of Downstream Effects of 
UV and Ozone Disinfection of a Physicochemical Wastewater. Water Quality 
Research Journal of Canada 31(2), 263-282. 
Gehr, R., Wagner, M., Veerasubramanian, P. and Payment, P. (2003) Disinfection 
efficiency of peracetic acid, UV and ozone after enhanced primary treatment of 
municipal wastewater. Water Research 37(19), 4573-4586. 
Gerrity, D., Gamage, S., Holady, J.C., Mawhinney, D.B., Quiñones, O., Trenholm, R.A. 
and Snyder, S.A. (2011) Pilot-scale evaluation of ozone and biological activated 
carbon for trace organic contaminant mitigation and disinfection. Water Research 
45(5), 2155-2165. 
Ghosh, G.C., Okuda, T., Yamashita, N. and Tanaka, H. (2009) Occurrence and 
elimination of antibiotics at four sewage treatment plants in Japan and their 
effects on bacterial ammonia oxidation. Water Science and Technology 59(4), 
779-786. 
Gilbert, R.I. (1980) The Analysis of Fluctuation Tests. Mutation Research 74(4), 283-
289. 
Glaze, W.H. and Kang, J.W. (1989) Advanced Oxidation Processes. Test of a Kinetic 
Model for the Oxidation of Organic Compounds with Ozone and Hydrogen 
Peroxide in a Semibatch Reactor. Industrial & Engineering Chemistry Research 
28(11), 1580-1587. 
Göbel, A., Thomsen, A., McArdell, C.S., Alder, A.C., Giger, W., Theiß, N., Löffler, D. 
and Ternes, T.A. (2005a) Extraction and determination of sulfonamides, 
macrolides, and trimethoprim in sewage sludge. Journal of Chromatography A 
1085(2), 179-189. 
 215 
Göbel, A., Thomsen, A., McArdell, C.S., Joss, A. and Giger, W. (2005b) Occurrence and 
sorption behavior of sulfonamides, macrolides, and trimethoprim in activated 
sludge treatment. Environmental Science & Technology 39(11), 3981-3989. 
Gonzales, S., Peña, A. and Rosario-Ortiz, F.L. (2012) Examining the Role of Effluent 
Organic Matter Components on the Decomposition of Ozone and Formation of 
Hydroxyl Radicals in Wastewater. Ozone: Science & Engineering 34(1), 42-48. 
Gorman, J.A. (2010) Drugs in our Water: A Legal Proposal for Responsible Nationwide 
Pharmaceutical Consumption. Journal of Land Use & Environmental Law 26(1), 
147-178. 
Gottschalk, C., Libra, J.A. and Saupe, A. (2000) Ozonation of water and waste water : a 
practical guide to understanding ozone and its application, Wiley-VCH, 
Weinheim; New York. 
Grünebaum, T. (2011) Elimination von Arzneimittelrückständen in kommunalen 
Kläranlagen - Schlussbericht Phase 1, Germany. 
Grung, M., Källqvist, T., Sakshaug, S., Skurtveit, S. and Thomas, K.V. (2008) 
Environmental assessment of Norwegian priority pharmaceuticals based on the 
EMEA guideline. Ecotoxicology and Environmental Safety 71(2), 328-340. 
Gulkowska, A., Leung, H.W., So, M.K., Taniyasu, S., Yamashita, N., Yeunq, L.W.Y., 
Richardson, B.J., Lei, A.P., Giesy, J.P. and Lam, P.K.S. (2008) Removal of 
antibiotics from wastewater by sewage treatment facilities in Hong Kong and 
Shenzhen, China. Water Research 42(1-2), 395-403. 
Haag, W.R. and Hoigné, J. (1983) Ozonation of Bromide-Containing Waters: Kinetics of 
Formation of Hypobromous Acid and Bromate. Environmental Science & 
Technology 17(5), 261-267. 
Haas, C.N. and Karra, S.B. (1984) Kinetics of Microbial Inactivation by Chlorine .1. 
Review of Results in Demand-Free Systems. Water Research 18(11), 1443-1449. 
Hannah, R., D'Aco, V.J., Anderson, P.D., Buzby, M.E., Caldwell, D.J., Cunningham, 
V.L., Ericson, J.F., Johnson, A.C., Parke, N.J., Samuelian, J.H. and Sumpter, J.P. 
(2009) Exposure Assessment of 17α-Ethinylestradiol in Surface Waters of the 
United States and Europe. Environmental Toxicology and Chemistry 28(12), 
2725-2732. 
Hansen, K.M.S., Andersen, H.R. and Ledin, A. (2010) Ozonation of estrogenic chemicals 
in biologically treated sewage. Water Science and Technology 62(3), 649-657. 
Hao, C.Y., Zhao, X.M., Tabe, S. and Yang, P. (2008) Optimization of a multiresidual 
method for the determination of waterborne emerging organic pollutants using 
solid-phase extraction and liquid chromatography/tandem mass spectrometry and 
isotope dilution mass spectrometry. Environmental Science & Technology 42(11), 
4068-4075. 
Harries, J.E., Sheahan, D.A., Jobling, S., Matthiessen, P., Neall, M., Sumpter, J.P., Tylor, 
T. and Zaman, N. (1997) Estrogenic activity in five United Kingdom rivers 
detected by measurement of vitellogenesis in caged male trout. Environmental 
Toxicology and Chemistry 16(3), 534-542. 
Hashimoto, T., Takahashi, K. and Murakami, T. (2006) Characteristics of estrogen 
decomposition by ozonation. Water Science and Technology 54(10), 87-93. 
 216 
Heberer, T. (2002) Occurrence, fate, and removal of pharmaceutical residues in the 
aquatic environment: a review of recent research data. Toxicology Letters 131(1-
2), 5-17. 
Hoigné, J. (1994) Characterization of Water Quality Criteria for Ozonation Processes. 
Part I: Minimal Set of Analytical Data. Ozone-Science & Engineering 16(2), 113-
120. 
Hoigné, J. and Bader, H. (1983a) Rate Constants of Reactions of Ozone with Organic and 
Inorganic Compounds in Water - I. Non-Dissociating Organic Compounds. Water 
Research 17(2), 173-183. 
Hoigné, J. and Bader, H. (1983b) Rate Constants of Reactions of Ozone with Organic and 
Inorganic Compounds in Water - II. Dissociating Organic Compounds. Water 
Research 17(2), 185-194. 
Hoigné, J. and Bader, H. (1976) Role of Hydroxyl Radical Reactions in Ozonation 
Processes in Aqueous Solutions. Water Research 10(5), 377-386. 
Hoigné, J., Bader, H., Haag, W.R. and Staehelin, J. (1985) Rate Constants of Reactions 
of Ozone with Organic and Inorganic Compounds in Water - III. Inorganic 
Compounds and Radicals. Water Research 19(8), 993-1004. 
Hollender, J., Zimmermann, S.G., Koepke, S., Krauss, M., McArdell, C.S., Ort, C., 
Singer, H., von Gunten, U. and Siegrist, H. (2009) Elimination of Organic 
Micropollutants in a Municipal Wastewater Treatment Plant Upgraded with a 
Full-Scale Post-Ozonation Followed by Sand Filtration. Environmental Science & 
Technology 43(20), 7862-7869. 
Hope, B.K., Pillsbury, L. and Boling, B. (2012) A state-wide survey in Oregon (USA) of 
trace metals and organic chemicals in municipal effluent. Science of the Total 
Environment (0). 
Hua, W.Y., Bennett, E.R., Maio, X.S., Metcalfe, C.D. and Letcher, R.J. (2006) 
Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater 
effluent and surface water from the Canadian side of the upper Detroit River. 
Environmental Toxicology and Chemistry 25(9), 2356-2365. 
Huang, C.H. and Sedlak, D.L. (2001) Analysis of estrogenic hormones in municipal 
wastewater effluent and surface water using enzyme-linked immunosorbent assay 
and gas chromatography/tandem mass spectrometry. Environmental Toxicology 
and Chemistry 20(1), 133-139. 
Huang, L. (2011) Ozonation of Erythromycin and the Effects of pH, Carbonate and 
Phosphate Buffers, and Initial Ozone Dose, The University of Texas at Austin, 
Austin. 
Huber, M.M., Canonica, S., Park, G.Y. and von Gunten, U. (2003) Oxidation of 
pharmaceuticals during ozonation and advanced oxidation processes. 
Environmental Science & Technology 37(5), 1016-1024. 
Huber, M.M., Göbel, A., Joss, A., Hermann, N., Löffler, D., McArdell, C.S., Ried, A., 
Siegrist, H., Ternes, T.A. and von Gunten, U. (2005) Oxidation of 
pharmaceuticals during ozonation of municipal wastewater effluents: A pilot 
study. Environmental Science & Technology 39(11), 4290-4299. 
Hunt, N.K. and Mariñas, B.J. (1999) Inactivation of Escherichia coli with ozone: 
Chemical and inactivation kinetics. Water Research 33(11), 2633-2641. 
 217 
Hunt, N.K. and Mariñas, B.J. (1997) Kinetics of Escherichia coli inactivation with ozone. 
Water Research 31(6), 1355-1362. 
Ifelebuegu, A.O. (2011) The fate and behavior of selected endocrine disrupting chemicals 
in full scale wastewater and sludge treatment unit processes. International 
Journal of Environmental Science and Technology 8(2), 245-254. 
Ishizaki, T., Sasaki, T., Suganuma, T., Horai, Y., Chiba, K., Watanabe, M., Asuke, W. 
and Hoshi, H. (1980) Pharmacokinetics of Ketoprofen Following Single Oral, 
Intramuscular and Rectal Doses and After Repeated Oral Administration. 
European Journal of Clinical Pharmacology 18(5), 407-414. 
Jackevicius, C.A., Tu, J.V., Ross, J.S., Ko, D.T., Carreon, D. and Krumholz, H.M. (2011) 
Use of Fibrates in the United States and Canada. Jama-Journal of the American 
Medical Association 305(12), 1217-1224. 
Jeong, J., Song, W.H., Cooper, W.J., Jung, J. and Greaves, J. (2010) Degradation of 
tetracycline antibiotics: Mechanisms and kinetic studies for advanced 
oxidation/reduction processes. Chemosphere 78(5), 533-540. 
Jin, S., Yang, F., Liao, T., Hui, Y. and Xu, Y. (2008) Seasonal variations of estrogenic 
compounds and their estrogenicities in influent and effluent from a municipal 
sewage treatment plant in China. Environmental Toxicology and Chemistry 27(1), 
146-153. 
Johnson, A.C. and Sumpter, J.P. (2001) Removal of endocrine-disrupting chemicals in 
activated sludge treatment works. Environmental Science & Technology 35(24), 
4697-4703. 
Jolibois, B. and Guerbet, M. (2005) Efficacy of two wastewater treatment plants in 
removing genotoxins. Archives of Environmental Contamination and Toxicology 
48(3), 289-295. 
Jones-Lepp, T.L. and Stevens, R. (2007) Pharmaceuticals and personal care products in 
biosolids/sewage sludge: the interface between analytical chemistry and 
regulation. Analytical and Bioanalytical Chemistry 387(4), 1173-1183. 
Joss, A., Keller, E., Alder, A.C., Göbel, A., McArdell, C.S., Ternes, T. and Siegrist, H. 
(2005) Removal of pharmaceuticals and fragrances in biological wastewater 
treatment. Water Research 39(14), 3139-3152. 
Joss, A., Zabczynski, S., Göbel, A., Hoffmann, B., Löffler, D., McArdell, C.S., Ternes, 
T.A., Thomsen, A. and Siegrist, H. (2006) Biological degradation of 
pharmaceuticals in municipal wastewater treatment: Proposing a classification 
scheme. Water Research 40(8), 1686-1696. 
Karlowsky, J.A., Lagacé-Wiens, P.R.S., Low, D.E. and Zhanel, G.G. (2009) Annual 
macrolide prescription rates and the emergence of macrolide resistance among 
Streptococcus pneumoniae in Canada from 1995 to 2005. International Journal of 
Antimicrobial Agents 34(4), 375-379. 
Karthikeyan, K.G. and Meyer, M.T. (2006) Occurrence of antibiotics in wastewater 
treatment facilities in Wisconsin, USA. Science of the Total Environment 361(1-
3), 196-207. 
Kavlock, R.J., Daston, G.P., DeRosa, C., Fenner-Crisp, P., Gray, L.E., Kaattari, S., 
Lucier, G., Luster, M., Mac, M.J., Maczka, C., Miller, R., Moore, J., Rolland, R., 
Scott, G., Sheehan, D.M., Sinks, T. and Tilson, H.A. (1996) Research needs for 
the risk assessment of health and environmental effects of endocrine disruptors: A 
 218 
report of the US EPA-sponsored workshop. Environmental Health Perspectives 
104, 715-740. 
Khan, S.J. and Ongerth, J.E. (2004) Modelling of pharmaceutical residues in Australian 
sewage by quantities of use and fugacity calculations. Chemosphere 54(3), 355-
367. 
Kim, H.S., Yamada, H. and Tsuno, H. (2007a) The removal of estrogenic activity and 
control of brominated by-products during ozonation of secondary effluents. Water 
Research 41(7), 1441-1446. 
Kim, I. and Tanaka, H. (2011) Energy Consumption for PPCPs Removal by O3 and 
O3/UV. Ozone-Science & Engineering 33(2), 150-157. 
Kim, I., Yamashita, N. and Tanaka, H. (2009) Performance of UV and UV/H2O2 
processes for the removal of pharmaceuticals detected in secondary effluent of a 
sewage treatment plant in Japan. Journal of Hazardous Materials 166(2-3), 1134-
1140. 
Kim, S.D., Cho, J., Kim, I.S., Vanderford, B.J. and Snyder, S.A. (2007b) Occurrence and 
removal of pharmaceuticals and endocrine disruptors in South Korean surface, 
drinking, and waste waters. Water Research 41(5), 1013-1021. 
Koh, Y.K.K., Chiu, T.Y., Boobis, A., Cartmell, E., Scrimshaw, M.D. and Lester, J.N. 
(2008) Treatment and removal strategies for estrogens from wastewater. 
Environmental Technology 29(3), 245-267. 
Komori, K., Tanaka, H., Okayasu, Y., Yasojima, M. and Sato, C. (2004) Analysis and 
occurrence of estrogen in wastewater in Japan. Water Science and Technology 
50(5), 93-100. 
Koutsouba, V., Heberer, T., Fuhrmann, B., Schmidt-Baumler, K., Tsipi, D. and Hiskia, 
A. (2003) Determination of polar pharmaceuticals in sewage water of Greece by 
gas chromatography-mass spectrometry. Chemosphere 51(2), 69-75. 
Kuspis, D.A. and Krenzelok, E.P. (1996) What happens to expired medications? A 
survey of community medication disposal. Veterinary and Human Toxicology 
38(1), 48-49. 
Langford, K. and Jason, L. (2002) Endocrine Disrupters in Wastewater and Sludge 
Treatment Processes. Birkett, J.W. and Lester, J.N. (eds), CRC Press. 
Larocque, R.L. (1999) Ozone applications in Canada - A state of the art review. Ozone-
Science & Engineering 21(2), 119-125. 
Launer, M., Lyko, S., Fahlenkamp, H., Jagemann, P. and Ehrhard, P. (2012) Application 
of CFD simulation for process optimization at a full-scale ozonation plant for the 
removal of micropollutants from secondary effluent, International Water 
Association, Goslar, Germany. 
Lazarova, V., Janex, M.L., Fiksdal, L., Oberg, C., Barcina, I. and Pommepuy, M. (1998) 
Advanced wastewater disinfection technologies: Short and long term efficiency. 
Water Science and Technology 38(12), 109-117. 
Le-Minh, N., Khan, S.J., Drewes, J.E. and Stuetz, R.M. (2010) Fate of antibiotics during 
municipal water recycling treatment processes. Water Research 44(15), 4295-
4323. 
Lee, C.O. (2010) Ozone and biofiltration as an alternative to reverse osmosis for 
removing PPCPs and EDCs from wastewater, The University of New Mexico, 
Albuquerque, New Mexico. 
 219 
Lee, C.O., Howe, K.J. and Thomson, B.M. (2012) Ozone and biofiltration as an 
alternative to reverse osmosis for removing PPCPs and micropollutants from 
treated wastewater. Water Research (0). 
Lee, R.B., Sarafin, K., Peart, T.E. and Svoboda, M.L. (2003) Acidic pharmaceuticals in 
sewage - Methodology, stability test, occurrence, and removal from Ontario 
samples. Water Quality Research Journal of Canada 38(4), 667-682. 
Leong, L.Y.C., Kuo, J., Tang, C.-C. and Water Environment Research Foundation (2008) 
Disinfection of Wastewater Effluent - Comparison of Alternative Technologies, 
IWA Publishing, London. 
Lévesque, L.E., Brophy, J.M. and Zhang, B. (2005) The risk for myocardial infarction 
with cyclooxygenase-2 inhibitors: A population study of elderly adults. Annals of 
Internal Medicine 142(7), 481-489. 
Liberti, L., Notarnicola, M. and Lopez, A. (2000) Advanced treatment for municipal 
wastewater reuse in agriculture. III - Ozone disinfection. Ozone-Science & 
Engineering 22(2), 151-166. 
Lindberg, R.H., Wennberg, P., Johansson, M.I., Tysklind, M. and Andersson, B.A.V. 
(2005) Screening of human antibiotic substances and determination of weekly 
mass flows in five sewage treatment plants in Sweden. Environmental Science & 
Technology 39(10), 3421-3429. 
Lishman, L., Smyth, S.A., Sarafin, K., Kleywegt, S., Toito, J., Peart, T., Lee, B., Servos, 
M., Beland, M. and Seto, P. (2006) Occurrence and reductions of pharmaceuticals 
and personal care products and estrogens by municipal wastewater treatment 
plants in Ontario, Canada. Science of the Total Environment 367(2-3), 544-558. 
Liu, Z.H., Kanjo, Y. and Mizutani, S. (2009) Removal mechanisms for endocrine 
disrupting compounds (EDCs) in wastewater treatment - physical means, 
biodegradation, and chemical advanced oxidation: A review. Science of the Total 
Environment 407(2), 731-748. 
McArdell, C.S., Molnar, E., Suter, M.J.F. and Giger, W. (2003) Occurrence and fate of 
macrolide antibiotics in wastewater treatment plants and in the Glatt Valley 
Watershed, Switzerland. Environmental Science & Technology 37(24), 5479-
5486. 
Mehinto, A.C. (2009) Impacts of the human pharmaceutical diclofenac in the aquatic 
environment, University of Exeter. 
Metcalf & Eddy, I., Tchobanoglous, G., Burton, F.L. and Stensel, H.D. (2002) 
Wastewater engineering : treatment and reuse, McGraw-Hill. 
Metcalfe, C.D., Koenig, B.G., Bennie, D.T., Servos, M., Ternes, T.A. and Hirsch, R. 
(2003a) Occurrence of neutral and acidic drugs in the effluents of Canadian 
sewage treatment plants. Environmental Toxicology and Chemistry 22(12), 2872-
2880. 
Metcalfe, C.D., Miao, X.S., Hua, W., Letcher, R. and Servos, M. (2004) Pharmaceuticals 
in the Environment: Sources, Fate, Effects and Risks. Kümmerer, K. (ed), pp. 67-
87, Springer-Verlag, Heidelberg Berlin. 
Metcalfe, C.D., Miao, X.S., Koenig, B.G. and Struger, J. (2003b) Distribution of acidic 
and neutral drugs in surface waters near sewage treatment plants in the lower 
Great Lakes, Canada. Environmental Toxicology and Chemistry 22(12), 2881-
2889. 
 220 
Mezyk, S.P., Abud, E.M., Swancutt, K.L., McKay, G. and Dionysiou, D.D. (2010) 
Contaminants of Emerging Concern in the Environment: Ecological and Human 
Health Considerations. Halden, R.U. (ed), pp. 213-225, American Chemical 
Society. 
Mezyk, S.P., Neubauer, T.J., Cooper, W.J. and Peller, J.R. (2007) Free-radical-induced 
oxidative and reductive degradation of sulfa drugs in water: Absolute kinetics and 
efficiencies of hydroxyl radical and hydrated electron reactions. Journal of 
Physical Chemistry A 111(37), 9019-9024. 
Miao, X.S., Bishay, F., Chen, M. and Metcalfe, C.D. (2004) Occurrence of antimicrobials 
in the final effluents of wastewater treatment plants in Canada. Environmental 
Science & Technology 38(13), 3533-3541. 
Miao, X.S., Yang, J.J. and Metcalfe, C.D. (2005) Carbamazepine and its metabolites in 
wastewater and in biosolids in a municipal wastewater treatment plant. 
Environmental Science & Technology 39(19), 7469-7475. 
Minnow Environmental, I. and CCME, C.C.o.M.o.t.E. (2005) Environmental risk-based 
approaches for managing municipal wastewater effluent (MWWE), Minnow 
Environmental Inc., Mississauga, Ont. 
Monteiro, S.C. and Boxall, A.B.A. (2010) Occurrence and Fate of Human 
Pharmaceuticals in the Environment. Reviews of Environmental Contamination 
and Toxicology, Vol 202 202, 53-154. 
Morris, J.C. (1988) The aqueous solubility of ozone - A review, pp. 14-16. 
Morris, J.C. and McKay, G. (1975) Formation of halogenated organics by chlorination 
of water supplies : a review, Office of Research and Development, U.S. 
Environmental Protection Agency, Washington. 
Muñoz, I., Tomàs, N., Mas, J., García-Reyes, J.F., Molina-Díaz, A. and Fernández-Alba, 
A.R. (2010) Potential chemical and microbiological risks on human health from 
urban wastewater reuse in agriculture. Case study of wastewater effluents in 
Spain. Journal of Environmental Science and Health Part B-Pesticides Food 
Contaminants and Agricultural Wastes 45(4), 300-309. 
Nakada, N., Shinohara, H., Murata, A., Kiri, K., Managaki, S., Sato, N. and Takada, H. 
(2007) Removal of selected pharmaceuticals and personal care products (PPCPs) 
and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation 
at a municipal sewage treatment plant. Water Research 41(19), 4373-4382. 
Nakada, N., Tanishima, T., Shinohara, H., Kiri, K. and Takada, H. (2006) Pharmaceutical 
chemicals and endocrine disrupters in municipal wastewater in Tokyo and their 
removal during activated sludge treatment. Water Research 40(17), 3297-3303. 
Nakonechny, M., Ikehata, K. and El-Din, M.G. (2008) Kinetics of estrone 
ozone/hydrogen peroxide advanced oxidation treatment. Ozone-Science & 
Engineering 30(4), 249-255. 
Nanaboina, V. and Korshin, G.V. (2010) Evolution of Absorbance Spectra of Ozonated 
Wastewater and Its Relationship with the Degradation of Trace-Level Organic 
Species. Environmental Science & Technology 44(16), 6130-6137. 
Nebel, C., Gottschling, R.D., Hutchison, R.L., McBride, T.J., Taylor, D.M., Pavoni, J.L., 
Tittlebaum, M.E., Spencer, H.E. and Fleischman, M. (1973) Ozone Disinfection 
of Industrial-Municipal Secondary Effluents. Journal Water Pollution Control 
Federation 45(12), 2493-2507. 
 221 
Nöthe, T., Fahlenkamp, H. and von Sonntag, C. (2009) Ozonation of Wastewater: Rate of 
Ozone Consumption and Hydroxyl Radical Yield. Environmental Science & 
Technology 43(15), 5990-5995. 
Okuda, T., Kobayashi, Y., Nagao, R., Yamashita, N., Tanaka, H., Tanaka, S., Fujii, S., 
Konishi, C. and Houwa, I. (2008) Removal efficiency of 66 pharmaceuticals 
during wastewater treatment process in Japan. Water Science and Technology 
57(1), 65-71. 
Oneby, M.A., Bromley, C.O., Borchardt, J.H. and Harrison, D.S. (2010) Ozone 
Treatment of Secondary Effluent at U.S. Municipal Wastewater Treatment Plants. 
Ozone-Science & Engineering 32(1), 43-55. 
Ontario MOE (2008) Design guidelines for sewage works, Ontario Ministry of the 
Environment. 
Ontario MOE (2001) Procedure F-5-4 Effluent Disinfection Requirements for Sewage 
Works Discharging to Surface Waters. Environment, O.M.o.t. (ed), Ontario 
Ministry of the Environment. 
Oppenheimer, J., Eaton, A., Badruzzaman, M., Haghani, A.W. and Jacangelo, J.G. (2011) 
Occurrence and suitability of sucralose as an indicator compound of wastewater 
loading to surface waters in urbanized regions. Water Research 45(13), 4019-
4027. 
Pagliaro, L.A. and Benet, L.Z. (1975) Critical Compilation of Terminal Half-Lives, 
Percent Excreted Unchanged, and Changes of Half-Life in Renal and Hepatic 
Dysfunction for Studies in Humans with References. Journal of Pharmacokinetics 
and Biopharmaceutics 3(5), 338-383. 
Paraskeva, P. and Graham, N.J.D. (2005) Treatment of a secondary municipal effluent by 
ozone, UV and microfiltration: microbial reduction and effect on effluent quality. 
Desalination 186(1-3), 47-56. 
Paraskeva, P., Lambert, S.D. and Graham, N.J.D. (1998) Influence of ozonation 
conditions on the treatability of secondary effluents Ozone-Science & 
Engineering 20(2), 133-150. 
Paraskeva, P., Lambert, S.D. and Graham, N.J.D. (1999) Ozone treatment of sewage 
works' final effluent. Journal of the Chartered Institution of Water and 
Environmental Management 13(6), 430-435. 
Pedrouzo, M., Borrull, F., Pocurull, E. and Marcé, R.M. (2011) Presence of 
Pharmaceuticals and Hormones in Waters from Sewage Treatment Plants. Water 
Air and Soil Pollution 217(1-4), 267-281. 
Petala, M., Tsiridis, V., Samaras, P., Zouboulis, A. and Sakellaropoulos, G.P. (2006) 
Wastewater reclamation by advanced treatment of secondary effluents. 
Desalination 195(1-3), 109-118. 
Petrović, M., Gonzalez, S. and Barceló, D. (2003) Analysis and removal of emerging 
contaminants in wastewater and drinking water. Trac-Trends in Analytical 
Chemistry 22(10), 685-696. 
Phelps, E.B. (1912) The Chemical Disinfection of Sewage. American Journal of Public 
Health 2(2), 72-76. 
Plósz, B.G., Leknes, H., Liltved, H. and Thomas, K.V. (2010) Diurnal variations in the 
occurrence and the fate of hormones and antibiotics in activated sludge 
 222 
wastewater treatment in Oslo, Norway. Science of the Total Environment 408(8), 
1915-1924. 
Puri, S.K. and Lassman, H.B. (1987) Roxithromycin: a Pharmacokinetic Review of a 
Macrolide. Journal of Antimicrobial Chemotherapy 20, 89-100. 
Race, J. (1918) Chlorination of water, J. Wiley and sons, New York. 
Radjenovic, J., Petrovic, M. and Barceló, D. (2007) Analysis of pharmaceuticals in 
wastewater and removal using a membrane bioreactor. Analytical and 
Bioanalytical Chemistry 387(4), 1365-1377. 
Radjenovic, J., Petrovic, M. and Barceló, D. (2009) Fate and distribution of 
pharmaceuticals in wastewater and sewage sludge of the conventional activated 
sludge (CAS) and advanced membrane bioreactor (MBR) treatment. Water 
Research 43(3), 831-841. 
Rakness, K.L., Najm, I., Elovitz, M., Rexing, D. and Via, S. (2005) Cryptosporidium log-
inactivation with ozone using effluent CT10, geometric mean CT10, extended 
integrated CT10 and extended CSTR calculations. Ozone-Science & Engineering 
27(5), 335-350. 
Rakness, K.L., Stover, E.L. and Krenek, D.L. (1984) Design, Start-up, and Operation of 
an Ozone Disinfection Unit. Journal Water Pollution Control Federation 56(11), 
1152-1159. 
Rao, S.S. and Lifshitz, R. (1995) The Muta-Chromoplate Method for Measuring 
Mutagenicity of Environmental-Samples and Pure-Chemicals. Environmental 
Toxicology and Water Quality 10(4), 307-313. 
Razavi, B., Song, W.H., Cooper, W.J., Greaves, J. and Jeong, J. (2009) Free-Radical-
Induced Oxidative and Reductive Degradation of Fibrate Pharmaceuticals: 
Kinetic Studies and Degradation Mechanisms. Journal of Physical Chemistry A 
113(7), 1287-1294. 
Real, F.J., Benitez, F.J., Acero, J.L., Sagasti, J.J.P. and Casas, F. (2009) Kinetics of the 
Chemical Oxidation of the Pharmaceuticals Primidone, Ketoprofen, and 
Diatrizoate in Ultrapure and Natural Waters. Industrial & Engineering Chemistry 
Research 48(7), 3380-3388. 
Reisz, E., Schmidt, W., Schuchmann, H.P. and von Sonntag, C. (2003) Photolysis of 
ozone in aqueous solutions in the presence of tertiary butanol. Environmental 
Science & Technology 37(9), 1941-1948. 
Reungoat, J., Escher, B.I., Macova, M., Argaud, F.X., Gernjak, W. and Keller, J. (2012) 
Ozonation and biological activated carbon filtration of wastewater treatment plant 
effluents. Water Research 46(3), 863-872. 
Reungoat, J., Escher, B.I., Macova, M. and Keller, J. (2011) Biofiltration of wastewater 
treatment plant effluent: Effective removal of pharmaceuticals and personal care 
products and reduction of toxicity. Water Research 45(9), 2751-2762. 
Reungoat, J., Macova, M., Escher, B.I., Carswell, S., Mueller, J.F. and Keller, J. (2010) 
Removal of micropollutants and reduction of biological activity in a full scale 
reclamation plant using ozonation and activated carbon filtration. Water Research 
44(2), 625-637. 
Rice, E.W., Allen, M.J. and Edberg, S.C. (1990) Efficacy of β-Glucuronidase Assay for 
Identification of Escherichia coli by the Defined-Substrate Technology. Applied 
and Environmental Microbiology 56(5), 1203-1205. 
 223 
Rice, R.G. (1999) Ozone in the United States of America - State-of-the-art. Ozone-
Science & Engineering 21(2), 99-118. 
Rice, R.G., Evison, L.M. and Robson, C.M. (1981) Ozone Disinfection of Municipal 
Wastewater - Current State-of-the-Art. Ozone-Science & Engineering 3(4), 239-
272. 
Ried, A., Mielcke, J. and Wieland, A. (2009) The Potential Use of Ozone in Municipal 
Wastewater. Ozone-Science & Engineering 31(6), 415-421. 
Rivas, F.J., Sagasti, J., Encinas, A. and Gimeno, O. (2011) Contaminants abatement by 
ozone in secondary effluents. Evaluation of second-order rate constants. Journal 
of Chemical Technology and Biotechnology 86(8), 1058-1066. 
Rivas, J., Gimeno, O., Borralho, T. and Carbajo, M. (2010) UV-C photolysis of 
endocrine disruptors. The influence of inorganic peroxides. Journal of Hazardous 
Materials 174(1-3), 393-397. 
Rosal, R., Rodríguez, A., Perdigón-Melón, J.A., Petre, A., García-Calvo, E., Gómez, 
M.J., Agüera, A. and Fernández-Alba, A.R. (2010) Occurrence of emerging 
pollutants in urban wastewater and their removal through biological treatment 
followed by ozonation. Water Research 44(2), 578-588. 
Rosario-Ortiz, F.L., Mezyk, S.P., Doud, D.F.R. and Snyder, S.A. (2008) Quantitative 
correlation of absolute hydroxyl radical rate constants with mon-isolated effluent 
organic matter bulk properties in water. Environmental Science & Technology 
42(16), 5924-5930. 
Rosenfeldt, E.J. and Linden, K.G. (2004) Degradation of endocrine disrupting chemicals 
bisphenol A, ethinyl estradiol, and estradiol during UV photolysis and advanced 
oxidation processes. Environmental Science & Technology 38(20), 5476-5483. 
Ruel, S.M., Choubert, J.M., Esperanza, M., Miège, C., Madrigal, P.N., Budzinski, H., Le 
Ménach, K., Lazarova, V. and Coquery, M. (2011) On-site evaluation of the 
removal of 100 micro-pollutants through advanced wastewater treatment 
processes for reuse applications. Water Science and Technology 63(11), 2486-
2497. 
Runnalls, T.J., Hala, D.N. and Sumpter, J.P. (2007) Preliminary studies into the effects of 
the human pharmaceutical Clofibric acid on sperm parameters in adult Fathead 
minnow. Aquatic Toxicology 84(1), 111-118. 
Ryu, J., Yoon, Y. and Oh, J. (2011) Occurrence of endocrine disrupting compounds and 
pharmaceuticals in 11 WWTPs in Seoul, Korea. Ksce Journal of Civil 
Engineering 15(1), 57-64. 
Sadezky, A., Löffler, D. and Ternes, T. (2008) Proposal of an environmental indicator 
and classification system of pharmaceutical product residues for environmental 
management, Federal Insitute of Hydrology BfG, Germany. 
Sarmah, A.K., Meyer, M.T. and Boxall, A.B.A. (2006) A global perspective on the use, 
sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics 
(VAs) in the environment. Chemosphere 65(5), 725-759. 
Sawyer, C.M. (1976) Wastewater disinfection : a state-of-the-art summary, Virginia 
Water Resources Research Center, Virginia Polytechnic Institute and State 
University, Blacksburg. 
 224 
Schaar, H., Clara, M., Gans, O. and Kreuzinger, N. (2010) Micropollutant removal during 
biological wastewater treatment and a subsequent ozonation step. Environmental 
Pollution 158(5), 1399-1404. 
Sedlak, D.L. and Pinkston, K.E. (2001) Factors affecting the concentrations of 
pharmaceuticals released to the aquatic environment. Water Resources Update 
120(September), 56-64. 
Shon, H.K., Vigneswaran, S. and Snyder, S.A. (2006) Effluent organic matter (EfOM) in 
wastewater: Constituents, effects, and treatment. Critical Reviews in 
Environmental Science and Technology 36(4), 327-374. 
Snyder, S.A., Keith, T.L., Verbrugge, D.A., Snyder, E.M., Gross, T.S., Kannan, K. and 
Giesy, J.P. (1999) Analytical methods for detection of selected estrogenic 
compounds in aqueous mixtures. Environmental Science & Technology 33(16), 
2814-2820. 
Snyder, S.A., Wert, E.C., Rexing, D.J., Zegers, R.E. and Drury, D.D. (2006) Ozone 
oxidation of endocrine disruptors and pharmaceuticals in surface water and 
wastewater. Ozone-Science & Engineering 28(6), 445-460. 
Snyder, S.A., Westerhoff, P., Yoon, Y. and Sedlak, D.L. (2003) Pharmaceuticals, 
personal care products, and endocrine disruptors in water: Implications for the 
water industry. Environmental Engineering Science 20(5), 449-469. 
Sosiak, A.J., Hebben, T. and Alberta. Alberta, E. (2005) A preliminary survey of 
pharmaceuticals and endocrine disrupting compounds in treated municipal 
wastewaters and receiving rivers of Alberta, Alberta Environment, Environmental 
Monitoring and Evaluation Branch, Edmonton. 
Sotelo, J.L., Beltrán, F.J., Benitez, F.J. and Beltrán-Heredia, J. (1989) Henry's Law 
Constant for the Ozone Water-System. Water Research 23(10), 1239-1246. 
Sowers, A.D., Mills, M.A. and Klaine, S.J. (2009) The developmental effects of a 
municipal wastewater effluent on the northern leopard frog, Rana pipiens. Aquatic 
Toxicology 94(2), 145-152. 
Stover, E.L. and Jarnis, R.W. (1981) Obtaining High-Level Wastewater Disinfection with 
Ozone. Journal Water Pollution Control Federation 53(11), 1637-1647. 
Stumpf, M., Ternes, T.A., Wilken, R.D., Rodrigues, S.V. and Baumann, W. (1999) Polar 
drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. 
Science of the Total Environment 225(1-2), 135-141. 
Sui, Q., Huang, J., Deng, S.B., Yu, G. and Fan, Q. (2010) Occurrence and removal of 
pharmaceuticals, caffeine and DEET in wastewater treatment plants of Beijing, 
China. Water Research 44(2), 417-426. 
Summerfelt, S.T. (2003) Ozonation and UV irradiation - an introduction and examples of 
current applications. Aquacultural Engineering 28(1-2), 21-36. 
Swan, G., Naidoo, V., Cuthbert, R., Green, R.E., Pain, D.J., Swarup, D., Prakash, V., 
Taggart, M., Bekker, L., Das, D., Diekmann, J., Diekmann, M., Killian, E., 
Meharg, A., Patra, R.C., Saini, M. and Wolter, K. (2006) Removing the threat of 
diclofenac to critically endangered Asian vultures. Plos Biology 4(3), 395-402. 
Sweetman, S.C. (2009) Martindale: The Complete Drug Reference, Pharmaceutical 
Press, London; Chicago. 
 225 
Tabe, S., Jamal, T., Seth, R., Yue, C., Yang, P., Zhao, X. and Schweitzer, L. (2009) 
PPCPs and EDCs—Occurrence in the Detroit River and Their Removal by 
Ozonation, p. 236, Denver, Colorado, U.S.A. 
Takahara, H., Nakayama, S. and Tsuno, H. (2006) Application of Ozone to Municipal 
Sewage Treatment, pp. 3-8, Berlin. 
Tauxe-Wuersch, A., De Alencastro, L.F., Grandjean, D. and Tarradellas, J. (2005) 
Occurrence of several acidic drugs in sewage treatment plants in Switzerland and 
risk assessment. Water Research 39(9), 1761-1772. 
Ternes, T.A. (1998) Occurrence of drugs in German sewage treatment plants and rivers. 
Water Research 32(11), 3245-3260. 
Ternes, T.A., Joss, A. and Siegrist, H. (2004) Scrutinizing pharmaceuticals and personal 
care products in wastewater treatment. Environmental Science & Technology 
38(20), 392a-399a. 
Ternes, T.A., Kreckel, P. and Mueller, J. (1999a) Behaviour and occurrence of estrogens 
in municipal sewage treatment plants - II. Aerobic batch experiments with 
activated sludge. Science of the Total Environment 225(1-2), 91-99. 
Ternes, T.A., Meisenheimer, M., McDowell, D., Sacher, F., Brauch, H.J., Haist-Gulde, 
B., Preuss, G., Wilme, U. and Zulei-Seibert, N. (2002) Removal of 
pharmaceuticals during drinking water treatment. Environmental Science & 
Technology 36(17), 3855-3863. 
Ternes, T.A., Stüber, J., Herrmann, N., McDowell, D., Ried, A., Kampmann, M. and 
Teiser, B. (2003) Ozonation: a tool for removal of pharmaceuticals, contrast 
media and musk fragrances from wastewater? Water Research 37(8), 1976-1982. 
Ternes, T.A., Stumpf, M., Mueller, J., Haberer, K., Wilken, R.D. and Servos, M. (1999b) 
Behavior and occurrence of estrogens in municipal sewage treatment plants - I. 
Investigations in Germany, Canada and Brazil. Science of the Total Environment 
225(1-2), 81-90. 
Tomiyasu, H., Fukutomi, H. and Gordon, G. (1985) Kinetics and Mechanism of Ozone 
Decomposition in Basic Aqueous Solution. Inorganic Chemistry 24(19), 2962-
2966. 
Tripathi, S., Pathak, V., Tripathi, D.M. and Tripathi, B.D. (2011) Application of ozone 
based treatments of secondary effluents. Bioresource Technology 102(3), 2481-
2486. 
Tyrrell, S.A., Rippey, S.R. and Watkins, W.D. (1995) Inactivation of Bacterial and Viral 
Indicators in Secondary Sewage Effluents, Using Chlorine and Ozone. Water 
Research 29(11), 2483-2490. 
USEPA (1986a) Ambient water quality criteria for bacteria - 1986, United States 
Environmental Protection Agency, Office of Water Regulations and Standards, 
Washington, DC. 
USEPA (1986b) Design manual : municipal wastewater disinfection, U.S. Environmental 
Protection Agency, Office of Research and Development, Water Engineering 
Research Laboratory, Center for Environmental Research Information, Cincinnati, 
OH. 
USEPA (1999) Disinfection profiling and benchmarking guidance manual, United States 
Environmental Protection Agency, Office of Water, Washington, D.C. 
 226 
USEPA (2009) Method 415.3 Determination of Total Organic Carbon and Specific UV 
Absorbance at 254 nm in Source Water and Drinking Water, U.S. Environmental 
Protection Agency, Ohio. 
van Leeuwen, J. and Prinsloo, J. (1980) Ozonation at the Stander water reclamation plant. 
Water S.A 6(2), 96-102. 
van Leeuwen, J.H., Pipe-Martin, C. and Lehmann, R.M. (2003) Water reclamation at 
South Caboolture, Queensland, Australia. Ozone-Science & Engineering 25(2), 
107-120. 
Venosa, A.D. and Meckes, M.C. (1983) Control of Ozone Disinfection by Exhaust Gas 
Monitoring. Journal Water Pollution Control Federation 55(9), 1163-1167. 
Vieno, N. (2007) Occurrence of pharmaceuticals in Finnish sewage treatment plants, 
surface waters and their elimination in drinking water treatment processes, 
Tampere University of Technology, Tampere. 
Viglino, L., Aboulfadl, K., Prévost, M. and Sauvé, S. (2008) Analysis of natural and 
synthetic estrogenic endocrine disruptors in environmental waters using online 
preconcentration coupled with LC-APPI-MS/MS. Talanta 76(5), 1088-1096. 
von Gunten, U. (2003a) Ozonation of drinking water: Part I. Oxidation kinetics and 
product formation. Water Research 37(7), 1443-1467. 
von Gunten, U. (2003b) Ozonation of drinking water: Part II. Disinfection and by-
product formation in presence of bromide, iodide or chlorine. Water Research 
37(7), 1469-1487. 
von Gunten, U. and Hoigné, J. (1994) Bromate Formation during Ozonation of Bromide-
Containing Waters: Interaction of Ozone and Hydroxyl Radical Reactions. 
Environmental Science & Technology 28(7), 1234-1242. 
von Gunten, U. and Ramseier, M. (2010) Critical review of literature for rate constants 
for reaction of chemical oxidants with inorganic and organic pollutants, Eawag, 
Swiss Federal Institute of Aquatic Science and Technology, 8600 Dübendorf, 
Switzerland. 
Ward, R.W. and DeGraeve, G.M. (1978) Acute Residual Toxicity of Several Wastewater 
Disinfectants to Aquatic Life. Water Resources Bulletin 14(3), 696-709. 
Wert, E., Gonzales, S., Dong, M.M. and Rosario-Ortiz, F. (2011) Evaluation of Enhanced 
Coagulation Pretreatment to Improve Ozone Oxidation Efficiency in Wastewater, 
International Water Association, Costa Mesa, California. 
Wert, E.C., Rosario-Ortiz, F.L., Drury, D.D. and Snyder, S.A. (2007) Formation of 
oxidation byproducts from ozonation of wastewater. Water Research 41(7), 1481-
1490. 
Wert, E.C., Rosario-Ortiz, F.L. and Snyder, S.A. (2009a) Effect of ozone exposure on the 
oxidation of trace organic contaminants in wastewater. Water Research 43(4), 
1005-1014. 
Wert, E.C., Rosario-Ortiz, F.L. and Snyder, S.A. (2009b) Using Ultraviolet Absorbance 
and Color To Assess Pharmaceutical Oxidation during Ozonation of Wastewater. 
Environmental Science & Technology 43(13), 4858-4863. 
Westerhoff, P., Aiken, G., Amy, G. and Debroux, J. (1999) Relationships between the 
structure of natural organic matter and its reactivity towards molecular ozone and 
hydroxyl radicals. Water Research 33(10), 2265-2276. 
 227 
Westerhoff, P., Yoon, Y., Snyder, S. and Wert, E. (2005) Fate of endocrine-disruptor, 
pharmaceutical, and personal care product chemicals during simulated drinking 
water treatment processes. Environmental Science & Technology 39(17), 6649-
6663. 
Whitby, G.E. and Scheible, O.K. (2004) The history of UV and wastewater. IUVA News 
6(3), 15-26. 
Williams, R.T. (1971) The metabolism of certain drugs and food chemicals in man. 
Annals of the New York Academy of Sciences 179, 141-154. 
Williams, R.T. and Parke, D.V. (1964) The Metabolic Fate of Drugs. Annu. Rev. 
Pharmacol. Annual Review of Pharmacology 4(1), 85-114. 
Winkler, M., Lawrence, J.R. and Neu, T.R. (2001) Selective degradation of ibuprofen 
and clofibric acid in two model river biofilm systems. Water Research 35(13), 
3197-3205. 
Wolfe, R.L., Stewart, M.H., Liang, S. and Mcguire, M.J. (1989) Disinfection of Model 
Indicator Organisms in a Drinking-Water Pilot-Plant by Using PEROXONE. 
Applied and Environmental Microbiology 55(9), 2230-2241. 
Xu, P., Janex, M.L., Savoye, P., Cockx, A. and Lazarova, V. (2002) Wastewater 
disinfection by ozone: main parameters for process design. Water Research 36(4), 
1043-1055. 
Xu, W.H., Zhang, G., Li, X.D., Zou, S.C., Li, P., Hu, Z.H. and Li, J. (2007) Occurrence 
and elimination of antibiotics at four sewage treatment plants in the Pearl River 
Delta (PRD), South China. Water Research 41(19), 4526-4534. 
Yang, L.M., Yu, L.E. and Ray, M.B. (2009) Photocatalytic Oxidation of Paracetamol: 
Dominant Reactants, Intermediates, and Reaction Mechanisms. Environmental 
Science & Technology 43(2), 460-465. 
Yang, X., Flowers, R.C., Weinberg, H.S. and Singer, P.C. (2011) Occurrence and 
removal of pharmaceuticals and personal care products (PPCPs) in an advanced 
wastewater reclamation plant. Water Research 45(16), 5218-5228. 
Yoon, Y., Westerhoff, P., Snyder, S.A., Wert, E.C. and Yoon, J. (2007) Removal of 
endocrine disrupting compounds and pharmaceuticals by nanofiltration and 
ultrafiltration membranes. Desalination 202(1-3), 16-23. 
Zhang, T. and Li, B. (2011) Occurrence, Transformation, and Fate of Antibiotics in 
Municipal Wastewater Treatment Plants. Critical Reviews in Environmental 
Science and Technology 41(11), 951-998. 
Zhang, Y.J., Geissen, S.U. and Gal, C. (2008) Carbamazepine and diclofenac: Removal 
in wastewater treatment plants and occurrence in water bodies. Chemosphere 
73(8), 1151-1161. 
Zhou, H.D., Huang, X., Wang, X.L., Zhi, X.H., Yang, C.D., Wen, X.H., Wang, Q.H., 
Tsuno, H. and Tanaka, H. (2010) Behaviour of selected endocrine-disrupting 
chemicals in three sewage treatment plants of Beijing, China. Environmental 
Monitoring and Assessment 161(1-4), 107-121. 
Zimmermann, S.G., Wittenwiler, M., Hollender, J., Krauss, M., Ort, C., Siegrist, H. and 
von Gunten, U. (2011) Kinetic assessment and modeling of an ozonation step for 
full-scale municipal wastewater treatment: Micropollutant oxidation, by-product 
formation and disinfection. Water Research 45(2), 605-617. 
 228 
Zita, A. and Hermansson, M. (1997) Effects of bacterial cell surface structures and 
hydrophobicity on attachment to activated sludge flocs. Applied and 
Environmental Microbiology 63(3), 1168-1170. 
Zorita, S., Mårtensson, L. and Mathiasson, L. (2009) Occurrence and removal of 
pharmaceuticals in a municipal sewage treatment system in the south of Sweden. 
Science of the Total Environment 407(8), 2760-2770. 
Zuccato, E., Calamari, D., Natangelo, M. and Fanelli, R. (2000) Presence of therapeutic 
drugs in the environment. Lancet 355(9217), 1789-1790. 
Zwiener, C. and Frimmel, F.H. (2003) Short-term tests with a pilot sewage plant and 
biofilm reactors for the biological degradation of the pharmaceutical compounds 
clofibric acid, ibuprofen, and diclofenac. Science of the Total Environment 309(1-
3), 201-211. 
 
  
 229 
 
VITA AUCTORIS 
 
Name:   Saileshkumar Singh 
Place of birth:  Mumbai, India 
Year of birth:  1973 
Education:  Institution of Mechanical Engineers (India) 
   1993 – 1998  Bachelor of Engineering (Mechanical) 
   University of Windsor, Canada 
   2008 – 2010  Master of Engineering (Environmental) 
   2010 – 2012  Master of Applied Science (Environmental) 
 
 
 
 
